BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
Number Citing Articles
1 Fu C, Li J, Li P, Cheng D. LncRNA DNAJC3-AS1 Promotes Hepatocellular Carcinoma (HCC) Progression via Sponging Premature miR-27b. Cancer Manag Res 2021;13:8575-83. [PMID: 34815712 DOI: 10.2147/CMAR.S321111] [Reference Citation Analysis]
2 Molinari M, Kaltenmeier C, Samra P, Liu H, Wessel C, Lou Klem M, Dharmayan S, Emmanuel B, Al Harakeh H, Tohme S, Geller D, Tevar A, Hughes CB, Humar A, Bataller R, Behari J. Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of 7226 Patients. Annals of Surgery Open 2021;2:e065. [DOI: 10.1097/as9.0000000000000065] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bi J, Liu Q, Sun Y, Hu X, He X, Xu C. CXCL14 inhibits the growth and promotes apoptosis of hepatocellular carcinoma cells via suppressing Akt/mTOR pathway. Journal of Receptors and Signal Transduction. [DOI: 10.1080/10799893.2020.1837870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Liu Z, Ma C, Wang Q, Yang H, Lu Z, Bi T, Xu Z, Li T, Zhang L, Zhang Y, Liu J, Wei X, Li J. Targeting FAM134B-mediated reticulophagy activates sorafenib-induced ferroptosis in hepatocellular carcinoma. Biochem Biophys Res Commun 2021;589:247-53. [PMID: 34929448 DOI: 10.1016/j.bbrc.2021.12.019] [Reference Citation Analysis]
5 Wu Y, Xiang Q, Lv X, Xiang X, Feng Z, Tian S, Tang J, Xiang T, Gong J. C2orf40 inhibits hepatocellular carcinoma through interaction with UBR5. J Gastroenterol Hepatol 2021. [PMID: 33576531 DOI: 10.1111/jgh.15441] [Reference Citation Analysis]
6 Xia H, Huang Z, Liu S, Zhao X, He R, Wang Z, Shi W, Chen W, Li Z, Yu L, Huang P, Kang P, Su Z, Xu Y, Yam JWP, Cui Y. Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. Front Oncol 2021;11:653846. [PMID: 33869059 DOI: 10.3389/fonc.2021.653846] [Reference Citation Analysis]
7 Ren FJ, Yao Y, Cai XY, Cai YT, Su Q, Fang GY. MiR-149-5p: An Important miRNA Regulated by Competing Endogenous RNAs in Diverse Human Cancers. Front Oncol 2021;11:743077. [PMID: 34722295 DOI: 10.3389/fonc.2021.743077] [Reference Citation Analysis]
8 He S, Yang J, Jiang S, Li Y, Han X. Circular RNA circ_0000517 regulates hepatocellular carcinoma development via miR-326/IGF1R axis. Cancer Cell Int 2020;20:404. [PMID: 32863763 DOI: 10.1186/s12935-020-01496-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
9 Rajasekar A, Devasena T, Suresh S, Senthil B, Sivaramakrishnan R, Pugazhendhi A. Curcumin nanospheres and nanorods: Synthesis, characterization and anticancer activity. Process Biochemistry 2022;112:248-53. [DOI: 10.1016/j.procbio.2021.12.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lv HC, Lv YY, Wang G, Zhang XH, Li SN, Yue XF, Lu W. Mechanism of miR-424-5p promoter methylation in promoting epithelial-mesenchymal transition of hepatocellular carcinoma cells. Kaohsiung J Med Sci 2022. [PMID: 35049148 DOI: 10.1002/kjm2.12499] [Reference Citation Analysis]
11 Yu X, Ye Z, Hou L, Zhang X, Liu Z, Wu R, Huang F, Wang G, Geng X, Zhao H. Hepatitis B virus x gene-downregulated growth-arrest specific 5 inhibits the cell viability and invasion of hepatocellular carcinoma cell lines by activating Y-box-binding protein 1/p21 signaling. J Cell Commun Signal 2021. [PMID: 34535871 DOI: 10.1007/s12079-021-00645-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Yin L, Zhou L, Xu R. Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis. Front Mol Biosci 2020;7:599142. [PMID: 33681288 DOI: 10.3389/fmolb.2020.599142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. Int J Mol Sci 2021;22:1931. [PMID: 33669204 DOI: 10.3390/ijms22041931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Takahashi A, Umemura A, Yano K, Okishio S, Kataoka S, Okuda K, Seko Y, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells. Front Oncol 2021;11:707473. [PMID: 34458148 DOI: 10.3389/fonc.2021.707473] [Reference Citation Analysis]
15 Maddah R, Shariati P, Arabpour J, Bazireh H, Shadpirouz M, Kafraj AS. Identification of critical genes and pathways associated with hepatocellular carcinoma and type 2 diabetes mellitus using integrated bioinformatics analysis. Informatics in Medicine Unlocked 2022;30:100956. [DOI: 10.1016/j.imu.2022.100956] [Reference Citation Analysis]
16 Enokida T, Moreira A, Bhardwaj N. Vaccines for immunoprevention of cancer. J Clin Invest 2021;131:146956. [PMID: 33938446 DOI: 10.1172/JCI146956] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Rao BC, Lou JM, Wang WJ, Li A, Cui GY, Yu ZJ, Ren ZG. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2020;19:109-15. [PMID: 32037278 DOI: 10.1016/j.hbpd.2020.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Goto K, Roca Suarez AA, Wrensch F, Baumert TF, Lupberger J. Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. Int J Mol Sci. 2020;21. [PMID: 32357520 DOI: 10.3390/ijms21093057] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
19 Liu S, Zhao W, Li X, Zhang, Gao Y, Peng Q, Du C, Jiang N. AGTRAP Is a Prognostic Biomarker Correlated With Immune Infiltration in Hepatocellular Carcinoma. Front Oncol 2021;11:713017. [PMID: 34595113 DOI: 10.3389/fonc.2021.713017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Li H, Chen Z, Zhang Y, Yuan P, Liu J, Ding L, Ye Q. MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis. Cancer Lett 2021;519:161-71. [PMID: 34303763 DOI: 10.1016/j.canlet.2021.07.029] [Reference Citation Analysis]
21 He Y, Fang D, Liang T, Pang H, Nong Y, Tang L, Yang Z, Lu C, Han X, Zhao S, Mo S, Meng Y, Han C, Peng T. Atractylodin may induce ferroptosis of human hepatocellular carcinoma cells. Ann Transl Med 2021;9:1535. [PMID: 34790741 DOI: 10.21037/atm-21-4386] [Reference Citation Analysis]
22 Zhang N, Xu H, Ren AH, Zhang Q, Yang DW, Ba T, Wang ZC, Yang ZH. Does Training in LI-RADS Version 2018 Improve Readers' Agreement with the Expert Consensus and Inter-reader Agreement in MRI Interpretation? J Magn Reson Imaging 2021. [PMID: 33963801 DOI: 10.1002/jmri.27688] [Reference Citation Analysis]
23 Park R, Lopes da Silva L, Nissaisorakarn V, Riano I, Williamson S, Sun W, Saeed A. Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials. J Hepatocell Carcinoma 2021;8:145-54. [PMID: 33791250 DOI: 10.2147/JHC.S268305] [Reference Citation Analysis]
24 Huang X, Lee F, Teng Y, Lingam CB, Chen Z, Sun M, Song Z, Balachander GM, Leo HL, Guo Q, Shah I, Yu H. Sequential drug delivery for liver diseases. Adv Drug Deliv Rev 2019;149-150:72-84. [PMID: 31734169 DOI: 10.1016/j.addr.2019.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Wu C, Zhou Y, Wang M, Dai G, Liu X, Lai L, Tang S. Bioinformatics Analysis Explores Potential Hub Genes in Nonalcoholic Fatty Liver Disease. Front Genet 2021;12:772487. [PMID: 34777484 DOI: 10.3389/fgene.2021.772487] [Reference Citation Analysis]
26 Lu T, Li C, Xiang C, Gong Y, Peng W, Chen C, Gas P. Overexpression of CISD1 Predicts Worse Survival in Hepatocarcinoma Patients. BioMed Research International 2022;2022:1-14. [DOI: 10.1155/2022/7823191] [Reference Citation Analysis]
27 Chen K, Zhu P, Liao Y, Yan L, Feng R, Zhai W. An Apoptotic Gene Signature for the Prognosis of Hepatocellular Carcinoma. Onco Targets Ther 2021;14:1589-604. [PMID: 33688206 DOI: 10.2147/OTT.S293610] [Reference Citation Analysis]
28 Liu Y, Wang Y, Guo X, He Y, Zhou J, Lv Q, Huang X, Li X. Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:709278. [PMID: 34540675 DOI: 10.3389/fonc.2021.709278] [Reference Citation Analysis]
29 Bockorny B, Bullock AJ, Abrams TA, Faintuch S, Alsop DC, Goldberg SN, Ahmed M, Miksad RA. Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma. Dig Dis Sci 2021. [PMID: 34297268 DOI: 10.1007/s10620-021-07156-2] [Reference Citation Analysis]
30 Mathur K, Mazhar A, Patel M, Dakhoul L, Burney H, Liu H, Nephew L, Chalasani N, deLemos A, Gawrieh S. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. Clin Transl Gastroenterol 2021;12:e00420. [PMID: 34730559 DOI: 10.14309/ctg.0000000000000420] [Reference Citation Analysis]
31 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Reference Citation Analysis]
32 Deng J, Chen W, Wu X, Zhou Y, Li J. Evaluating the predictive power of circulating tumor cells for the prognosis of transarterial chemoembolization treatment on patients with advanced hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e24060. [PMID: 33429769 DOI: 10.1097/MD.0000000000024060] [Reference Citation Analysis]
33 Christou CD, Tsoulfas G. Role of three-dimensional printing and artificial intelligence in the management of hepatocellular carcinoma: Challenges and opportunities. World J Gastrointest Oncol 2022; 14(4): 765-793 [DOI: 10.4251/wjgo.v14.i4.765] [Reference Citation Analysis]
34 Kotiyal S, Evason KJ. Exploring the Interplay of Telomerase Reverse Transcriptase and β-Catenin in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4202. [PMID: 34439356 DOI: 10.3390/cancers13164202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Sun C, Ma S, Chen Y, Kim NH, Kailas S, Wang Y, Gu W, Chen Y, Tuason JPW, Bhan C, Manem N, Huang Y, Cheng C, Zhou Z, Zhou Q, Zhu Y. Diagnostic Value, Prognostic Value, and Immune Infiltration of LOX Family Members in Liver Cancer: Bioinformatic Analysis. Front Oncol 2022;12:843880. [DOI: 10.3389/fonc.2022.843880] [Reference Citation Analysis]
36 Cui Z, Xiao L, Chen F, Wang J, Lin H, Li D, Wu Z. High mRNA Expression of CENPL and Its Significance in Prognosis of Hepatocellular Carcinoma Patients. Dis Markers 2021;2021:9971799. [PMID: 34457090 DOI: 10.1155/2021/9971799] [Reference Citation Analysis]
37 Chen X, Liao L, Li Y, Huang H, Huang Q, Deng S. Screening and Functional Prediction of Key Candidate Genes in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Biomed Res Int 2020;2020:7653506. [PMID: 33102593 DOI: 10.1155/2020/7653506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Zeng X, Tan C, Mo M, Qin X, Ma X, Huang K, Wang X, Liang W, Yang L. CircRNA profiling identifies circRNF180 as a tumor suppressor in hepatocellular carcinoma. Epigenomics 2021;13:513-30. [PMID: 33683141 DOI: 10.2217/epi-2020-0385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Al-Khaykanee AM, Abdel-Rahman AA, Essa A, Gadallah AA, Ali BH, Al-Aqar AA, Badr EAE, Shehab-Eldeen S. Genetic polymorphism of fibroblast growth factor receptor 2 and trinucleotide repeat-containing 9 influence the susceptibility to HCV-induced hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;45:101636. [PMID: 33740609 DOI: 10.1016/j.clinre.2021.101636] [Reference Citation Analysis]
40 Ma A, Biersack B, Goehringer N, Nitzsche B, Höpfner M. Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma. JPM 2022;12:738. [DOI: 10.3390/jpm12050738] [Reference Citation Analysis]
41 Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00078-x] [Reference Citation Analysis]
42 Xu Q, Xu H, Deng R, Li N, Mu R, Qi Z, Shen Y, Wang Z, Wen J, Zhao J, Weng D, Huang W. Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy. Front Cell Dev Biol 2021;9:669145. [PMID: 34422799 DOI: 10.3389/fcell.2021.669145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Jin C, Li Y, Su Y, Guo Z, Wang X, Wang S, Zhang F, Zhang Z, Shao J, Zheng S. Novel copper complex CTB regulates methionine cycle induced TERT hypomethylation to promote HCC cells senescence via mitochondrial SLC25A26. Cell Death Dis 2020;11:844. [PMID: 33041323 DOI: 10.1038/s41419-020-03048-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Chen J, Wang H, Zhou L, Liu Z, Chen H, Tan X. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma. Cancer Med 2022. [PMID: 35560794 DOI: 10.1002/cam4.4812] [Reference Citation Analysis]
45 Niu X, Wang W, Liang T, Li S, Yang C, Xu X, Li L, Liu S. CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer. Cancer Sci 2021. [PMID: 34727389 DOI: 10.1111/cas.15190] [Reference Citation Analysis]
46 Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O'Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat Cancer 2021;2:891-903. [PMID: 34796337 DOI: 10.1038/s43018-021-00234-4] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Boey A, Ho HK. All Roads Lead to the Liver: Metal Nanoparticles and Their Implications for Liver Health. Small 2020;16:2000153. [DOI: 10.1002/smll.202000153] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
48 Yamamoto M, Kobayashi T, Honmyo N, Oshita A, Abe T, Kohashi T, Onoe T, Fukuda S, Omori I, Imaoka Y, Ohdan H. Liver resection is associated with good outcomes for hepatocellular carcinoma patients beyond the Barcelona Clinic Liver Cancer criteria: A multicenter study with the Hiroshima Surgical study group of Clinical Oncology. Surgery 2021:S0039-6060(21)00891-6. [PMID: 34756748 DOI: 10.1016/j.surg.2021.09.009] [Reference Citation Analysis]
49 Shen S, Yan J, Zhang Y, Dong Z, Xing J, He Y. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma. Ann Transl Med 2021;9:59. [PMID: 33553352 DOI: 10.21037/atm-20-7396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
50 Fishbein A, Wang W, Yang H, Yang J, Hallisey VM, Deng J, Verheul SML, Hwang SH, Gartung A, Wang Y, Bielenberg DR, Huang S, Kieran MW, Hammock BD, Panigrahy D. Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression. Proc Natl Acad Sci U S A 2020;117:21576-87. [PMID: 32801214 DOI: 10.1073/pnas.2007412117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
51 Ding Y, Sun Z, Zhang S, Li Y, Han X, Xu Q, Zhou L, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:7020637. [PMID: 34195281 DOI: 10.1155/2021/7020637] [Reference Citation Analysis]
52 Akasu M, Shimada S, Kabashima A, Akiyama Y, Shimokawa M, Akahoshi K, Kudo A, Yamaoka S, Tanabe M, Tanaka S. Intrinsic activation of β-catenin signaling by CRISPR/Cas9-mediated exon skipping contributes to immune evasion in hepatocellular carcinoma. Sci Rep 2021;11:16732. [PMID: 34429454 DOI: 10.1038/s41598-021-96167-0] [Reference Citation Analysis]
53 Silva L, Egea J, Villanueva L, Ruiz M, Llopiz D, Repáraz D, Aparicio B, Lasarte-Cia A, Lasarte JJ, Ruiz de Galarreta M, Lujambio A, Sangro B, Sarobe P. Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses Against Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3397. [PMID: 33207844 DOI: 10.3390/cancers12113397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Abyadeh M, Meyfour A, Gupta V, Zabet Moghaddam M, Fitzhenry MJ, Shahbazian S, Hosseini Salekdeh G, Mirzaei M. Recent Advances of Functional Proteomics in Gastrointestinal Cancers- a Path towards the Identification of Candidate Diagnostic, Prognostic, and Therapeutic Molecular Biomarkers. Int J Mol Sci 2020;21:E8532. [PMID: 33198323 DOI: 10.3390/ijms21228532] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
56 Yin LC, Xiao G, Zhou R, Huang XP, Li NL, Tan CL, Xie FJ, Weng J, Liu LX. MicroRNA-361-5p Inhibits Tumorigenesis and the EMT of HCC by Targeting Twist1. Biomed Res Int 2020;2020:8891876. [PMID: 33381597 DOI: 10.1155/2020/8891876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Péneau C, Imbeaud S, La Bella T, Hirsch TZ, Caruso S, Calderaro J, Paradis V, Blanc JF, Letouzé E, Nault JC, Amaddeo G, Zucman-Rossi J. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut 2021:gutjnl-2020-323153. [PMID: 33563643 DOI: 10.1136/gutjnl-2020-323153] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
58 Xie C, Cao K, Peng D, Qin L. RPLP1 is highly expressed in hepatocellular carcinoma tissues and promotes proliferation, invasion and migration of human hepatocellular carcinoma Hep3b cells. Exp Ther Med 2021;22:752. [PMID: 34035849 DOI: 10.3892/etm.2021.10184] [Reference Citation Analysis]
59 Guo Y, Hu J, Zhao Z, Zhong G, Gong J, Cai D. Identification of a Prognostic Model Based on 2-Gene Signature and Analysis of Corresponding Tumor Microenvironment in Alcohol-Related Hepatocellular Carcinoma. Front Oncol 2021;11:719355. [PMID: 34646769 DOI: 10.3389/fonc.2021.719355] [Reference Citation Analysis]
60 Zheng J, Gong GG, Zheng SJ, Zhang Y, Feng YQ. High Coverage Profiling of Carboxylated Metabolites in HepG2 Cells Using Secondary Amine-Assisted Ultrahigh-Performance Liquid Chromatography Coupled to High-Resolution Mass Spectrometry. Anal Chem 2021;93:1604-11. [PMID: 33356171 DOI: 10.1021/acs.analchem.0c04048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Zhang C, Yang M. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3740. [PMID: 34359642 DOI: 10.3390/cancers13153740] [Reference Citation Analysis]
62 Merle P. The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:E238. [PMID: 33440630 DOI: 10.3390/cancers13020238] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
63 Dai X, Guo Y, Hu Y, Bao X, Zhu X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Fang W. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics 2021;11:3489-501. [PMID: 33537099 DOI: 10.7150/thno.54648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
64 Yan Q, Tang Y, He F, Xue J, Zhou R, Zhang X, Luo H, Zhou D, Wang X. Global analysis of DNA methylation in hepatocellular carcinoma via a whole-genome bisulfite sequencing approach. Genomics 2021;113:3618-34. [PMID: 34461228 DOI: 10.1016/j.ygeno.2021.08.024] [Reference Citation Analysis]
65 Zhang Y, Li L, Liu R, Zeng C. DNA Primase Subunit 1 Expression in Hepatocellular Carcinoma and Its Clinical Implication. Biomed Res Int 2020;2020:9689312. [PMID: 32908930 DOI: 10.1155/2020/9689312] [Reference Citation Analysis]
66 Diao YK, Liu JW, Wu H, Wang MD, Fan XP, Chen TH, Wang JY, Zhou YH, Gu WM, Wang H, Li J, Liang YJ, Chen ZY, Lau WY, Liang L, Li C, Zhang CW, Shen F, Huang DS, Yang T. Long-term oncologic outcomes of liver resection for hepatocellular carcinoma in adolescents and young adults: A multicenter study from A hepatitis B virus-endemic area. Am J Surg 2021:S0002-9610(21)00123-9. [PMID: 33741185 DOI: 10.1016/j.amjsurg.2021.03.009] [Reference Citation Analysis]
67 Tang X, Liu B, Zhang C, Tang W, Liang S, Xiao Y, Deng R, Li Z. SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway. Front Oncol 2021;11:773045. [PMID: 34950583 DOI: 10.3389/fonc.2021.773045] [Reference Citation Analysis]
68 Zheng Q, Zhang Q, Yu X, He Y, Guo W. FENDRR: A pivotal, cancer-related, long non-coding RNA. Biomed Pharmacother 2021;137:111390. [PMID: 33761608 DOI: 10.1016/j.biopha.2021.111390] [Reference Citation Analysis]
69 Cao P, Ma B, Sun D, Zhang W, Qiu J, Qin L, Xue X. hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR-139-3p/CCL5 axis. Cancer Sci 2021. [PMID: 34890089 DOI: 10.1111/cas.15238] [Reference Citation Analysis]
70 Lee YT, Tran BV, Wang JJ, Liang IY, You S, Zhu Y, Agopian VG, Tseng HR, Yang JD. The Role of Extracellular Vesicles in Disease Progression and Detection of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3076. [PMID: 34203086 DOI: 10.3390/cancers13123076] [Reference Citation Analysis]
71 Perumalswami PV, Wyatt B, Bowman CA, Patel K, Mageras A, Lewis SC, Branch AD. Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C. Cancer Med 2022. [PMID: 35261196 DOI: 10.1002/cam4.4508] [Reference Citation Analysis]
72 Xu G, Zhou X, Xing J, Xiao Y, Jin B, Sun L, Yang H, Du S, Xu H, Mao Y. Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma. Cancer Cell Int 2020;20:547. [PMID: 33292241 DOI: 10.1186/s12935-020-01638-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
73 Yuen SC, Amaefule AQ, Kim HH, Owoo BV, Gorman EF, Mattingly TJ 2nd. A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment. Pharmacoecon Open 2021. [PMID: 34427897 DOI: 10.1007/s41669-021-00298-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Tao L, Wang S, Yang L, Jiang L, Li J, Wang X. Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma. Clin Exp Immunol 2020;201:161-70. [PMID: 32319079 DOI: 10.1111/cei.13444] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
75 Iacuzzi V, Zanchetta M, Gagno S, Poetto AS, Orleni M, Marangon E, Guardascione M, Foltran L, Posocco B, Toffoli G. A LC–MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma. Journal of Pharmaceutical and Biomedical Analysis 2020;187:113358. [DOI: 10.1016/j.jpba.2020.113358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
76 Du X, Guo CN, Bao XD. A Powerful Nomogram Based on the Novel D-Index to Predict Prognosis After Surgical Resection of Hepatocellular Carcinoma. Cancer Manag Res 2021;13:2581-94. [PMID: 33762849 DOI: 10.2147/CMAR.S305253] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Long G, Fang T, Su W, Mi X, Zhou L. The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma. Scand J Gastroenterol 2020;55:1441-6. [PMID: 33119422 DOI: 10.1080/00365521.2020.1839127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Gong J, Li R, Chen Y, Zhuo Z, Chen S, Cao J, Zhang Q, Chong Y, Hu B. HCC subtypes based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues. Brief Bioinform 2021:bbaa427. [PMID: 33515024 DOI: 10.1093/bib/bbaa427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Topel H, Bagirsakci E, Comez D, Bagci G, Cakan-Akdogan G, Atabey N. lncRNA HOTAIR overexpression induced downregulation of c-Met signaling promotes hybrid epithelial/mesenchymal phenotype in hepatocellular carcinoma cells. Cell Commun Signal 2020;18:110. [PMID: 32650779 DOI: 10.1186/s12964-020-00602-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
80 Li W, Wu H, Xu X, Zhang Y. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations. Aging (Albany NY) 2021;13:11564-94. [PMID: 33867349 DOI: 10.18632/aging.202853] [Reference Citation Analysis]
81 Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, Zhang X, Bu X, He W, Wan G. RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J 2020;39:e103181. [PMID: 32368828 DOI: 10.15252/embj.2019103181] [Cited by in Crossref: 41] [Cited by in F6Publishing: 48] [Article Influence: 20.5] [Reference Citation Analysis]
82 Yin L, Zhou L, Gao S, Feng Y, Zhu H, Xiang J, Xu R. Classification of Hepatocellular Carcinoma Based on N6-Methylandenosine–Related lncRNAs Profiling. Front Mol Biosci 2022;9:807418. [DOI: 10.3389/fmolb.2022.807418] [Reference Citation Analysis]
83 Li Q, Sun M, Wang M, Feng M, Yang F, Li L, Zhao J, Chang C, Dong H, Xie T, Chen J. Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application. Cancer Sci 2021;112:1695-706. [PMID: 33605517 DOI: 10.1111/cas.14861] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
84 He Z, Tian M, Fu X. Reduced expression of miR-30c-5p promotes hepatocellular carcinoma progression by targeting RAB32. Mol Ther Nucleic Acids 2021;26:603-12. [PMID: 34703646 DOI: 10.1016/j.omtn.2021.08.033] [Reference Citation Analysis]
85 Chang Y, Liu Q, Zhou Z, Ding Y, Yang M, Xu W, Chen K, Zhang Q, Wang Z, Li H. Can Statin Treatment Reduce the Risk of Hepatocellular Carcinoma? A Systematic Review and Meta-Analysis. Technol Cancer Res Treat 2020;19:1533033820934881. [PMID: 32552476 DOI: 10.1177/1533033820934881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Lin ZZ, Bo N, Fan YC, Wu YT, Yao HL, Chen S, Yu HF, Jiang LH. Xanthomicrol suppresses human hepatocellular carcinoma cells migration and invasion ability via Μu-opioid receptor. J Pharm Pharmacol 2021:rgab104. [PMID: 34355768 DOI: 10.1093/jpp/rgab104] [Reference Citation Analysis]
87 Kabashima A, Shimada S, Shimokawa M, Akiyama Y, Tanabe M, Tanaka S. Molecular and immunological paradigms of hepatocellular carcinoma: Special reference to therapeutic approaches. J Hepatobiliary Pancreat Sci 2021;28:62-75. [PMID: 33259135 DOI: 10.1002/jhbp.874] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
88 Liu S, Nalesnik MA, Singhi A, Wood-Trageser MA, Randhawa P, Ren BG, Humar A, Liu P, Yu YP, Tseng GC, Michalopoulos G, Luo JH. Transcriptome and Exome Analyses of Hepatocellular Carcinoma Reveal Patterns to Predict Cancer Recurrence in Liver Transplant Patients. Hepatol Commun 2021. [PMID: 34725972 DOI: 10.1002/hep4.1846] [Reference Citation Analysis]
89 Shen R, Ke L, Li Q, Dang X, Shen S, Shen J, Li S, Liang L, Peng B, Kuang M, Ma Y, Yang Z, Hua Y. Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma. Hepatol Int 2022. [PMID: 35211843 DOI: 10.1007/s12072-022-10299-7] [Reference Citation Analysis]
90 Wu R, Fan X, Wang Y, Shen M, Zheng Y, Zhao S, Yang L. Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy. Front Immunol 2022;13:833878. [DOI: 10.3389/fimmu.2022.833878] [Reference Citation Analysis]
91 Zhen Z, Shen Z, Sun P. Downregulation of Low-density lipoprotein receptor-related protein 1B (LRP1B) inhibits the progression of hepatocellular carcinoma cells by activating the endoplasmic reticulum stress signaling pathway. Bioengineered 2022;13:9467-81. [PMID: 35389768 DOI: 10.1080/21655979.2022.2060778] [Reference Citation Analysis]
92 Zhang Y, Yu H, Fu S, Tan L, Liu J, Zhou B, Li L, Liu Y, Wang C, Li P, Liu J. Synthesis and Anti-Hepatocarcinoma Effect of Amino Acid Derivatives of Pyxinol and Ocotillol. Molecules 2021;26:780. [PMID: 33546225 DOI: 10.3390/molecules26040780] [Reference Citation Analysis]
93 Wang Y, Gao R, Li J, Tang S, Li S, Tong Q, Li S. Downregulation of hsa_circ_0074854 Suppresses the Migration and Invasion in Hepatocellular Carcinoma via Interacting with HuR and via Suppressing Exosomes-Mediated Macrophage M2 Polarization. Int J Nanomedicine 2021;16:2803-18. [PMID: 33880025 DOI: 10.2147/IJN.S284560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Xiaoyun S, Yuyuan Z, Jie X, Yingjie N, Qing X, Yuezhen D, Haiguang X. PHF19 activates hedgehog signaling and promotes tumorigenesis in hepatocellular carcinoma. Exp Cell Res 2021;406:112690. [PMID: 34129846 DOI: 10.1016/j.yexcr.2021.112690] [Reference Citation Analysis]
95 Huang A, Guo DZ, Wang YP, Yang GH, Sun QM, Zhang X, He YF, Song K, Huang XW, Yang XR, Fan J, Zhou J, Hu J. Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation. J Cancer 2021;12:7190-200. [PMID: 34729120 DOI: 10.7150/jca.59612] [Reference Citation Analysis]
96 Mu W, Guo L, Liu Y, Yang H, Ning S, Lv G. Long Noncoding RNA SNHG1 Regulates LMNB2 Expression by Sponging miR-326 and Promotes Cancer Growth in Hepatocellular Carcinoma. Front Oncol 2021;11:784067. [PMID: 34917510 DOI: 10.3389/fonc.2021.784067] [Reference Citation Analysis]
97 Taye BW, Clark PJ, Hartel G, Powell EE, Valery PC. Remoteness of residence predicts tumor stage, receipt of treatment, and mortality in patients with hepatocellular carcinoma. JGH Open 2021;5:754-62. [PMID: 34263069 DOI: 10.1002/jgh3.12580] [Reference Citation Analysis]
98 Lin Y, Zhu J, Pan L, Zhang J, Tan Z, Olivares J, Singal AG, Parikh ND, Lubman DM. A Panel of Glycopeptides as Candidate Biomarkers for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation. J Proteome Res 2021;20:3278-89. [PMID: 33929864 DOI: 10.1021/acs.jproteome.1c00175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Zhou Y, Lin B, Li K, Zhao Y, Sun Z, He C, Jha RK. Preparation of Near-Infrared/Photoacoustic Dual-Mode Imaging and Photothermal/Chemo Synergistic Theranostic Nanoparticles and Their Imaging and Treating of Hepatic Carcinoma. Front Oncol 2021;11:750807. [PMID: 34604095 DOI: 10.3389/fonc.2021.750807] [Reference Citation Analysis]
100 Guo D, Zhang X, Cui H, Yu D, Zhang H, Shi X, Pang C, Li J, Guo W, Zhang S. ACADL Functions as a Tumor Suppressor in Hepatocellular Carcinoma Metastasis by Inhibiting Matrix Metalloproteinase 14. Front Oncol 2022;12:821484. [DOI: 10.3389/fonc.2022.821484] [Reference Citation Analysis]
101 Lee YT, Wang JJ, Luu M, Tseng HR, Rich NE, Lu SC, Nissen NN, Noureddin M, Singal AG, Yang JD. State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States. Hepatology 2021. [PMID: 33728665 DOI: 10.1002/hep.31811] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Yan J, Cao J, Chen Z. Mining prognostic markers of Asian hepatocellular carcinoma patients based on the apoptosis-related genes. BMC Cancer 2021;21:175. [PMID: 33602168 DOI: 10.1186/s12885-021-07886-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Yang WJ, Sun YF, Jin AL, Lv LH, Zhu J, Wang BL, Zhou Y, Zhang CY, Wang H, Hu B, Wang PX, Te L, Pan BS, Zhou J, Fan J, Yang XR, Guo W. BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. Cell Death Dis 2020;11:895. [PMID: 33093445 DOI: 10.1038/s41419-020-03115-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
104 Liu ZG, Chen XH, Yu ZJ, Lv J, Ren ZG. Recent progress in pulsed electric field ablation for liver cancer. World J Gastroenterol 2020; 26(24): 3421-3431 [PMID: 32655266 DOI: 10.3748/wjg.v26.i24.3421] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Escaliante LADS, Busato B, Petkowicz CLO, Cadena SMSC, Noleto GR. Cytotoxic effect of xyloglucan and oxovanadium (IV/V) xyloglucan complex in HepG2 cells. Int J Biol Macromol 2021;185:40-8. [PMID: 34144065 DOI: 10.1016/j.ijbiomac.2021.06.089] [Reference Citation Analysis]
106 Ezhilarasan D. Advantages and challenges in nanomedicines for chronic liver diseases: A hepatologist's perspectives. Eur J Pharmacol 2021;893:173832. [PMID: 33359144 DOI: 10.1016/j.ejphar.2020.173832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Shrestha R, Bridle KR, Cao L, Crawford DHG, Jayachandran A. Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells. Curr Oncol 2021;28:2150-72. [PMID: 34208001 DOI: 10.3390/curroncol28030200] [Reference Citation Analysis]
108 Krupenko NI, Sharma J, Fogle HM, Pediaditakis P, Strickland KC, Du X, Helke KL, Sumner S, Krupenko SA. Knockout of Putative Tumor Suppressor Aldh1l1 in Mice Reprograms Metabolism to Accelerate Growth of Tumors in a Diethylnitrosamine (DEN) Model of Liver Carcinogenesis. Cancers (Basel) 2021;13:3219. [PMID: 34203215 DOI: 10.3390/cancers13133219] [Reference Citation Analysis]
109 Gao Y, Liu J, Zhao D, Diao G. A Novel Prognostic Model for Identifying the Risk of Hepatocellular Carcinoma Based on Angiogenesis Factors. Front Genet 2022;13:857215. [DOI: 10.3389/fgene.2022.857215] [Reference Citation Analysis]
110 Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S. Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. Br J Cancer 2021;125:190-9. [PMID: 33824476 DOI: 10.1038/s41416-021-01334-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Oh H, Lee JH. Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. Ann Transl Med 2020;8:1530. [PMID: 33313275 DOI: 10.21037/atm-20-3526] [Reference Citation Analysis]
112 Feng S, Ding Z, Wang J, Qian Z, Li S, Zhang C, Xin H, Liu S, Ding G, Hu M, Meng Y, Li N. Investigation of Plasma cell-free cancer genome chromosomal instability as a tool for targeted minimally invasive biomarkers for primary liver cancer diagnoses. Cancer Med 2020;9:5075-85. [PMID: 32458568 DOI: 10.1002/cam4.3142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
113 Shetty S, U A, Kumar R, Bharati S. Electrical conductivity spectra of hepatic tumors reflect hepatocellular carcinoma progression in mice. Biomed Phys Eng Express 2020;6. [PMID: 35062002 DOI: 10.1088/2057-1976/abbbd5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Wei Y, Wang Y, Liu N, Qi R, Xu Y, Li K, Feng Y, Shi B. A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model. Front Pharmacol 2022;12:820446. [DOI: 10.3389/fphar.2021.820446] [Reference Citation Analysis]
115 King MJ, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. European Journal of Radiology 2020;133:109351. [DOI: 10.1016/j.ejrad.2020.109351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Lv W, Yao Q, Wang F. A Novel Hypoxic-Angiogenesis-Immune-Related Gene Model for Prognostic and Therapeutic Effect Prediction in Hepatocellular Carcinoma Patients. Disease Markers 2022;2022:1-27. [DOI: 10.1155/2022/9428660] [Reference Citation Analysis]
117 Marquardt P, Liu PH, Immergluck J, Olivares J, Arroyo A, Rich NE, Parikh ND, Yopp AC, Singal AG. Hepatocellular Carcinoma Screening Process Failures in Patients with Cirrhosis. Hepatol Commun 2021;5:1481-9. [PMID: 34510836 DOI: 10.1002/hep4.1735] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Wang G, Jiang Y, Lu C, Jiang W, Wu S, Hua Y. CircFOXM1 promotes proliferation and metastasis of hepatocellular carcinoma via regulating miR-1179/SPAG5 axis. Sci Rep 2021;11:23890. [PMID: 34903799 DOI: 10.1038/s41598-021-03285-w] [Reference Citation Analysis]
119 Ghaderi-Zefrehi H, Rezaei M, Sadeghi F, Heiat M. Genetic polymorphisms in DNA repair genes and hepatocellular carcinoma risk. DNA Repair (Amst) 2021;107:103196. [PMID: 34416543 DOI: 10.1016/j.dnarep.2021.103196] [Reference Citation Analysis]
120 Petkevich AA, Abramov AA, Pospelov VI, Malinina NA, Kuhareva EI, Mazurchik NV, Tarasova OI. Exosomal and non-exosomal miRNA expression levels in patients with HCV-related cirrhosis and liver cancer. Oncotarget 2021;12:1697-706. [PMID: 34434498 DOI: 10.18632/oncotarget.28036] [Reference Citation Analysis]
121 Wang Y, Li N, Tian D, Zhou CW, Wang YH, Yang C, Zeng MS. Analysis of m6A-Related lncRNAs for Prognosis Value and Response to Immune Checkpoint Inhibitors Therapy in Hepatocellular Carcinoma. Cancer Manag Res 2021;13:6451-71. [PMID: 34429653 DOI: 10.2147/CMAR.S322179] [Reference Citation Analysis]
122 Hu Y, Qiu W, Kong Z, Wu S, Liu Y, Zhu C, Qin X. LncRNA GSTM3TV2 Promotes Cell Proliferation and Invasion via miR-597/FOSL2 Axis in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:3445970. [PMID: 34458365 DOI: 10.1155/2021/3445970] [Reference Citation Analysis]
123 Zhang Z, Tan X, Luo J, Yao H, Si Z, Tong JS. The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma. Cell Death Dis 2020;11:902. [PMID: 33097691 DOI: 10.1038/s41419-020-03123-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
124 Zhang L, Li Y, Dai Y, Wang D, Wang X, Cao Y, Liu W, Tao Z. Glycolysis-related gene expression profiling serves as a novel prognosis risk predictor for human hepatocellular carcinoma. Sci Rep 2021;11:18875. [PMID: 34556750 DOI: 10.1038/s41598-021-98381-2] [Reference Citation Analysis]
125 Zhou QM, Lu YF, Zhou JP, Yang XY, Wang XJ, Yu JN, Du YZ, Yu RS. Self-amplification of oxidative stress with tumour microenvironment-activatable iron-doped nanoplatform for targeting hepatocellular carcinoma synergistic cascade therapy and diagnosis. J Nanobiotechnology 2021;19:361. [PMID: 34749740 DOI: 10.1186/s12951-021-01102-0] [Reference Citation Analysis]
126 Wang X, He S, Zheng X, Huang S, Chen H, Chen H, Luo W, Guo Z, He X, Zhao Q. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma. BMC Cancer 2021;21:1001. [PMID: 34493238 DOI: 10.1186/s12885-021-08699-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Azbazdar Y, Karabicici M, Erdal E, Ozhan G. Regulation of Wnt Signaling Pathways at the Plasma Membrane and Their Misregulation in Cancer. Front Cell Dev Biol 2021;9:631623. [PMID: 33585487 DOI: 10.3389/fcell.2021.631623] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
128 Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2021:S0168-8278(21)02037-7. [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Zhang D, Lin Z, Wu M, Cai Z, Zheng Y, He L, Li Z, Zhou J, Sun L, Chen G, Zeng Y, Li J, Liu J, Yang H, Liu X. Cytosolic Delivery of Thiolated Neoantigen Nano-Vaccine Combined with Immune Checkpoint Blockade to Boost Anti-Cancer T Cell Immunity. Adv Sci (Weinh) 2021;8:2003504. [PMID: 33747739 DOI: 10.1002/advs.202003504] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
130 Cooke P, Sindhu KK, Lehrer EJ, Maron SZ, Rosenzweig KE, Buckstein M. Palliating Symptoms in Patients With Hepatocellular Carcinoma Involving the Inferior Vena Cava With External Beam Radiation Therapy. Cureus 2021;13:e14107. [PMID: 33927921 DOI: 10.7759/cureus.14107] [Reference Citation Analysis]
131 Huang DQ, Hoang JK, Leong J, Riveiro-Barciela M, Maeda M, Yang JD, Accarino EV, Thin K, Trinh L, Cheung RC, Roberts LR, Buti M, Schwartz M, Nguyen MH. Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Liver Int 2021;41:1922-32. [PMID: 33713386 DOI: 10.1111/liv.14877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Sung PS, Choi MH, Yang H, Lee SK, Chun HJ, Jang JW, Choi JY, Yoon SK, Choi JI, Lee YJ, Bae SH. Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Front Oncol 2020;10:600233. [PMID: 33330098 DOI: 10.3389/fonc.2020.600233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Xiao H, Li X, Zheng C, Liu Q, Sun C, Huang J, Wang Y, Yuan Y. Intracellular pH-responsive polymeric micelle for simultaneous chemotherapy and MR imaging of hepatocellular carcinoma. J Nanopart Res 2020;22. [DOI: 10.1007/s11051-020-04821-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
134 Chi F, Cao Y, Chen Y. Analysis and Validation of circRNA-miRNA Network in Regulating m6A RNA Methylation Modulators Reveals CircMAP2K4/miR-139-5p/YTHDF1 Axis Involving the Proliferation of Hepatocellular Carcinoma. Front Oncol 2021;11:560506. [PMID: 33708621 DOI: 10.3389/fonc.2021.560506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Chen JG, Zhu J, Zhang YH, Chen YS, Lu JH, Zhu YR, Chen HZ, Shen AG, Wang GR, Groopman JD, Kensler TW. Liver cancer mortality over six decades in an epidemic area: what we have learned. PeerJ 2021;9:e10600. [PMID: 33604165 DOI: 10.7717/peerj.10600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
136 Bean J, Mohan RD. Hepatocellular carcinoma reduces ATXN7L3 to evade estrogen-dependent growth suppression. EBioMedicine 2021;63:103179. [PMID: 33340995 DOI: 10.1016/j.ebiom.2020.103179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Zheng G, Sundquist K, Sundquist J, Chen T, Försti A, Hemminki A, Liska V, Hemminki K. Second Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers. Clin Epidemiol 2021;13:683-91. [PMID: 34377034 DOI: 10.2147/CLEP.S318737] [Reference Citation Analysis]
138 Tayarani-Najaran Z, Tayarani-Najaran N, Eghbali S. A Review of Auraptene as an Anticancer Agent. Front Pharmacol 2021;12:698352. [PMID: 34239445 DOI: 10.3389/fphar.2021.698352] [Reference Citation Analysis]
139 Meng F, Zhang H, Peng H, Lu S. Comparison of 10-Year Survival Outcomes for Early Single Hepatocellular Carcinoma following Different Treatments. Biomed Res Int 2021;2021:6638117. [PMID: 34150908 DOI: 10.1155/2021/6638117] [Reference Citation Analysis]
140 Niu B, Wei S, Sun J, Zhao H, Wang B, Chen G. Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation. Pharm Biol 2022;60:75-86. [PMID: 34962429 DOI: 10.1080/13880209.2021.2017468] [Reference Citation Analysis]
141 Mehta V, Chander H, Munshi A. Complex roles of discoidin domain receptor tyrosine kinases in cancer. Clin Transl Oncol 2021;23:1497-510. [PMID: 33634432 DOI: 10.1007/s12094-021-02552-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Tang M, Hu X, Wang Y, Yao X, Zhang W, Yu C, Cheng F, Li J, Fang Q. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res 2021;163:105207. [PMID: 32971268 DOI: 10.1016/j.phrs.2020.105207] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
143 Kim BH. How long should physicians follow up with patients after curative treatment for hepatocellular carcinoma? Clin Mol Hepatol 2019;26:579-81. [PMID: 32962329 DOI: 10.3350/cmh.2020.0200] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
144 Lei D, Chen Y, Zhou Y, Hu G, Luo F. A Starvation-Based 9-mRNA Signature Correlates With Prognosis in Patients With Hepatocellular Carcinoma. Front Oncol 2021;11:716757. [PMID: 34900672 DOI: 10.3389/fonc.2021.716757] [Reference Citation Analysis]
145 Li S, Zhao J, Lv L, Dong D. Identification and Validation of TYMS as a Potential Biomarker for Risk of Metastasis Development in Hepatocellular Carcinoma. Front Oncol 2021;11:762821. [PMID: 34858842 DOI: 10.3389/fonc.2021.762821] [Reference Citation Analysis]
146 Wei J, Cui W, Fan W, Wang Y, Li J. Unresectable Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Combined With Microwave Ablation vs. Combined With Cryoablation. Front Oncol 2020;10:1285. [PMID: 32850395 DOI: 10.3389/fonc.2020.01285] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Lu J, Qian J, Yin S, Zhou L, Zheng S, Zhang W. Mechanisms of RNA N6-Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology. Front Oncol 2020;10:1105. [PMID: 32733807 DOI: 10.3389/fonc.2020.01105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
148 Zhou L, Wang J, Lyu SC, Pan LC, Shi XJ, Du GS, He Q. PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma. Technol Cancer Res Treat 2021;20:15330338211045820. [PMID: 34605709 DOI: 10.1177/15330338211045820] [Reference Citation Analysis]
149 Li F, Liu CS, Wu P, Ling AS, Pan Q, Li XN. CCT4 suppression inhibits tumor growth in hepatocellular carcinoma by interacting with Cdc20. Chin Med J (Engl) 2021;134:2721-9. [PMID: 34732665 DOI: 10.1097/CM9.0000000000001851] [Reference Citation Analysis]
150 Hao F, Wang N, Wang X, Chen Y, Wang J. Identification of prognostic long non-coding RNA signature with potential drugs in hepatocellular carcinoma. Aging (Albany NY) 2021;13:18789-805. [PMID: 34285143 DOI: 10.18632/aging.203322] [Reference Citation Analysis]
151 Wang J, Li J, Chen L, Fan Z, Cheng J. MicroRNA-499 Suppresses the Growth of Hepatocellular Carcinoma by Downregulating Astrocyte Elevated Gene-1. Technol Cancer Res Treat 2020;19:1533033820920253. [PMID: 32691684 DOI: 10.1177/1533033820920253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
152 Wang H, Yu S, Cai Q, Ma D, Yang L, Zhao J, Jiang L, Zhang X, Yu Z. The Prognostic Model Based on Tumor Cell Evolution Trajectory Reveals a Different Risk Group of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:737723. [PMID: 34660596 DOI: 10.3389/fcell.2021.737723] [Reference Citation Analysis]
153 Wei R, Zhu WW, Yu GY, Wang X, Gao C, Zhou X, Lin ZF, Shao WQ, Wang SH, Lu M, Qin LX. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma. Int J Cancer 2021;148:1233-44. [PMID: 33205453 DOI: 10.1002/ijc.33371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Karabicici M, Azbazdar Y, Ozhan G, Senturk S, Firtina Karagonlar Z, Erdal E. Changes in Wnt and TGF-β Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7. Front Cell Dev Biol 2021;9:639779. [PMID: 34458250 DOI: 10.3389/fcell.2021.639779] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Murakami K, Kumata H, Miyagi S, Kamei T, Sasano H. The prognostic significance of neuroendocrine markers and somatostatin receptor 2 in hepatocellular carcinoma. Pathol Int 2021. [PMID: 34320691 DOI: 10.1111/pin.13149] [Reference Citation Analysis]
156 Chan LK, Tsui YM, Ho DW, Ng IO. Cellular heterogeneity and plasticity in liver cancer. Semin Cancer Biol 2021:S1044-579X(21)00050-X. [PMID: 33647386 DOI: 10.1016/j.semcancer.2021.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
157 da Silva EFG, Lima KG, Krause GC, Haute GV, Pedrazza L, Catarina AV, Gassen RB, de Souza Basso B, Dias HB, Luft C, Garcia MCR, Costa BP, Antunes GL, Basso LA, Donadio MVF, Machado P, de Oliveira JR. CPBMF65, a synthetic human uridine phosphorylase-1 inhibitor, reduces HepG2 cell proliferation through cell cycle arrest and senescence. Invest New Drugs 2020;38:1653-63. [DOI: 10.1007/s10637-020-00941-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Chen L, Zhou J, Deng Q, Feng J, Qiu Q, Huang W, Chen Y, Li Y. Ultrasound-visualized, site-specific vascular embolization using magnetic protein microcapsules. J Mater Chem B 2021;9:2407-16. [PMID: 33623935 DOI: 10.1039/d0tb02715d] [Reference Citation Analysis]
159 Deng L, Huang S, Chen B, Tang Y, Huang F, Li D, Tang D. Tumor-Linked Macrophages Promote HCC Development by Mediating the CCAT1/Let-7b/HMGA2 Signaling Pathway. Onco Targets Ther 2020;13:12829-43. [PMID: 33363387 DOI: 10.2147/OTT.S283786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
160 He Z, Bao K, Zhang J, Ju D, Luo M, Liu L, Gao X. Multifunctional nanoparticles for targeted delivery of apoptin plasmid in cancer treatment. e-Polymers 2022;22:342-56. [DOI: 10.1515/epoly-2022-0020] [Reference Citation Analysis]
161 Lan W, Santofimia-Castaño P, Xia Y, Zhou Z, Huang C, Fraunhoffer N, Barea D, Cervello M, Giannitrapani L, Montalto G, Peng L, Iovanna J. Targeting NUPR1 with the small compound ZZW-115 is an efficient strategy to treat hepatocellular carcinoma. Cancer Lett 2020;486:8-17. [PMID: 32446862 DOI: 10.1016/j.canlet.2020.04.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
162 Ma H, Li Z, Yuan J, Zhang L, Xie X, Yin X, Chen R, Ren Z. Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation. Gastroenterol Res Pract 2021;2021:8878417. [PMID: 33488700 DOI: 10.1155/2021/8878417] [Reference Citation Analysis]
163 Mehta R, Tang Qinghe, Tsilimigras DI, Paredes A, Dillhoff M, Cloyd JM, Ejaz A, Tsung A, Spolverato G, Pawlik TM. Long-term outcomes after resection of alcohol-related versus hepatitis-related hepatocellular carcinoma: A SEER-Medicare database analysis. Am J Surg 2021;222:167-72. [PMID: 33131693 DOI: 10.1016/j.amjsurg.2020.10.033] [Reference Citation Analysis]
164 Bai Y, Qi W, Liu L, Zhang J, Pang L, Gan T, Wang P, Wang C, Chen H. Identification of Seven-Gene Hypoxia Signature for Predicting Overall Survival of Hepatocellular Carcinoma. Front Genet 2021;12:637418. [PMID: 33912215 DOI: 10.3389/fgene.2021.637418] [Reference Citation Analysis]
165 Sartorius K, An P, Winkler C, Chuturgoon A, Li X, Makarova J, Kramvis A. The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma: The Influence of HBx and miRNA Dysregulation. Front Immunol 2021;12:661204. [PMID: 33995383 DOI: 10.3389/fimmu.2021.661204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Wang F, Xu C, Li G, Lv P, Gu J. Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma. Exp Cell Res 2021;409:112910. [PMID: 34801560 DOI: 10.1016/j.yexcr.2021.112910] [Reference Citation Analysis]
167 Xu M, Zhu S, Xu R, Lin N. Identification of CELSR2 as a novel prognostic biomarker for hepatocellular carcinoma. BMC Cancer 2020;20:313. [PMID: 32293343 DOI: 10.1186/s12885-020-06813-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
168 Iacobazzi RM, Vischio F, Arduino I, Canepa F, Laquintana V, Notarnicola M, Scavo MP, Bianco G, Fanizza E, Lopedota AA, Cutrignelli A, Lopalco A, Azzariti A, Curri ML, Franco M, Giannelli G, Lee BC, Depalo N, Denora N. Magnetic implants in vivo guiding sorafenib liver delivery by superparamagnetic solid lipid nanoparticles. J Colloid Interface Sci 2021;608:239-54. [PMID: 34626971 DOI: 10.1016/j.jcis.2021.09.174] [Reference Citation Analysis]
169 Shi GY, Sun Y, Liang XC, Xie JD. Clinical significance of expression of serum insulin-like growth factor-1 in patients with primary liver cancer and diabetes mellitus. Shijie Huaren Xiaohua Zazhi 2021; 29(5): 236-241 [DOI: 10.11569/wcjd.v29.i5.236] [Reference Citation Analysis]
170 Shan Y, Yang G, Huang H, Zhou Y, Hu X, Lu Q, Guo P, Hou J, Cao L, Tian F, Pan Q. Ubiquitin-Like Modifier Activating Enzyme 1 as a Novel Diagnostic and Prognostic Indicator That Correlates With Ferroptosis and the Malignant Phenotypes of Liver Cancer Cells. Front Oncol 2020;10:592413. [PMID: 33344241 DOI: 10.3389/fonc.2020.592413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
171 Rosas-Cruz A, Salinas-Jazmín N, Velázquez MAV. Dopamine Receptors in Cancer: Are They Valid Therapeutic Targets? Technol Cancer Res Treat 2021;20:15330338211027913. [PMID: 34212819 DOI: 10.1177/15330338211027913] [Reference Citation Analysis]
172 Ding Y, Sun Z, Zhang S, Han X, Li Y, Xu Q, Zhou L, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Down-regulation of small nuclear RNA (snRNA) RNU5E-1 in hepatocellular carcinoma presents with vital clinical significance. J Gastrointest Oncol 2020;11:738-46. [PMID: 32953157 DOI: 10.21037/jgo-20-49] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Huang Z, Wen J, Yu J, Liao J, Liu S, Cai N, Liang H, Chen X, Ding Z, Zhang B. MicroRNA-148a-3p inhibits progression of hepatocelluar carcimoma by repressing SMAD2 expression in an Ago2 dependent manner. J Exp Clin Cancer Res 2020;39:150. [PMID: 32746934 DOI: 10.1186/s13046-020-01649-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
174 Wang H, Li Y, Lu J, Qiu M, Cheng D, Zhang X, Yuan W. Shengbai decoction enhances the anti-tumor efficacy of cyclophosphamide on hepatoma 22-bearing mice. Biomed Pharmacother 2021;140:111775. [PMID: 34062413 DOI: 10.1016/j.biopha.2021.111775] [Reference Citation Analysis]
175 Pu J, Wu X, Wu Y, Shao Z, Luo C, Tang Q, Wang J, Wei H, Lu Y. Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1. Aging (Albany NY) 2021;13:12207-23. [PMID: 33952719 DOI: 10.18632/aging.103797] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 Lin S, Lin Y, Wu Z, Xia W, Miao C, Peng T, Zhao Z, Ji C, Mo Z, Liu X, Jian Z. circRPS16 Promotes Proliferation and Invasion of Hepatocellular Carcinoma by Sponging miR-876-5p to Upregulate SPINK1. Front Oncol 2021;11:724415. [PMID: 34595116 DOI: 10.3389/fonc.2021.724415] [Reference Citation Analysis]
177 Harada K, Ohashi R, Naito K, Kanki K. Hedgehog Signal Inhibitor GANT61 Inhibits the Malignant Behavior of Undifferentiated Hepatocellular Carcinoma Cells by Targeting Non-Canonical GLI Signaling. Int J Mol Sci 2020;21:E3126. [PMID: 32354204 DOI: 10.3390/ijms21093126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
178 Poch FGM, Eminger KJ, Neizert CA, Geyer B, Rieder C, Ballhausen H, Niehues SM, Vahldiek JL, Lehmann KS. Cooling Effects Occur in Hepatic Microwave Ablation At Low Vascular Flow Rates and in Close Proximity to Liver Vessels - Ex Vivo. Surg Innov 2022;:15533506221074619. [PMID: 35227134 DOI: 10.1177/15533506221074619] [Reference Citation Analysis]
179 Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M, Zannella C, Franci G. Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. Cancers (Basel) 2021;13:2761. [PMID: 34199429 DOI: 10.3390/cancers13112761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
180 Hong GQ, Cai D, Gong JP, Lai X. Innate immune cells and their interaction with T cells in hepatocellular carcinoma. Oncol Lett 2021;21:57. [PMID: 33281968 DOI: 10.3892/ol.2020.12319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
181 Huang Y, Tian H, Zhang M, He J, Liu J, Ni P. Monoclonal Antibody-conjugated Polyphosphoester-hyd-DOX Prodrug Nanoparticles for Targeted Chemotherapy of Liver Cancer Cells. Chin J Polym Sci 2021;39:1392-402. [DOI: 10.1007/s10118-021-2582-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Wang JW, Ma L, Liang Y, Yang XJ, Wei S, Peng H, Qiu SP, Lu X, Zhu YQ, Wang BL. RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC signaling via the IRE1α-XBP1s pathway. Cell Death Discov 2021;7:298. [PMID: 34663798 DOI: 10.1038/s41420-021-00696-6] [Reference Citation Analysis]
183 Gu Y, Wang C, Chen S, Tang J, Guo X, Hu W, Cui A, Zhang D, Yu K, Chen M. A Critical Role of Peptidylprolyl Isomerase A Pseudogene 22/microRNA-197-3p/Peptidylprolyl Isomerase A Axis in Hepatocellular Carcinoma. Front Genet 2021;12:604461. [PMID: 33790943 DOI: 10.3389/fgene.2021.604461] [Reference Citation Analysis]
184 Abouzed TK, Eldomany EB, Khatab SA, Aldhahrani A, Gouda WM, Elgazzar AM, Soliman MM, Kassab MA, El-Shazly SA, Althobaiti F, Dorghamm DA. The modulatory effect of bee honey against diethyl nitrosamine and carbon tetrachloride instigated hepatocellular carcinoma in Wistar rats. Toxicol Res (Camb) 2021;10:1092-103. [PMID: 34992771 DOI: 10.1093/toxres/tfab094] [Reference Citation Analysis]
185 Xu K, Wu CL, Wang ZX, Wang HJ, Yin FJ, Li WD, Liu CC, Fan HN. VEGF Family Gene Expression as Prognostic Biomarkers for Alzheimer's Disease and Primary Liver Cancer. Comput Math Methods Med 2021;2021:3422393. [PMID: 34845413 DOI: 10.1155/2021/3422393] [Reference Citation Analysis]
186 He J, Li G, Liu X, Ma L, Zhang P, Zhang J, Zheng S, Wang J, Liu J. Diagnostic and Prognostic Values of MANF Expression in Hepatocellular Carcinoma. Biomed Res Int 2020;2020:1936385. [PMID: 32382531 DOI: 10.1155/2020/1936385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
187 Omer DM, Dozier J, Cao Z, Zhu H, McCain DA. A case report on a large, peduncular intra-abdominal hepatocellular carcinoma extending into the retroperitoneum. Clin Case Rep 2021;9:1288-91. [PMID: 33768828 DOI: 10.1002/ccr3.3751] [Reference Citation Analysis]
188 He H, Yi Y, Cai X, Wang J, Ni X, Fu Y, Qiu S. Down-regulation of EOMES drives T-cell exhaustion via abolishing EOMES-mediated repression of inhibitory receptors of T cells in liver cancer. J Cell Mol Med 2021;25:161-9. [PMID: 33325636 DOI: 10.1111/jcmm.15898] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
189 Kim B, Kim SS, Cho SW, Cheong JY, Huh J, Kim JK, Lee JH, Ahn HR, Cho HJ. Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma. Eur Radiol 2021;31:2507-17. [PMID: 33033862 DOI: 10.1007/s00330-020-07357-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
190 Yang Z, Gimple RC, Zhou N, Zhao L, Gustafsson JÅ, Zhou S. Targeting Nuclear Receptors for Cancer Therapy: Premises, Promises, and Challenges. Trends Cancer 2021;7:541-56. [PMID: 33341430 DOI: 10.1016/j.trecan.2020.11.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
191 Xie J, Qi Z, Luo X, Yan F, Xing W, Zeng W, Chen D, Li Q. Integration Analysis of m6A Regulators and m6A-Related Genes in Hepatocellular Carcinoma. BIO Integration 2021;2:94-108. [DOI: 10.15212/bioi-2021-0002] [Reference Citation Analysis]
192 Aja I, Ruiz-Larrea MB, Courtois A, Krisa S, Richard T, Ruiz-Sanz JI. Screening of Natural Stilbene Oligomers from Vitis vinifera for Anticancer Activity on Human Hepatocellular Carcinoma Cells. Antioxidants (Basel) 2020;9:E469. [PMID: 32492881 DOI: 10.3390/antiox9060469] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
193 Kong J, Yao C, Dong S, Wu S, Xu Y, Li K, Ji L, Shen Q, Zhang Q, Zhan R, Cui H, Zhou C, Niu H, Li G, Sun W, Zheng L. ICAM-1 Activates Platelets and Promotes Endothelial Permeability through VE-Cadherin after Insufficient Radiofrequency Ablation. Adv Sci (Weinh) 2021;8:2002228. [PMID: 33643788 DOI: 10.1002/advs.202002228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
194 Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:13051. [PMID: 34884853 DOI: 10.3390/ijms222313051] [Reference Citation Analysis]
195 Zhang W, Liu Z, Chen J, Dong S, Cen B, Zheng S, Xu X. A preoperative model for predicting microvascular invasion and assisting in prognostic stratification in liver transplantation for HCC regarding empirical criteria. Transl Oncol 2021;14:101200. [PMID: 34399173 DOI: 10.1016/j.tranon.2021.101200] [Reference Citation Analysis]
196 Wembulua BS, Diallo K, Thioubou MA, Nguma JDB, Manga NM. Hepatitis B-related hepatocellular carcinoma in a 36-year-old pregnant woman: prognosis and management dilemma. Pan Afr Med J 2020;36:298. [PMID: 33117492 DOI: 10.11604/pamj.2020.36.298.22658] [Reference Citation Analysis]
197 Lee YT, Wang JJ, Luu M, Noureddin M, Kosari K, Agopian VG, Rich NE, Lu SC, Tseng HR, Nissen NN, Singal AG, Yang JD. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. J Natl Cancer Inst 2021:djab079. [PMID: 34010422 DOI: 10.1093/jnci/djab079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
198 Shen M, Zhang R, Jia W, Zhu Z, Zhao X, Zhao L, Huang G, Liu J. Nuclear scaffold protein p54nrb/NONO facilitates the hypoxia-enhanced progression of hepatocellular carcinoma. Oncogene 2021;40:4167-83. [PMID: 34079086 DOI: 10.1038/s41388-021-01848-9] [Reference Citation Analysis]
199 Lei D, Chen Y, Zhou Y, Hu G, Luo F. An angiogenesis-related long noncoding RNA signature correlates with prognosis in patients with hepatocellular carcinoma. Biosci Rep 2021;41:BSR20204442. [PMID: 33764367 DOI: 10.1042/BSR20204442] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
200 Rashdan HRM, Shehadi IA, Abdelmonsef AH. Synthesis, Anticancer Evaluation, Computer-Aided Docking Studies, and ADMET Prediction of 1,2,3-Triazolyl-Pyridine Hybrids as Human Aurora B Kinase Inhibitors. ACS Omega 2021;6:1445-55. [PMID: 33490804 DOI: 10.1021/acsomega.0c05116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
201 Rui T, Zhang X, Feng S, Huang H, Zhan S, Xie H, Zhou L, Ling Q, Zheng S. The Similar Effects of miR-512-3p and miR-519a-2-5p on the Promotion of Hepatocellular Carcinoma: Different Tunes Sung With Equal Skill. Front Oncol 2020;10:1244. [PMID: 32850377 DOI: 10.3389/fonc.2020.01244] [Reference Citation Analysis]
202 Huang C, Zhu XD, Shen YH, Wu D, Ji Y, Ge NL, Chen LL, Tan CJ, Zhou J, Fan J, Sun HC. Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomark Res 2021;9:19. [PMID: 33743822 DOI: 10.1186/s40364-021-00274-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
203 Hu K, Lu S, Li M, Zhang F, Tang B, Yuan J, Shan Y, Xu P, Chen R, Ren Z, Yin X. A Novel Pre-treatment Model Predicting Risk of Developing Refractoriness to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma. J Cancer 2020;11:4589-96. [PMID: 32489476 DOI: 10.7150/jca.44847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
204 Zhao M, Duan X, Mi L, Shi J, Li N, Yin X, Han X, Wang J, Han G, Hou J, Yin F. Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index. Future Oncol 2022;18:2269-88. [PMID: 35440159 DOI: 10.2217/fon-2021-1087] [Reference Citation Analysis]
205 Fu Y, Ci H, Du W, Dong Q, Jia H. CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity. Pharmaceutics 2022;14:275. [DOI: 10.3390/pharmaceutics14020275] [Reference Citation Analysis]
206 Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. Cancers (Basel) 2020;12:E1576. [PMID: 32549224 DOI: 10.3390/cancers12061576] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
207 Guo D, Zhang D, Ren M, Lu G, Zhang X, He S, Li Y. THBS4 promotes HCC progression by regulating ITGB1 via FAK/PI3K/AKT pathway. FASEB J 2020;34:10668-81. [PMID: 32567740 DOI: 10.1096/fj.202000043R] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
208 Lin Z, Xu Q, Miao D, Yu F. An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma. Front Oncol 2021;11:644416. [PMID: 33828988 DOI: 10.3389/fonc.2021.644416] [Reference Citation Analysis]
209 Kuznietsova H, Dziubenko N, Herheliuk T, Prylutskyy Y, Tauscher E, Ritter U, Scharff P. Water-Soluble Pristine C60 Fullerene Inhibits Liver Alterations Associated with Hepatocellular Carcinoma in Rat. Pharmaceutics 2020;12:E794. [PMID: 32842595 DOI: 10.3390/pharmaceutics12090794] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
210 Hong R, Gu J, Niu G, Hu Z, Zhang X, Song T, Han S, Hong L, Ke C. PRELP has prognostic value and regulates cell proliferation and migration in hepatocellular carcinoma. J Cancer 2020;11:6376-89. [PMID: 33033521 DOI: 10.7150/jca.46309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
211 Wu L, Feng J, Li J, Yu Q, Ji J, Wu J, Dai W, Guo C. The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomed Pharmacother 2021;133:111036. [PMID: 33378947 DOI: 10.1016/j.biopha.2020.111036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
212 Wang L, Rasul A, Liu Z, Pan Y, Wang W, Li J, Li X. The Loss of Masculine With Declined Serum DHT Is Associated With High Risk of Hepatocellular Carcinoma in Chinese Men. Front Endocrinol (Lausanne) 2020;11:362. [PMID: 32695068 DOI: 10.3389/fendo.2020.00362] [Reference Citation Analysis]
213 Shi L, Shang X, Nie K, Lin Z, Zheng M, Wang M, Yuan H, Zhu Z. Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma. J Clin Pathol 2021;74:504-12. [PMID: 33004423 DOI: 10.1136/jclinpath-2020-206979] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
214 Wang H, Du D, Huang J, Wang S, He X, Yuan S, Xiao J. GPR27 Regulates Hepatocellular Carcinoma Progression via MAPK/ERK Pathway. CMAR 2022;Volume 14:1165-77. [DOI: 10.2147/cmar.s335749] [Reference Citation Analysis]
215 Zhang Y, Wang Y. Circular RNAs in Hepatocellular Carcinoma: Emerging Functions to Clinical Significances. Front Oncol 2021;11:667428. [PMID: 34055634 DOI: 10.3389/fonc.2021.667428] [Reference Citation Analysis]
216 Li Y, Zhang R, Xu Z, Wang Z. Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer. IJN 2022;Volume 17:909-25. [DOI: 10.2147/ijn.s349426] [Reference Citation Analysis]
217 Zhang Y, Chen H, Chen S, Li W. Prognostic value of liver stiffness measurement in patients with hepatocellular carcinoma (HCC) treated by radiofrequency ablation: a meta-analysis. Int J Hyperthermia 2021;38:1052-9. [PMID: 34251953 DOI: 10.1080/02656736.2021.1947529] [Reference Citation Analysis]
218 Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Reference Citation Analysis]
219 Devan AR, Kumar AR, Nair B, Anto NP, Muraleedharan A, Mathew B, Kim H, Nath LR. Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma. Pharmaceuticals (Basel) 2021;14:656. [PMID: 34358082 DOI: 10.3390/ph14070656] [Reference Citation Analysis]
220 Liu P, Han B, Zhang Y, Wang X, Ahmad S. Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma. Computational Intelligence and Neuroscience 2022;2022:1-14. [DOI: 10.1155/2022/7102500] [Reference Citation Analysis]
221 Wang L, Li B, Yi X, Xiao X, Zheng Q, Ma L. Circ_0036412 affects the proliferation and cell cycle of hepatocellular carcinoma via hedgehog signaling pathway. J Transl Med 2022;20:154. [PMID: 35382824 DOI: 10.1186/s12967-022-03305-x] [Reference Citation Analysis]
222 Chen G, Wang Y, Zhao X, Xie XZ, Zhao JG, Deng T, Chen ZY, Chen HB, Tong YF, Yang Z, Ding XW, Guo PY, Yu HT, Wu LJ, Zhang SN, Zhu QD, Li JJ, Shan YF, Yu FX, Yu ZP, Xia JL. A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation. J Exp Clin Cancer Res 2021;40:218. [PMID: 34193219 DOI: 10.1186/s13046-021-02011-8] [Reference Citation Analysis]
223 Donato F, Moneda M, Portolani N, Rossini A, Molfino S, Ministrini S, Contessi GB, Pesenti S, De Palma G, Gaia A, Zanardini E, Sileo CV, Magoni M. Polychlorinated biphenyls and risk of hepatocellular carcinoma in the population living in a highly polluted area in Italy. Sci Rep 2021;11:3064. [PMID: 33542320 DOI: 10.1038/s41598-021-82657-8] [Reference Citation Analysis]
224 Rehman O, Jaferi U, Padda I, Khehra N, Atwal H, Mossabeh D, Bhangu R. Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma. Clin Exp Hepatol 2021;7:249-57. [PMID: 34712825 DOI: 10.5114/ceh.2021.109312] [Reference Citation Analysis]
225 Huang Y, Chen S, Qin W, Wang Y, Li L, Li Q, Yuan X. A Novel RNA Binding Protein-Related Prognostic Signature for Hepatocellular Carcinoma. Front Oncol 2020;10:580513. [PMID: 33251144 DOI: 10.3389/fonc.2020.580513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
226 He Y, Shi M, Wu X, Ma J, Ng KT, Xia Q, Zhu L, Fu PP, Man K, Tsui SK, Lin G. Mutational Signature Analysis Reveals Widespread Contribution of Pyrrolizidine Alkaloid Exposure to Human Liver Cancer. Hepatology 2021;74:264-80. [PMID: 33462832 DOI: 10.1002/hep.31723] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
227 Boppana V, Sahni S, Glass J, Chang C, McCarthy DM. HCC You Cannot See. Dig Dis Sci 2021;66:2185-9. [PMID: 34089136 DOI: 10.1007/s10620-021-07070-7] [Reference Citation Analysis]
228 Baby J, Devan AR, Kumar AR, Gorantla JN, Nair B, Aishwarya TS, Nath LR. Cogent role of flavonoids as key orchestrators of chemoprevention of hepatocellular carcinoma: A review. J Food Biochem 2021;45:e13761. [PMID: 34028054 DOI: 10.1111/jfbc.13761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
229 Shi L, Wang F, Zhang Y, Yang Y, Qu Z, Sun D. Downregulated Expression of miRNA-130a-5p Aggravates Hepatoma Progression via Targeting PTP4A2. Comput Math Methods Med 2021;2021:4439505. [PMID: 34992672 DOI: 10.1155/2021/4439505] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Gao Y, You M, Fu J, Tian M, Zhong X, Du C, Hong Z, Zhu Z, Liu J, Markowitz GJ, Wang FS, Yang P. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B. J Hepatol 2021:S0168-8278(21)02027-4. [PMID: 34689996 DOI: 10.1016/j.jhep.2021.08.029] [Reference Citation Analysis]
231 Younis MA, Khalil IA, Harashima H. Gene Therapy for Hepatocellular Carcinoma: Highlighting the Journey from Theory to Clinical Applications. Adv Therap 2020;3:2000087. [DOI: 10.1002/adtp.202000087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
232 Kamimura K, Suda T, Fukuhara Y, Okuda S, Watanabe Y, Yokoo T, Osaki A, Waguri N, Ishikawa T, Sato T, Aoyagi Y, Takamura M, Wakai T, Terai S. Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers. Sci Rep 2021;11:6255. [PMID: 33737617 DOI: 10.1038/s41598-021-85498-7] [Reference Citation Analysis]
233 Chen C, Ai QD, Wei YH. Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-κB pathway and regulating transporter mediated drug efflux. J Ethnopharmacol 2021;264:113388. [PMID: 32918990 DOI: 10.1016/j.jep.2020.113388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
234 Xu XF, Yang XK, Song Y, Chen BJ, Yu X, Xu T, Chen ZL. Dysregulation of Non-coding RNAs mediates Cisplatin Resistance in Hepatocellular Carcinoma and therapeutic strategies. Pharmacol Res 2021;:105906. [PMID: 34543740 DOI: 10.1016/j.phrs.2021.105906] [Reference Citation Analysis]
235 Wu Q, Wang SP, Sun XX, Tao YF, Yuan XQ, Chen QM, Dai L, Li CL, Zhang JY, Yang AL. HuaChanSu suppresses tumor growth and interferes with glucose metabolism in hepatocellular carcinoma cells by restraining Hexokinase-2. Int J Biochem Cell Biol 2022;142:106123. [PMID: 34826616 DOI: 10.1016/j.biocel.2021.106123] [Reference Citation Analysis]
236 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2021.10.009] [Reference Citation Analysis]
237 Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver Resection Versus Local Ablation Therapies for Hepatocellular Carcinoma Within the Milan Criteria: A Systemic Review and Meta-analysis. Ann Surg. 2020;. [PMID: 33074898 DOI: 10.1097/sla.0000000000004350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
238 Álvarez-Mercado AI, Caballeria-Casals A, Rojano-Alfonso C, Chávez-Reyes J, Micó-Carnero M, Sanchez-Gonzalez A, Casillas-Ramírez A, Gracia-Sancho J, Peralta C. Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection. Biomedicines 2021;9:1158. [PMID: 34572344 DOI: 10.3390/biomedicines9091158] [Reference Citation Analysis]
239 McKay A, Pantoja C, Hall R, Matthews S, Spalding P, Banerjee R. Patient understanding and experience of non-invasive imaging diagnostic techniques and the liver patient pathway. J Patient Rep Outcomes 2021;5:89. [PMID: 34508298 DOI: 10.1186/s41687-021-00363-5] [Reference Citation Analysis]
240 Song P, Huang H, Ma Y, Wu C, Yang X, Choi HY. Davidone C Induces the Death of Hepatocellular Carcinoma Cells by Promoting Apoptosis and Autophagy. Molecules 2021;26:5219. [PMID: 34500653 DOI: 10.3390/molecules26175219] [Reference Citation Analysis]
241 Yang H, Yang H, Zhang W, Wang J, Sun L, Gao J, Zhao H, Wang Z, Aziz AUR. Identification of m6A-Related lncRNA to Predict the Prognosis of Patients with Hepatocellular Carcinoma. BioMed Research International 2022;2022:1-19. [DOI: 10.1155/2022/4169150] [Reference Citation Analysis]
242 Trotovšek B, Djokić M, Čemažar M, Serša G. New era of electrochemotherapy in treatment of liver tumors in conjunction with immunotherapies. World J Gastroenterol 2021; 27(48): 8216-8226 [DOI: 10.3748/wjg.v27.i48.8216] [Reference Citation Analysis]
243 Shao S, Hu Q, Wu W, Wang M, Huang J, Zhao X, Tang G, Liang T. Tumor-triggered personalized microRNA cocktail therapy for hepatocellular carcinoma. Biomater Sci 2020;8:6579-91. [DOI: 10.1039/d0bm00794c] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
244 Sun DW, An L, Huang HY, Sun XD, Lv GY. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true? Clin Transl Oncol 2021;23:82-91. [PMID: 32462395 DOI: 10.1007/s12094-020-02390-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
245 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Wu M, Yang S, Feng X, Li C, Liu X, Zhang Z, Xiao Y, Liu C, Dong J. Combining Preoperative and Postoperative Inflammatory Indicators Can Better Predict the Recurrence of Hepatocellular Carcinoma After Partial Hepatectomy. J Inflamm Res 2021;14:3231-45. [PMID: 34285546 DOI: 10.2147/JIR.S316177] [Reference Citation Analysis]
247 Lin JC, Zhu NX, Wu LF. Research progress of circRNAs in chemotherapy resistance of digestive system neoplasms. Shijie Huaren Xiaohua Zazhi 2021; 29(21): 1237-1247 [DOI: 10.11569/wcjd.v29.i21.1237] [Reference Citation Analysis]
248 Tan C, Xia P, Zhang H, Xu K, Liu P, Guo D, Liu Z. YY1-Targeted RBM15B Promotes Hepatocellular Carcinoma Cell Proliferation and Sorafenib Resistance by Promoting TRAM2 Expression in an m6A-Dependent Manner. Front Oncol 2022;12:873020. [DOI: 10.3389/fonc.2022.873020] [Reference Citation Analysis]
249 Zhou W, Zhang S, Cai Z, Gao F, Deng W, Wen Y, Qiu ZW, Hou ZK, Chen XL. A glycolysis-related gene pairs signature predicts prognosis in patients with hepatocellular carcinoma. PeerJ 2020;8:e9944. [PMID: 33062428 DOI: 10.7717/peerj.9944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
250 Yan Y, Nie Y, Peng C, Xing F, Ji S, Liu H, Zhu C. The circular RNA hsa_circ_0001394 promotes hepatocellular carcinoma progression by targeting the miR-527/UBE2A axis. Cell Death Discov 2022;8:81. [PMID: 35210429 DOI: 10.1038/s41420-022-00866-0] [Reference Citation Analysis]
251 Chen Y, Li Y, Zheng G, Zhou P. Construction and analysis of macrophage infiltration related circRNA-miRNA-mRNA regulatory networks in hepatocellular carcinoma. PeerJ 2020;8:e10198. [PMID: 33150086 DOI: 10.7717/peerj.10198] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
252 Hu B, Yang XB, Sang XT. Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:315-30. [PMID: 33204664 DOI: 10.2147/JHC.S272109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
253 Xu Q, Xu H, Chen S, Huang W. Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:710207. [PMID: 34409040 DOI: 10.3389/fcell.2021.710207] [Reference Citation Analysis]
254 Sachdeva M, Arora SK. Prognostic role of immune cells in hepatocellular carcinoma. EXCLI J 2020;19:718-33. [PMID: 32636725 DOI: 10.17179/excli2020-1455] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
255 Wu M, Shi K, Huang R, Liu C, Yin L, Yong W, Sun J, Wang G, Zhong Z, Gao M. Facile preparation of 177Lu-microspheres for hepatocellular carcinoma radioisotope therapy. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.01.007] [Reference Citation Analysis]
256 Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey J, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00427-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
257 Feng LH, Sun HC, Zhu XD, Zhang SZ, Li XL, Li KS, Liu XF, Lei M, Li Y, Tang ZY. Irbesartan inhibits metastasis by interrupting the adherence of tumor cell to endothelial cell induced by angiotensin II in hepatocellular carcinoma. Ann Transl Med 2021;9:207. [PMID: 33708834 DOI: 10.21037/atm-20-5293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
258 Hong L, Zhou Y, Xie X, Wu W, Shi C, Lin H, Shi Z. A stemness-based eleven-gene signature correlates with the clinical outcome of hepatocellular carcinoma. BMC Cancer 2021;21:716. [PMID: 34147074 DOI: 10.1186/s12885-021-08351-0] [Reference Citation Analysis]
259 Xu T, Wang L, Jia P, Song X, Zhao Z. An Integrative Transcriptomic and Methylation Approach for Identifying Differentially Expressed Circular RNAs Associated with DNA Methylation Change. Biomedicines 2021;9:657. [PMID: 34201256 DOI: 10.3390/biomedicines9060657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Tang Y, Yang X, Feng K, Hu C, Li S. High expression of aldolase A is associated with tumor progression and poor prognosis in hepatocellular carcinoma. J Gastrointest Oncol 2021;12:174-83. [PMID: 33708434 DOI: 10.21037/jgo-20-534] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
261 Mccain JD, Chascsa DM, Lindor KD. Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients. Expert Opinion on Orphan Drugs 2021;9:53-66. [DOI: 10.1080/21678707.2021.1898370] [Reference Citation Analysis]
262 Chen CT, Wu PH, Hu CC, Nien HC, Wang JT, Sheu JC, Chow LP. Aberrant Upregulation of Indoleamine 2,3-Dioxygenase 1 Promotes Proliferation and Metastasis of Hepatocellular Carcinoma Cells via Coordinated Activation of AhR and β-Catenin Signaling. Int J Mol Sci 2021;22:11661. [PMID: 34769098 DOI: 10.3390/ijms222111661] [Reference Citation Analysis]
263 Kato T, Yamada T, Nakamura H, Igarashi A, Anders RA, Sesaki H, Iijima M. The Loss of Nuclear PTEN Increases Tumorigenesis in a Preclinical Mouse Model for Hepatocellular Carcinoma. iScience 2020;23:101548. [PMID: 33083717 DOI: 10.1016/j.isci.2020.101548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
264 Sun J, Fang R, Wang H, Xu DX, Yang J, Huang X, Cozzolino D, Fang M, Huang Y. A review of environmental metabolism disrupting chemicals and effect biomarkers associating disease risks: Where exposomics meets metabolomics. Environ Int 2021;158:106941. [PMID: 34689039 DOI: 10.1016/j.envint.2021.106941] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Elsherbiny NM, Eisa NH, El-Sherbiny M, Said E. Chemo-preventive effect of crocin against experimentally-induced hepatocarcinogenesis via regulation of apoptotic and Nrf2 signaling pathways. Environ Toxicol Pharmacol 2020;80:103494. [PMID: 32942000 DOI: 10.1016/j.etap.2020.103494] [Reference Citation Analysis]
266 Bruneau A, Hundertmark J, Guillot A, Tacke F. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Front Med (Lausanne) 2021;8:725390. [PMID: 34650994 DOI: 10.3389/fmed.2021.725390] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
267 Jin X, Fu W, Li D, Wang N, Chen J, Zeng Z, Guo J, Liu H, Zhong X, Peng H, Yu X, Sun J, Zhang X, Wang X, Xu B, Lin Y, Liu J, Kutter C, Li Y. High Expression of LINC01268 is Positively Associated with Hepatocellular Carcinoma Progression via Regulating MAP3K7. Onco Targets Ther 2021;14:1753-69. [PMID: 33727826 DOI: 10.2147/OTT.S295814] [Reference Citation Analysis]
268 Asai A, Yasuoka H, Matsui M, Tsuchimoto Y, Fukunishi S, Higuchi K. Programmed Death 1 Ligand Expression in the Monocytes of Patients with Hepatocellular Carcinoma Depends on Tumor Progression. Cancers (Basel) 2020;12:E2286. [PMID: 32824016 DOI: 10.3390/cancers12082286] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
269 Kim H, Lee JY, Park SJ, Kwag E, Koo O, Shin JH. ZNF746/PARIS promotes the occurrence of hepatocellular carcinoma. Biochem Biophys Res Commun 2021;563:98-104. [PMID: 34062393 DOI: 10.1016/j.bbrc.2021.05.051] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
270 Duan JL, Nie RC, Xiang ZC, Chen JW, Deng MH, Liang H, Wang FW, Luo RZ, Xie D, Cai MY. Prognostic Model for the Risk Stratification of Early and Late Recurrence in Hepatitis B Virus-Related Small Hepatocellular Carcinoma Patients with Global Histone Modifications. J Hepatocell Carcinoma 2021;8:493-505. [PMID: 34095004 DOI: 10.2147/JHC.S309451] [Reference Citation Analysis]
271 Bhattacharya B, Huang DQ, Low SHH, Tan GH, Han MJ, Singh S, Tang B, Chang SC, Lim JSY, Omar MFM, Dan YY, Soong R. Effect of cell microenvironment on the drug sensitivity of hepatocellular cancer cells. Oncotarget 2021;12:674-85. [PMID: 33868588 DOI: 10.18632/oncotarget.27910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
272 Su SG, Li QL, Zhang MF, Zhang PW, Shen H, Zhang CZ. An E2F1/DDX11/EZH2 Positive Feedback Loop Promotes Cell Proliferation in Hepatocellular Carcinoma. Front Oncol 2020;10:593293. [PMID: 33614480 DOI: 10.3389/fonc.2020.593293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
273 Cai Q, Zhu M, Duan J, Wang H, Chen J, Xiao Y, Wang Y, Wang J, Yu X, Yang H. Comprehensive Analysis of Immune-Related Prognosis of TK1 in Hepatocellular Carcinoma. Front Oncol 2022;11:786873. [DOI: 10.3389/fonc.2021.786873] [Reference Citation Analysis]
274 Ficht X, Iannacone M. Immune surveillance of the liver by T cells. Sci Immunol. 2020;5:eaba2351. [PMID: 32887842 DOI: 10.1126/sciimmunol.aba2351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
275 Wei X, Yang W, Zhang F, Cheng F, Rao J, Lu L. PIGU promotes hepatocellular carcinoma progression through activating NF-κB pathway and increasing immune escape. Life Sci 2020;260:118476. [PMID: 32971102 DOI: 10.1016/j.lfs.2020.118476] [Reference Citation Analysis]
276 Xia X, Tang P, Liu H, Li Y. Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:798-808. [PMID: 34966643 DOI: 10.14218/JCTH.2021.00017] [Reference Citation Analysis]
277 Chen R, Bai Y, Liu T, Zhang G, Han Y, Chen L, Gao H, Wei W, Wang M. Evaluation of Glypican-3 Expression in Hepatocellular Carcinoma by Using IDEAL IQ Magnetic Resonance Imaging. Acad Radiol 2021;28:e227-34. [PMID: 32540197 DOI: 10.1016/j.acra.2020.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
278 Pu T, Li ZH, Jiang D, Chen JM, Guo Q, Cai M, Chen ZX, Xie K, Zhao YJ, Liu FB. Nomogram based on inflammation-related markers for predicting survival of patients undergoing hepatectomy for hepatocellular carcinoma. World J Clin Cases 2021; 9(36): 11193-11207 [DOI: 10.12998/wjcc.v9.i36.11193] [Reference Citation Analysis]
279 Fairhurst RA, Knoepfel T, Buschmann N, Leblanc C, Mah R, Todorov M, Nimsgern P, Ripoche S, Niklaus M, Warin N, Luu VH, Madoerin M, Wirth J, Graus-Porta D, Weiss A, Kiffe M, Wartmann M, Kinyamu-Akunda J, Sterker D, Stamm C, Adler F, Buhles A, Schadt H, Couttet P, Blank J, Galuba I, Trappe J, Voshol J, Ostermann N, Zou C, Berghausen J, Del Rio Espinola A, Jahnke W, Furet P. Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. J Med Chem 2020;63:12542-73. [PMID: 32930584 DOI: 10.1021/acs.jmedchem.0c01019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
280 Mezina A, Philips N, Bogus Z, Erez N, Xiao R, Fan R, Olthoff KM, Reddy KR, Samadder NJ, Nielsen SM, Hatchell KE, Esplin ED, Rustgi AK, Katona BW, Hoteit MA, Nathanson KL, Wangensteen KJ. Multigene Panel Testing in Individuals With Hepatocellular Carcinoma Identifies Pathogenic Germline Variants. JCO Precis Oncol 2021;5:PO. [PMID: 34250406 DOI: 10.1200/PO.21.00079] [Reference Citation Analysis]
281 Chen MH, Lu SN, Chen CH, Lin PC, Jiang JK, D'yachkova Y, Lukanowski M, Cheng R, Chen LT. How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers? Cancers (Basel) 2021;13:3536. [PMID: 34298750 DOI: 10.3390/cancers13143536] [Reference Citation Analysis]
282 Tachi K, Agyei-Nkansah A, Archampong T. Hepatocellular carcinoma in Ghana: a retrospective analysis of a tertiary hospital data. Pan Afr Med J 2020;36:43. [PMID: 32774619 DOI: 10.11604/pamj.2020.36.43.21085] [Reference Citation Analysis]
283 Sha M, Cao J, Zong ZP, Xu N, Zhang JJ, Tong Y, Xia Q. Identification of genes predicting unfavorable prognosis in hepatitis B virus-associated hepatocellular carcinoma. Ann Transl Med 2021;9:975. [PMID: 34277775 DOI: 10.21037/atm-21-2085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Yang PM, Lin LS, Liu TP. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Biomolecules 2020;10:E117. [PMID: 31936661 DOI: 10.3390/biom10010117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
285 Yan J, Ying X, Malhotra A, Talenfeld A, Charalel R, Lee KS, Trost D, Kesselman A. Safety and Efficacy of Microwave Ablation for Hepatocellular Carcinoma in the Setting of Transjugular Intrahepatic Portosystemic Shunt. Cardiovasc Intervent Radiol 2021. [PMID: 34859308 DOI: 10.1007/s00270-021-03012-y] [Reference Citation Analysis]
286 Yang S, Lin H, Song J. Efficacy and safety of various primary treatment strategies for very early and early hepatocellular carcinoma: a network meta-analysis. Cancer Cell Int 2021;21:681. [PMID: 34923980 DOI: 10.1186/s12935-021-02365-1] [Reference Citation Analysis]
287 Chen M, Wong CM. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis. Mol Cancer 2020;19:44. [PMID: 32111216 DOI: 10.1186/s12943-020-01172-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 24.0] [Reference Citation Analysis]
288 Qin SK, Li Q, Ming Xu J, Liang J, Cheng Y, Fan Y, Jiang J, Ye H, Tao H, Li L, Zheng L, Wei Z, Li S, Meng K, Ye B, Sun Y. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival. Cancer Sci. 2020;111:4218-4231. [PMID: 32889778 DOI: 10.1111/cas.14641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
289 Yang C, Du P, Lu W. MiR-424 Acts as a Novel Biomarker in the Diagnosis of Patients with Hepatocellular Carcinoma. Cancer Biother Radiopharm 2021. [PMID: 34287021 DOI: 10.1089/cbr.2020.4141] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
290 Shah RA, Alkhouri N, Kowdley KV. Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. Expert Opinion on Emerging Drugs 2020;25:251-60. [DOI: 10.1080/14728214.2020.1796968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
291 Worlikar T, Mendiratta-Lala M, Vlaisavljevich E, Hubbard R, Shi J, Hall TL, Cho CS, Lee FT, Greve J, Xu Z. Effects of Histotripsy on Local Tumor Progression in an in vivo Orthotopic Rodent Liver Tumor Model. BME Front 2020;2020:9830304. [PMID: 34327513 DOI: 10.34133/2020/9830304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
292 Xu H, Cao D, Zheng Y, Zhou D, Chen X, Lei J, Ge W, Xu X. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis. Int Immunopharmacol 2021;100:108135. [PMID: 34530205 DOI: 10.1016/j.intimp.2021.108135] [Reference Citation Analysis]
293 Coffin CS, Mulrooney-Cousins PM, Michalak TI. Hepadnaviral Lymphotropism and Its Relevance to HBV Persistence and Pathogenesis. Front Microbiol 2021;12:695384. [PMID: 34421849 DOI: 10.3389/fmicb.2021.695384] [Reference Citation Analysis]
294 Huang Y, Ge W, Zhou J, Gao B, Qian X, Wang W. The Role of Tumor Associated Macrophages in Hepatocellular Carcinoma. J Cancer 2021;12:1284-94. [PMID: 33531974 DOI: 10.7150/jca.51346] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
295 Wang C, Li Q, Xiao B, Fang H, Huang B, Huang F, Wang Y. Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells. J Clin Lab Anal 2021;35:e23677. [PMID: 33274495 DOI: 10.1002/jcla.23677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
296 Yang L, Ma X, Guo K, Li J, Zhang C, Wu L. Dual-functional antitumor conjugates improving the anti-metastasis effect of combretastatin A4 by targeting tubulin polymerization and matrix metalloproteinases. Eur J Med Chem 2022;238:114439. [PMID: 35551039 DOI: 10.1016/j.ejmech.2022.114439] [Reference Citation Analysis]
297 Carloni R, Rizzo A, Ricci AD, Frega G, Federico AD, Palloni A, Marco MD, Gadaleta-Caldarola G, Brandi G. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? Future Oncol 2022. [PMID: 35109664 DOI: 10.2217/fon-2021-0905] [Reference Citation Analysis]
298 Man Z, Chen Y, Gao L, Xei G, Li Q, Lu Q, Yan J. A Prognostic Model Based on RNA Binding Protein Predicts Clinical Outcomes in Hepatocellular Carcinoma Patients. Front Oncol 2020;10:613102. [PMID: 33643914 DOI: 10.3389/fonc.2020.613102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Wan S, Nie Y, Zhu X. Development of a prognostic scoring model for predicting the survival of elderly patients with hepatocellular carcinoma. PeerJ 2020;8:e8497. [PMID: 32117619 DOI: 10.7717/peerj.8497] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
300 Xu Q, Xu H, Deng R, Wang Z, Li N, Qi Z, Zhao J, Huang W. Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma. Cancer Cell Int 2021;21:342. [PMID: 34217320 DOI: 10.1186/s12935-021-02049-w] [Reference Citation Analysis]
301 Han Y, Jiang W, Wang Y, Zhao M, Li Y, Ren L. Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma. BMC Cancer 2022;22:431. [PMID: 35443674 DOI: 10.1186/s12885-022-09530-3] [Reference Citation Analysis]
302 Li Z, Wang F, Liang B, Su Y, Sun S, Xia S, Shao J, Zhang Z, Hong M, Zhang F, Zheng S. Methionine metabolism in chronic liver diseases: an update on molecular mechanism and therapeutic implication. Signal Transduct Target Ther 2020;5:280. [PMID: 33273451 DOI: 10.1038/s41392-020-00349-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
303 Ding Y, Sun Z, Zhang S, Zhou L, Xu Q, Zhou D, Li Y, Han X, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Identification of snoRNA SNORA71A as a Novel Biomarker in Prognosis of Hepatocellular Carcinoma. Dis Markers 2020;2020:8879944. [PMID: 33062075 DOI: 10.1155/2020/8879944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
304 Chan LK, Ng IO. Joining the dots for better liver cancer treatment. Nat Rev Gastroenterol Hepatol 2020;17:74-5. [PMID: 31712772 DOI: 10.1038/s41575-019-0238-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
305 Xu Q, Chen S, Hu Y, Huang W. Prognostic Role of ceRNA Network in Immune Infiltration of Hepatocellular Carcinoma. Front Genet 2021;12:739975. [PMID: 34589117 DOI: 10.3389/fgene.2021.739975] [Reference Citation Analysis]
306 Yang W, Ni Y, Yang S, Ji Y, Yang X, Cheng F, Wang X, Zhang F, Rao J. The oncogene Mct-1 promotes progression of hepatocellular carcinoma via enhancement of Yap-mediated cell proliferation. Cell Death Discov 2021;7:57. [PMID: 33753742 DOI: 10.1038/s41420-021-00413-3] [Reference Citation Analysis]
307 Elpek GO. Molecular pathways in viral hepatitis-associated liver carcinogenesis: An update. World J Clin Cases 2021; 9(19): 4890-4917 [PMID: 34307543 DOI: 10.12998/wjcc.v9.i19.4890] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
308 Pan B, Pan W, Lu Z, Xia C. Pharmacological Mechanisms Underlying the Hepatoprotective Effects of Ecliptae herba on Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2021;2021:5591402. [PMID: 34326886 DOI: 10.1155/2021/5591402] [Reference Citation Analysis]
309 Eresen A, Yang J, Scotti A, Cai K, Yaghmai V, Zhang Z. Combination of natural killer cell-based immunotherapy and irreversible electroporation for the treatment of hepatocellular carcinoma. Ann Transl Med 2021;9:1089. [PMID: 34423001 DOI: 10.21037/atm-21-539] [Reference Citation Analysis]
310 Hu C, Song Y, Zhang J, Dai L, Tang C, Li M, Liao W, Zhou Y, Xu Y, Zhang YY, Zhou Y. Preoperative Gadoxetic Acid-Enhanced MRI Based Nomogram Improves Prediction of Early HCC Recurrence After Ablation Therapy. Front Oncol 2021;11:649682. [PMID: 34094938 DOI: 10.3389/fonc.2021.649682] [Reference Citation Analysis]
311 Ren AH, Xu H, Yang DW, Zhang N, Ba T, Wang ZC, Yang ZH. Systematic Training of Liver Imaging Reporting and Data System Magnetic Resonance Imaging v2018 can Improve the Diagnosis of Hepatocellular Carcinoma for Different Radiologists. J Clin Transl Hepatol 2021;9:537-44. [PMID: 34447683 DOI: 10.14218/JCTH.2021.00180] [Reference Citation Analysis]
312 Zhou G, Zeng Y, Luo Y, Guo S, Bao L, Zhang Q. Urine miR-93-5p is a promising biomarker for early detection of HBV-related hepatocellular carcinoma. Eur J Surg Oncol 2021:S0748-7983(21)00579-5. [PMID: 34175168 DOI: 10.1016/j.ejso.2021.06.015] [Reference Citation Analysis]
313 Vanderborght B, Lefere S, Vlierberghe HV, Devisscher L. The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma. Cells 2020;9:E2382. [PMID: 33143149 DOI: 10.3390/cells9112382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
314 Sabaawy HE, Ryan BM, Khiabanian H, Pine SR. JAK/STAT of all trades: Linking inflammation with cancer development, tumor progression, and therapy resistance. Carcinogenesis 2021:bgab075. [PMID: 34415330 DOI: 10.1093/carcin/bgab075] [Reference Citation Analysis]
315 Liu H, Jiang X, Qiao Q, Chen L, Matsuda K, Jiang G, Yu T, Wang Y, Lin H, Liang X, Cai X. Association of circulating 25-Hydroxyvitamin D and its related genetic variations with hepatocellular carcinoma incidence and survival. Ann Transl Med 2020;8:1080. [PMID: 33145299 DOI: 10.21037/atm-20-1637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
316 Zheng X, Jin W, Wang S, Ding H. Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:729705. [PMID: 34566989 DOI: 10.3389/fimmu.2021.729705] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Kamimura K, Yokoo T, Abe H, Terai S. Gene Therapy for Liver Cancers: Current Status from Basic to Clinics. Cancers (Basel) 2019;11:E1865. [PMID: 31769427 DOI: 10.3390/cancers11121865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
318 Liang J, Zhi Y, Deng W, Zhou W, Li X, Cai Z, Zhu Z, Zeng J, Wu W, Dong Y, Huang J, Zhang Y, Xu S, Feng Y, Ding F, Zhang J. Development and validation of ferroptosis-related lncRNAs signature for hepatocellular carcinoma. PeerJ 2021;9:e11627. [PMID: 34178478 DOI: 10.7717/peerj.11627] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
319 Shu H, Zhang L, Chen Y, Guo Y, Li L, Chen F, Cao Z, Yan G, Lu C, Liu C, Zhang S. Quantification of Intact O-Glycopeptides on Haptoglobin in Sera of Patients With Hepatocellular Carcinoma and Liver Cirrhosis. Front Chem 2021;9:705341. [PMID: 34336790 DOI: 10.3389/fchem.2021.705341] [Reference Citation Analysis]
320 Hsu JY, Liu PP, Liu AB, Huang HK, Loh CH. High 1-year risk of stroke in patients with hepatocellular carcinoma: a nationwide registry-based cohort study. Sci Rep 2021;11:10444. [PMID: 34001950 DOI: 10.1038/s41598-021-89867-0] [Reference Citation Analysis]
321 Kedar Mukthinuthalapati VVP, Sewram V, Ndlovu N, Kimani S, Abdelaziz AO, Chiao EY, Abou-Alfa GK. Hepatocellular Carcinoma in Sub-Saharan Africa. JCO Glob Oncol 2021;7:756-66. [PMID: 34043413 DOI: 10.1200/GO.20.00425] [Reference Citation Analysis]
322 Liu YS, Lin XZ, Chen CY, Chiu YC, Kang JW, Tsai HW, Hung HY, Ho CM, Ou MC. Safety and effectiveness of new embolization microspheres SCBRM for intermediate-stage hepatocellular carcinoma: A feasibility study. Bosn J Basic Med Sci 2021;21:339-45. [PMID: 32841586 DOI: 10.17305/bjbms.2020.4770] [Reference Citation Analysis]
323 Lu Y, Zhang J, Wu Y. Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis. Mol Med Rep 2021;24:609. [PMID: 34184075 DOI: 10.3892/mmr.2021.12247] [Reference Citation Analysis]
324 Liu X, Jiang N, Xu X, Liu C, Liu Z, Zhang Y, Kang W. Anti-Hepatoma Compound Determination by the Method of Spectrum Effect Relationship, Component Knock-Out, and UPLC-MS2 in Scheflera heptaphylla (L.)Frodin Harms and Its Mechanism. Front Pharmacol 2020;11:1342. [PMID: 33013373 DOI: 10.3389/fphar.2020.01342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
325 Riaño I, Martín L, Varela M, Serrano T, Núñez O, Mínguez B, Rodrigues PM, Perugorria MJ, Banales JM, Arenas JI. Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial). Cancers (Basel) 2020;12:E1900. [PMID: 32674461 DOI: 10.3390/cancers12071900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
326 Tsai YF, Liu FC, Chen CY, Lin JR, Yu HP. Effect of Mycophenolate Mofetil Therapy on Recurrence of Hepatocellular Carcinoma after Liver Transplantation: A Population-Based Cohort Study. J Clin Med 2021;10:1558. [PMID: 33917215 DOI: 10.3390/jcm10081558] [Reference Citation Analysis]
327 Kovac JD, Ivanovic A, Milovanovic T, Micev M, Alessandrino F, Gore RM. An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation. Radiol Oncol 2021;55:130-43. [PMID: 33544992 DOI: 10.2478/raon-2021-0004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
328 Jin Z, Sun D, Song M, Zhu W, Liu H, Wang J, Shi G, Wang F. Comprehensive Analysis of HOX Family Members as Novel Diagnostic and Prognostic Markers for Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/5758601] [Reference Citation Analysis]
329 Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien P. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol 2020;17:755-72. [DOI: 10.1038/s41575-020-0314-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
330 Huang DQ, Muthiah MD, Zhou L, Jumat H, Tan WX, Lee GH, Lim SG, Kow A, Bonney G, Shridhar I, Lim YT, Wee A, Pang YH, Soon G, Chow P, Dan YY. Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy. Cell Mol Gastroenterol Hepatol 2021;11:1313-25. [PMID: 33340714 DOI: 10.1016/j.jcmgh.2020.12.009] [Reference Citation Analysis]
331 Kaushik AC, Mehmood A, Wei DQ, Dai X. Robust Biomarker Screening Using Spares Learning Approach for Liver Cancer Prognosis. Front Bioeng Biotechnol 2020;8:241. [PMID: 32318552 DOI: 10.3389/fbioe.2020.00241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
332 Morishita A, Oura K, Tadokoro T, Fujita K, Tani J, Masaki T. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. Cancers (Basel) 2021;13:514. [PMID: 33572780 DOI: 10.3390/cancers13030514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
333 Chen B, Gu Y, Shen H, Liu Q, Wang H, Li Y, Liu X, Liu Y, Du Q, Sun H, Liao X. Borealin Promotes Tumor Growth and Metastasis by Activating the Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma. JHC 2022;Volume 9:171-88. [DOI: 10.2147/jhc.s336452] [Reference Citation Analysis]
334 Hiraoka A, Tanizawa Y, Huang YJ, Cai Z, Sakaguchi S. Association of Albumin-Bilirubin Grade and Sequential Treatment with Standard Systemic Therapies for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Using a Japanese Administrative Database. Drugs Real World Outcomes 2021;8:301-14. [PMID: 33792850 DOI: 10.1007/s40801-021-00245-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
335 Takaya H, Namisaki T, Takeda S, Kaji K, Ogawa H, Ishida K, Tsuji Y, Takagi H, Ozutsumi T, Fujinaga Y, Furukawa M, Kitagawa K, Nishimura N, Sawada Y, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. J Clin Med 2021;10:4838. [PMID: 34768358 DOI: 10.3390/jcm10214838] [Reference Citation Analysis]
336 Zhang S, Zhao H, Chen Y, Zhang Y, Zhong WL. GNL3 Regulates SIRT1 Transcription and Promotes Hepatocellular Carcinoma Stem Cell-Like Features and Metastasis. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/1555670] [Reference Citation Analysis]
337 Ogasawara S, Choo SP, Li JT, Yoo C, Wang B, Lee D, Chow PKH. Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion. Cancers (Basel) 2021;13:2626. [PMID: 34071818 DOI: 10.3390/cancers13112626] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Du Y, Zhang D, Wang Y, Wu M, Zhang C, Zheng Y, Zheng A, Liu X. A highly stable multifunctional aptamer for enhancing antitumor immunity against hepatocellular carcinoma by blocking dual immune checkpoints. Biomater Sci 2021;9:4159-68. [PMID: 33970170 DOI: 10.1039/d0bm02210a] [Reference Citation Analysis]
339 Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, Shim JH, Lim YS, Lee HC, Lee J, Tai D, Chan SL, Ryoo BY. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. Liver Cancer 2021;10:107-14. [PMID: 33977087 DOI: 10.1159/000512781] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
340 He Y, Xu R, Peng L, Hu X. Tumor infiltrating lymphocytes associated competitive endogenous RNA networks as predictors of outcome in hepatic carcinoma based on WGCNA analysis. PLoS One 2021;16:e0254829. [PMID: 34324544 DOI: 10.1371/journal.pone.0254829] [Reference Citation Analysis]
341 Shen J, Shen H, Ke L, Chen J, Dang X, Liu B, Hua Y. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Front Immunol 2022;13:815575. [DOI: 10.3389/fimmu.2022.815575] [Reference Citation Analysis]
342 Choudhury N, Quraishi SB, Atiqullah A, Khan MSI, Al Mahtab M, Akbar SM. High Prevalence of Wilson's Diseases with Low Prevalence of Kayser-Fleischer Rings among Patients with Cryptogenic Chronic Liver Diseases in Bangladesh. Euroasian J Hepatogastroenterol 2019;9:67-70. [PMID: 32117693 DOI: 10.5005/jp-journals-10018-1299] [Reference Citation Analysis]
343 Liu S, Zhang Y, Qiu L, Zhang S, Meng Y, Huang C, Chen Z, Zhang B, Han J. Uncovering N4-Acetylcytidine-Related mRNA Modification Pattern and Landscape of Stemness and Immunity in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:861000. [DOI: 10.3389/fcell.2022.861000] [Reference Citation Analysis]
344 Tonon F, Farra R, Zennaro C, Pozzato G, Truong N, Parisi S, Rizzolio F, Grassi M, Scaggiante B, Zanconati F, Bonazza D, Grassi G, Dapas B. Xenograft Zebrafish Models for the Development of Novel Anti-Hepatocellular Carcinoma Molecules. Pharmaceuticals (Basel) 2021;14:803. [PMID: 34451900 DOI: 10.3390/ph14080803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
345 Sun Q, Zhang X, Gong X, Hu Z, Zhang Q, He W, Chang X, Hu Z, Chen Y. Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data. Hepatol Int 2021. [PMID: 34258665 DOI: 10.1007/s12072-021-10219-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
346 Banerjee I, Fisher PB, Sarkar D. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). Adv Cancer Res 2021;152:329-81. [PMID: 34353442 DOI: 10.1016/bs.acr.2021.05.003] [Reference Citation Analysis]
347 Ko G, Choi JW, Shin K, Kim YG, Kang T, Kim D, Lee N, Kim HC, Hyeon T. In Vivo Sol-Gel Reaction of Tantalum Alkoxide for Endovascular Embolization. Adv Healthc Mater 2021;:e2101908. [PMID: 34783195 DOI: 10.1002/adhm.202101908] [Reference Citation Analysis]
348 Liu C, Zhang M, Zhao J, Zhu X, Zhu L, Yan M, Zhang X, Zhang R. LncRNA FOXD3-AS1 Mediates AKT Pathway to Promote Growth and Invasion in Hepatocellular Carcinoma Through Regulating RICTOR. Cancer Biother Radiopharm 2020;35:292-300. [PMID: 32191537 DOI: 10.1089/cbr.2019.3335] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
349 Fan Y, Wang L, Ding Y, Sheng Q, Zhang C, Li Y, Han C, Lu B, Dou X. Long non-coding RNA RP4-694A7.2 Promotes Hepatocellular Carcinoma Cell Proliferation and Metastasis through the Regulation of PSAT1. J Cancer 2021;12:5633-43. [PMID: 34405023 DOI: 10.7150/jca.59348] [Reference Citation Analysis]
350 Zhu P, Feng R, Lu X, Liao Y, Du Z, Zhai W, Chen K. Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma. Aging (Albany NY) 2021;13:4138-56. [PMID: 33493134 DOI: 10.18632/aging.202380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
351 Vilfranc CL, Che LX, Patra KC, Niu L, Olowokure O, Wang J, Shah SA, Du CY. BIR repeat-containing ubiquitin conjugating enzyme (BRUCE) regulation of β-catenin signaling in the progression of drug-induced hepatic fibrosis and carcinogenesis. World J Hepatol 2021; 13(3): 343-361 [PMID: 33815677 DOI: 10.4254/wjh.v13.i3.343] [Reference Citation Analysis]
352 Feng Y, Dramani Maman ST, Zhu X, Liu X, Bongolo CC, Liang C, Tu J. Clinical value and potential mechanisms of LINC00221 in hepatocellular carcinoma based on integrated analysis. Epigenomics 2021;13:299-317. [PMID: 33406920 DOI: 10.2217/epi-2020-0363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
353 Jiang T, Zhang XS, Pan F, Lyu SC, Wang J, Huang MX, He Q, Lang R. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation. Medicine (Baltimore) 2021;100:e26487. [PMID: 34190174 DOI: 10.1097/MD.0000000000026487] [Reference Citation Analysis]
354 Wang F, Liu H, Bai Y, Li H, Wang Z, Xu X. Performance of SPINK1 and SPINK1-based diagnostic model in detection of hepatocellular carcinoma. J Clin Lab Anal 2021;35:e24025. [PMID: 34569662 DOI: 10.1002/jcla.24025] [Reference Citation Analysis]
355 Feng M, Pan Y, Kong R, Shu S. Therapy of Primary Liver Cancer. Innovation (N Y) 2020;1:100032. [PMID: 32914142 DOI: 10.1016/j.xinn.2020.100032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
356 Galati G, Massimo Vainieri AF, Maria Fulgenzi CA, Di Donato S, Silletta M, Gallo P, Onorato A, Vespasiani-Gentilucci U, Picardi A. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Curr Drug Metab 2020;21:866-84. [PMID: 32957880 DOI: 10.2174/1389200221999200918141239] [Reference Citation Analysis]
357 Wang Z, Fu Y, Xia A, Chen C, Qu J, Xu G, Zou X, Wang Q, Wang S. Prognostic and predictive role of a metabolic rate-limiting enzyme signature in hepatocellular carcinoma. Cell Prolif 2021;54:e13117. [PMID: 34423480 DOI: 10.1111/cpr.13117] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
358 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Reference Citation Analysis]
359 Heydari R, Jangravi Z, Maleknia S, Seresht-Ahmadi M, Bahari Z, Salekdeh GH, Meyfour A. Y chromosome is moving out of sex determination shadow. Cell Biosci 2022;12:4. [PMID: 34983649 DOI: 10.1186/s13578-021-00741-y] [Reference Citation Analysis]
360 Arechederra M, Bazai SK, Abdouni A, Sequera C, Mead TJ, Richelme S, Daian F, Audebert S, Dono R, Lozano A, Gregoire D, Hibner U, Allende DS, Apte SS, Maina F. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol 2021;74:893-906. [PMID: 33197513 DOI: 10.1016/j.jhep.2020.11.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
361 Fan W, Chen L, Wu X, Zhang T. Circ_0031242 Silencing Mitigates the Progression and Drug Resistance in DDP-Resistant Hepatoma Cells by the miR-924/POU3F2 Axis. Cancer Manag Res 2021;13:743-55. [PMID: 33531841 DOI: 10.2147/CMAR.S272851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
362 Chen PP, Zhang ZS, Wu JC, Zheng JF, Lin F. LncRNA SNHG12 promotes proliferation and epithelial mesenchymal transition in hepatocellular carcinoma through targeting HEG1 via miR-516a-5p. Cell Signal 2021;84:109992. [PMID: 33774129 DOI: 10.1016/j.cellsig.2021.109992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
363 Domovitz T, Gal-Tanamy M. Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. J Clin Med 2021;10:551. [PMID: 33540858 DOI: 10.3390/jcm10030551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
364 Ortega JF, Heidor R, Auriemo AP, Affonso JM, D'Amico T, Herz C, de Conti A, Ract J, Gioieli LA, Purgatto E, Lamy E, Pogribny I, Moreno FS. Butyrate-containing structured lipids act on HDAC4, HDAC6, DNA damage and telomerase activity during promotion of experimental hepatocarcinogenesis. Carcinogenesis 2021:bgab039. [PMID: 33999989 DOI: 10.1093/carcin/bgab039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
365 Gan Q, Shao J, Cao Y, Lei J, Xie P, Ge J, Hu G. USP33 regulates c-Met expression by deubiquitinating SP1 to facilitate metastasis in hepatocellular carcinoma. Life Sci 2020;261:118316. [PMID: 32835698 DOI: 10.1016/j.lfs.2020.118316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
366 Al-Harazi O, Kaya IH, Al-Eid M, Alfantoukh L, Al Zahrani AS, Al Sebayel M, Kaya N, Colak D. Identification of Gene Signature as Diagnostic and Prognostic Blood Biomarker for Early Hepatocellular Carcinoma Using Integrated Cross-Species Transcriptomic and Network Analyses. Front Genet 2021;12:710049. [PMID: 34659334 DOI: 10.3389/fgene.2021.710049] [Reference Citation Analysis]
367 Zhou Y, Yang G, Gong XQ, Tao YY, Wang R, Zheng J, Yang C, Peng J, Yang L, Li JD, Zhang XM. A study of the correlations between IVIM-DWI parameters and the histologic differentiation of hepatocellular carcinoma. Sci Rep 2021;11:10392. [PMID: 34001962 DOI: 10.1038/s41598-021-89784-2] [Reference Citation Analysis]
368 Cabrera R, Singal AG, Colombo M, Kelley RK, Lee H, Mospan AR, Meyer T, Newell P, Parikh ND, Sangro B, Reddy KR, Watkins S, Zink RC, Di Bisceglie AM. A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC. Hepatol Commun 2021;5:538-47. [PMID: 33681685 DOI: 10.1002/hep4.1652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
369 Liu Q, Zhao S, Meng F, Wang H, Sun L, Li G, Gao F, Chen F. Nrf2 Down-Regulation by Camptothecin Favors Inhibiting Invasion, Metastasis and Angiogenesis in Hepatocellular Carcinoma. Front Oncol 2021;11:661157. [PMID: 34178646 DOI: 10.3389/fonc.2021.661157] [Reference Citation Analysis]
370 Tang Y, Cao J, Cai Z, An H, Li Y, Peng Y, Chen N, Luo A, Tao H, Li K. Epigallocatechin gallate induces chemopreventive effects on rats with diethylnitrosamine‑induced liver cancer via inhibition of cell division cycle 25A. Mol Med Rep 2020;22:3873-85. [PMID: 33000276 DOI: 10.3892/mmr.2020.11463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
371 Huang J, Lok V, Ngai CH, Chu C, Patel HK, Thoguluva Chandraseka V, Zhang L, Chen P, Wang S, Lao XQ, Tse LA, Xu W, Zheng ZJ, Wong MCS. Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis. Liver Cancer 2021;10:330-45. [PMID: 34414121 DOI: 10.1159/000515304] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
372 Qiang R, Zhao Z, Tang L, Wang Q, Wang Y, Huang Q. Identification of 5 Hub Genes Related to the Early Diagnosis, Tumour Stage, and Poor Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma by Bioinformatics Analysis. Comput Math Methods Med 2021;2021:9991255. [PMID: 34603487 DOI: 10.1155/2021/9991255] [Reference Citation Analysis]
373 Zhang Y, Kong D, Wang H. Mucosal-Associated Invariant T cell in liver diseases. Int J Biol Sci. 2020;16:460-470. [PMID: 32015682 DOI: 10.7150/ijbs.39016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
374 Zhu Z, Shen S, Zhao S, Wang Z. Hsa_circ_0006916 Knockdown Represses the Development of Hepatocellular Carcinoma via Modulating miR-599/SRSF2 Axis. Onco Targets Ther 2020;13:11301-13. [PMID: 33177838 DOI: 10.2147/OTT.S267471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
375 Ludwig JM, Iezzi R, Theysohn JM, Albrecht T, Posa A, Gross A. European Multicenter Study on Degradable Starch Microsphere TACE: The Digestible Way to Conquer HCC in Patients with High Tumor Burden. Cancers (Basel) 2021;13:5122. [PMID: 34680272 DOI: 10.3390/cancers13205122] [Reference Citation Analysis]
376 Luo A, Dong H, Lin X, Liao Y, Liang B, Chen L, Lin G, Hao Y. Time trends of major cancers incidence and mortality in Guangzhou, China 2004-2015: A Joinpoint and Age-Period-Cohort Analysis. Cancer Med 2021;10:2865-76. [PMID: 33724715 DOI: 10.1002/cam4.3744] [Reference Citation Analysis]
377 Zhang H, Yi J, Yoon D, Ryoo Z, Lee I, Kim M. Imatinib and GNF-5 Exhibit an Inhibitory Effect on Growth of Hepatocellar Carcinoma Cells by Downregulating S-phase Kinase-associated Protein 2. J Cancer Prev 2020;25:252-7. [PMID: 33409258 DOI: 10.15430/JCP.2020.25.4.252] [Reference Citation Analysis]
378 Zhao M, Dong G, Meng Q, Lin S, Li X. Circ-HOMER1 enhances the inhibition of miR-1322 on CXCL6 to regulate the growth and aggressiveness of hepatocellular carcinoma cells. J Cell Biochem 2020;121:4440-9. [PMID: 32037619 DOI: 10.1002/jcb.29672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
379 Li Y, He X, Zhang X, Xu Y, Wu Y, Xu X. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma. Life Sci 2021;265:118799. [PMID: 33220285 DOI: 10.1016/j.lfs.2020.118799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
380 Liu Y, Li YQ, Huang SH, Li YL, Xia JW, Jia JS, Wei F, Wang JH, Dai GQ, Wang YC, Li XY, Han LX, Zhang XL, Xiang XD, Zhao WT, Xiao D, Lin XL. Liver-specific over-expression of Cripto-1 in transgenic mice promotes hepatocyte proliferation and deregulated expression of hepatocarcinogenesis-related genes and signaling pathways. Aging (Albany NY) 2021;13:21155-90. [PMID: 34517344 DOI: 10.18632/aging.203402] [Reference Citation Analysis]
381 Ramirez-Pedraza M, Fernández M. Interplay Between Macrophages and Angiogenesis: A Double-Edged Sword in Liver Disease. Front Immunol 2019;10:2882. [PMID: 31921146 DOI: 10.3389/fimmu.2019.02882] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
382 Baldovin M, Saratziotis A, Zanotti C, Emanuelli E. Orbital metastasis from hepatocellular carcinoma revealed by sudden exophthalmos. BMJ Case Rep 2021;14:e242136. [PMID: 33980563 DOI: 10.1136/bcr-2021-242136] [Reference Citation Analysis]
383 Lei HJ, Wang SY, Chau IY, Li AF, Chau YP, Hsia CY, Chou SC, Kao YC, Chau GY. Hepatoma upregulated protein and Ki-67 expression in resectable hepatocellular carcinoma. J Chin Med Assoc 2021;84:623-32. [PMID: 33883465 DOI: 10.1097/JCMA.0000000000000540] [Reference Citation Analysis]
384 Lin YM, Taiji R, Calandri M, Odisio BC. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. Curr Oncol Rep 2021;23:67. [PMID: 33855606 DOI: 10.1007/s11912-021-01056-4] [Reference Citation Analysis]
385 Yang JD, Mara KC, Gores GJ, Roberts LR. Reply. Hepatology 2020;72:364-5. [PMID: 31901172 DOI: 10.1002/hep.31098] [Reference Citation Analysis]
386 Alqahtani SA, Colombo M. Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. Cells 2021;10:3091. [PMID: 34831314 DOI: 10.3390/cells10113091] [Reference Citation Analysis]
387 Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front Oncol 2020;10:601710. [PMID: 33330100 DOI: 10.3389/fonc.2020.601710] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
388 Melnik BC. Dairy consumption and hepatocellular carcinoma risk. Ann Transl Med 2021;9:736. [PMID: 33987434 DOI: 10.21037/atm-2020-ubih-06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
389 Liu H, Zhang C. Paeonol induces antitumor effects in hepatocellular carcinoma cells through survivin via the cyclooxygenase-2/prostaglandin E2 signaling pathway. Transl Cancer Res 2020;9:7183-95. [PMID: 35117322 DOI: 10.21037/tcr-20-322A] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
390 Janciauskiene S, Wrenger S, Günzel S, Gründing AR, Golpon H, Welte T. Potential Roles of Acute Phase Proteins in Cancer: Why Do Cancer Cells Produce or Take Up Exogenous Acute Phase Protein Alpha1-Antitrypsin? Front Oncol 2021;11:622076. [PMID: 33680966 DOI: 10.3389/fonc.2021.622076] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
391 Han LY, Yang JR, Zhao ZH, Gao S, Fan YC, Wang K. RIPK3 mRNA level acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma. Pathol Res Pract 2020;216:153147. [PMID: 32853963 DOI: 10.1016/j.prp.2020.153147] [Reference Citation Analysis]
392 Moore KJ, Hubbard AK, Williams LA, Spector LG. Childhood cancer incidence among specific Asian and Pacific Islander populations in the United States. Int J Cancer 2020;147:3339-48. [PMID: 32535909 DOI: 10.1002/ijc.33153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
393 Chandrashekar DS, Golonka RM, Yeoh BS, Gonzalez DJ, Heikenwälder M, Gerwirtz AT, Varambally S, Vijay-Kumar M. Fermentable fiber-induced hepatocellular carcinoma in mice recapitulates gene signatures found in human liver cancer. PLoS One 2020;15:e0234726. [PMID: 32559205 DOI: 10.1371/journal.pone.0234726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
394 Wu J, Ren X, Wang N, Zhou R, Chen M, Cai Y, Lin S, Zhang H, Xie X, Dang C, Zhang S, Zhou Z. A Mutation-Related Long Noncoding RNA Signature of Genome Instability Predicts Immune Infiltration and Hepatocellular Carcinoma Prognosis. Front Genet 2021;12:779554. [PMID: 34880908 DOI: 10.3389/fgene.2021.779554] [Reference Citation Analysis]
395 Tsai YC, Sou FM, Liu YW, Wu YJ, Yong CC, Chen DW, Huang PY, Cho WR, Chuang CH, Hsiao CC, Hu TH, Tsai MC. Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection. BMC Gastroenterol 2021;21:386. [PMID: 34666694 DOI: 10.1186/s12876-021-01944-w] [Reference Citation Analysis]
396 Liu X, Li T, Kong D, You H, Kong F, Tang R. Prognostic implications of alcohol dehydrogenases in hepatocellular carcinoma. BMC Cancer 2020;20:1204. [PMID: 33287761 DOI: 10.1186/s12885-020-07689-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
397 Elkhadragy L, Regan MR, M Totura W, Goli KD, Patel S, Garcia K, Stewart M, Schook LB, Gaba RC, Schachtschneider KM. Generation of genetically tailored porcine liver cancer cells by CRISPR/Cas9 editing. Biotechniques 2021;70:37-48. [PMID: 33222517 DOI: 10.2144/btn-2020-0119] [Reference Citation Analysis]
398 Sanz-garcía C, Fernández-iglesias A, Gracia-sancho J, Arráez-aybar LA, Nevzorova YA, Cubero FJ. The Space of Disse: The Liver Hub in Health and Disease. Livers 2021;1:3-26. [DOI: 10.3390/livers1010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
399 Huo J, Wu L, Zang Y. Development and Validation of a Metabolic-related Prognostic Model for Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:169-79. [PMID: 34007798 DOI: 10.14218/JCTH.2020.00114] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
400 Jiang Z, Zhang Y, Liu X, Liang J, Qiu G, Zhu X, Chen J, Li L. Identification of a Functional ceRNA Network to Explore Potential Biomarkers for Hepatocellular Carcinoma. Onco Targets Ther 2020;13:12341-55. [PMID: 33293827 DOI: 10.2147/OTT.S278912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
401 Ali ES, Rychkov GY, Barritt GJ. Targeting Ca2+ Signaling in the Initiation, Promotion and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2755. [PMID: 32987945 DOI: 10.3390/cancers12102755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
402 Ran X, Zhang C, Wang X, Zhao Q, Zhao Q, Yuan C, Kuang Y, Chen X, Chen X. Expression of CD28 in Hepatocellular Carcinoma and Its Prognostic Value. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.118605] [Reference Citation Analysis]
403 Qiu J, Zhang S, Wang P, Wang H, Sha B, Peng H, Ju Z, Rao J, Lu L. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway. Cancer Med 2020;9:8159-72. [PMID: 32977361 DOI: 10.1002/cam4.3411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
404 Mikhail AS, Mauda-Havakuk M, Negussie AH, Hong N, Hawken NM, Carlson CJ, Owen JW, Franco-Mahecha O, Wakim PG, Lewis Writing- AL, Pritchard WF, Karanian JW, Wood BJ. Evaluation of Immune-Modulating Drugs for Use in Drug-eluting Microsphere Transarterial Embolization. Int J Pharm 2022;:121466. [PMID: 35065205 DOI: 10.1016/j.ijpharm.2022.121466] [Reference Citation Analysis]
405 Ma YS, Liu JB, Lin L, Zhang H, Wu JJ, Shi Y, Jia CY, Zhang DD, Yu F, Wang HM, Yin YZ, Jiang XH, Wang PY, Tian LL, Cao PS, Wu XM, Lu HM, Gu LP, Zhang JJ, Cong GJ, Luo P, Zhong XM, Cai B, Shi MX, Zhang SQ, Li L, Zhang WJ, Liu Y, Li ZZ, Wu TM, Wu ZJ, Wang GR, Lv ZW, Ling CC, Chu KJ, Fu D. Exosomal microRNA-15a from mesenchymal stem cells impedes hepatocellular carcinoma progression via downregulation of SALL4. Cell Death Discov 2021;7:224. [PMID: 34455417 DOI: 10.1038/s41420-021-00611-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
406 Zhang J, Chen Y, Zhou C, Liu J, Liu S, Shi H, Zu Q, Solimando AG. Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-6. [DOI: 10.1155/2022/7982118] [Reference Citation Analysis]
407 Wang H, Wang R, Huang D, Li S, Gao B, Kang Z, Tang B, Xie J, Yan F, Liang R, Li H, Yan J. Homoharringtonine Exerts Anti-tumor Effects in Hepatocellular Carcinoma Through Activation of the Hippo Pathway. Front Pharmacol 2021;12:592071. [PMID: 33716735 DOI: 10.3389/fphar.2021.592071] [Reference Citation Analysis]
408 Huang Y, Yang X, Meng Y, Shao C, Liao J, Li F, Li R, Jing Y, Huang A. The hepatic senescence-associated secretory phenotype promotes hepatocarcinogenesis through Bcl3-dependent activation of macrophages. Cell Biosci 2021;11:173. [PMID: 34530917 DOI: 10.1186/s13578-021-00683-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
409 Roy S, Banerjee P, Ekser B, Bayless K, Zawieja D, Alpini G, Glaser SS, Chakraborty S. Targeting Lymphangiogenesis and Lymph Node Metastasis in Liver Cancer. Am J Pathol 2021;191:2052-63. [PMID: 34509441 DOI: 10.1016/j.ajpath.2021.08.011] [Reference Citation Analysis]
410 Sigurdsson B, Sigurdardottir R, Arnardottir MB, Lund SH, Jonasson JG, Björnsson ES. A nationwide study on hepatocellular carcinoma. Cancer Epidemiology 2020;69:101835. [DOI: 10.1016/j.canep.2020.101835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
411 Lin Z, Qu S, Peng W, Yang P, Zhang R, Zhang P, Guo D, Du J, Wu W, Tao K, Wang J. Up-Regulated CCDC34 Contributes to the Proliferation and Metastasis of Hepatocellular Carcinoma. Onco Targets Ther 2020;13:51-60. [PMID: 32021254 DOI: 10.2147/OTT.S237399] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
412 Al Mahtab M, Rahim MA, Noor-E-Alam SM, Alam MA, Khondaker FA, Moben AL, Ghosh J, Khan MSI. Treatment by Transarterial Chemoembolization and Sorafenib for Hepatocellular Carcinoma vs Advanced Hepatocellular Carcinoma in Bangladesh: A Real-life Situation. Euroasian J Hepatogastroenterol 2019;9:63-6. [PMID: 32117692 DOI: 10.5005/jp-journals-10018-1300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
413 Yang T, Chen Y, Xu J, Li J, Liu H, Liu N. Bioinformatics screening the novel and promising targets of curcumin in hepatocellular carcinoma chemotherapy and prognosis. BMC Complement Med Ther 2022;22:21. [PMID: 35078445 DOI: 10.1186/s12906-021-03487-9] [Reference Citation Analysis]
414 Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee KH, Chen E, Siegel AB, Ryoo BY. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer 2021;10:275-84. [PMID: 34239813 DOI: 10.1159/000515553] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Yan J, Man Z, Gao L, Cai L, Lu Q, Dong J. The role of CpG island methylator phenotype in the clinical course of hepatocellular carcinoma. Bioinformatics 2021:btab600. [PMID: 34406374 DOI: 10.1093/bioinformatics/btab600] [Reference Citation Analysis]
416 Lewinska M, Santos-Laso A, Arretxe E, Alonso C, Zhuravleva E, Jimenez-Agüero R, Eizaguirre E, Pareja MJ, Romero-Gómez M, Jimenez MA, Suppli MP, Knop FK, Oversoe SK, Villadsen GE, Decaens T, Carrilho FJ, de Oliveira CP, Sangro B, Macias RIR, Banales JM, Andersen JB. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. EBioMedicine 2021;73:103661. [PMID: 34740106 DOI: 10.1016/j.ebiom.2021.103661] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
417 Wang H, Yu H, Qian YW, Cao ZY, Wu MC, Cong WM. Postoperative adjuvant transcatheter arterial chemoembolization improves the prognosis of patients with huge hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021;20:232-9. [PMID: 33455865 DOI: 10.1016/j.hbpd.2020.12.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
418 Ganguly S, Dewanjee S, Sen R, Chattopadhyay D, Ganguly S, Gaonkar R, Debnath MC. Apigenin-loaded galactose tailored PLGA nanoparticles: A possible strategy for liver targeting to treat hepatocellular carcinoma. Colloids Surf B Biointerfaces 2021;204:111778. [PMID: 33915380 DOI: 10.1016/j.colsurfb.2021.111778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
419 Klöhn M, Schrader JA, Brüggemann Y, Todt D, Steinmann E. Beyond the Usual Suspects: Hepatitis E Virus and Its Implications in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5867. [PMID: 34831021 DOI: 10.3390/cancers13225867] [Reference Citation Analysis]
420 Sun JR, Kong CF, Xiao KM, Yang JL, Qu XK, Sun JH. Integrated Analysis of lncRNA-Mediated ceRNA Network Reveals a Prognostic Signature for Hepatocellular Carcinoma. Front Genet 2020;11:602542. [PMID: 33381151 DOI: 10.3389/fgene.2020.602542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
421 Saito N, Tanaka T, Minamiguchi K, Taiji R, Nishiofuku H, Matsumoto T, Hirai T, Kichikawa K, Kawahara N, Matsuda D, Akiyama I. Ultrasonic Heating Detects Lipiodol Deposition within Liver Tumors after Transarterial Embolization: An In Vivo Approach. Biology (Basel) 2021;10:901. [PMID: 34571777 DOI: 10.3390/biology10090901] [Reference Citation Analysis]
422 Premkumar M, Anand AC. Overview of Complications in Cirrhosis. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.021] [Reference Citation Analysis]
423 Fang T, Lu Q. A-kinase interacting protein 1 (AKIP1) associates with advanced overall disease condition, tumor properties, and unfavorable prognosis in hepatocellular carcinoma patients. J Clin Lab Anal 2020;34:e23213. [PMID: 32133702 DOI: 10.1002/jcla.23213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
424 Yang YC, Chien MH, Lai TC, Tung MC, Jan YH, Chang WM, Jung SM, Chen MH, Yeh CN, Hsiao M. Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma. J Biomed Sci 2021;28:29. [PMID: 33888099 DOI: 10.1186/s12929-021-00727-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
425 Pérez-López A, Martín-Sabroso C, Torres-Suárez AI, Aparicio-Blanco J. Timeline of Translational Formulation Technologies for Cancer Therapy: Successes, Failures, and Lessons Learned Therefrom. Pharmaceutics 2020;12:E1028. [PMID: 33126622 DOI: 10.3390/pharmaceutics12111028] [Reference Citation Analysis]
426 Feng X, Jiang T, Yang C, Pang S, Ding Z, Hu H, Wang H, Dong L, Yang N. RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding. Cell Death Dis 2021;13:6. [PMID: 34921137 DOI: 10.1038/s41419-021-04447-4] [Reference Citation Analysis]
427 Gupta R, Kleinjans J, Caiment F. Identifying novel transcript biomarkers for hepatocellular carcinoma (HCC) using RNA-Seq datasets and machine learning. BMC Cancer 2021;21:962. [PMID: 34445986 DOI: 10.1186/s12885-021-08704-9] [Reference Citation Analysis]
428 Ma W, Yao Y, Xu G, Wu X, Li J, Wang G, Chen X, Wang K, Chen Y, Guo Y, Li Y, Tan D, Guo H, Liu Z, Yuan Y, Claret FX. Identification of a seven-long non-coding RNA signature associated with Jab1/CSN5 in predicting hepatocellular carcinoma. Cell Death Discov 2021;7:178. [PMID: 34247194 DOI: 10.1038/s41420-021-00560-7] [Reference Citation Analysis]
429 Zhang C, Liu S, Yang M. Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options. Front Endocrinol (Lausanne) 2021;12:808526. [PMID: 35002979 DOI: 10.3389/fendo.2021.808526] [Reference Citation Analysis]
430 Wang L, Ke Q, Lin N, Huang Q, Zeng Y, Liu J. The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2019;36:1288-96. [PMID: 31852267 DOI: 10.1080/02656736.2019.1692148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
431 Chen VC, Lee MJ, Yang YH, Lu ML, Chiu WC, Dewey ME. Selective serotonin reuptake inhibitors use and hepatocellular carcinoma in patients with alcohol use disorder. Drug Alcohol Depend 2021;219:108495. [PMID: 33429293 DOI: 10.1016/j.drugalcdep.2020.108495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
432 Wu HL, Kuo HC, Li CC, Wu YM, Lin SP, Chang KY, Hou MC, Tsou MY, Cherng YG, Chen JT, Tai YH. A comparison of prognostic performance of perioperative inflammation markers in surgical resection for hepatocellular carcinoma. J Chin Med Assoc 2021;84:614-22. [PMID: 33883464 DOI: 10.1097/JCMA.0000000000000534] [Reference Citation Analysis]
433 Xie H, Alem Glison DM, Kim RD. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential. Expert Opin Investig Drugs 2021;:1-8. [PMID: 34913780 DOI: 10.1080/13543784.2022.2017879] [Reference Citation Analysis]
434 Wang Y, Xianyu Y. Nanobody and Nanozyme-Enabled Immunoassays with Enhanced Specificity and Sensitivity. Small Methods 2022;:e2101576. [PMID: 35266636 DOI: 10.1002/smtd.202101576] [Reference Citation Analysis]
435 Wu D, Yin YQ, Li Y, Zhang L, Jiang YH, Wang Z. CK2α causes stemness and chemotherapy resistance in liver cancer through the Hedgehog signaling pathway. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00173-9. [PMID: 34548224 DOI: 10.1016/j.hbpd.2021.09.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
436 Xue M, Lin X, Lin QX, Pu X, Liu J, Li XF, Hou J, Liu X, Chen R. Association between hepatitis B and E virus infection and hepatocellular carcinoma risk. Int J Cancer 2021;148:2974-81. [PMID: 33554326 DOI: 10.1002/ijc.33505] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
437 Cheng Y, Gunasegaran B, Singh HD, Dutertre C, Loh CY, Lim JQ, Crawford JC, Lee HK, Zhang X, Lee B, Becht E, Lim WJ, Yeong J, Chan CY, Chung A, Goh BK, Chow PK, Chan JK, Ginhoux F, Tai D, Chen J, Lim SG, Zhai W, Choo SP, Newell EW. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 2021;54:1825-1840.e7. [DOI: 10.1016/j.immuni.2021.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
438 Huo J, Wu L, Zang Y. Construction and Validation of a Reliable Six-Gene Prognostic Signature Based on the TP53 Alteration for Hepatocellular Carcinoma. Front Oncol 2021;11:618976. [PMID: 34178618 DOI: 10.3389/fonc.2021.618976] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
439 Wang W, Yang X, Li C, Li Y, Wang H, Han X. Immunogenic Cell Death (ICD) of Murine H22 Cells Induced by Lentinan. Nutr Cancer 2021;:1-10. [PMID: 33715541 DOI: 10.1080/01635581.2021.1897632] [Reference Citation Analysis]
440 Muhammad H, Tehreem A, Ting PS, Gurakar M, Li SY, Simsek C, Alqahtani SA, Kim AK, Kohli R, Gurakar A. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. J Clin Transl Hepatol 2021;9:738-48. [PMID: 34722189 DOI: 10.14218/JCTH.2021.00125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
441 Rimassa L, Personeni N, Czauderna C, Foerster F, Galle P. Systemic treatment of HCC in special populations. J Hepatol 2021;74:931-43. [PMID: 33248171 DOI: 10.1016/j.jhep.2020.11.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
442 Ding Y, Sun Z, Zhang S, Xu Q, Zhou L, Zhou D, Li Y, Han X, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Revealing the clinical significance and prognostic value of small nucleolar RNA SNORD31 in hepatocellular carcinoma. Biosci Rep 2020;40:BSR20201479. [PMID: 32697317 DOI: 10.1042/BSR20201479] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Aatresh AA, Alabhya K, Lal S, Kini J, Saxena PUP. LiverNet: efficient and robust deep learning model for automatic diagnosis of sub-types of liver hepatocellular carcinoma cancer from H&E stained liver histopathology images. Int J Comput Assist Radiol Surg 2021;16:1549-63. [PMID: 34053009 DOI: 10.1007/s11548-021-02410-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
444 Pericleous M, Khan SA. Epidemiology of HPB malignancy in the elderly. European Journal of Surgical Oncology 2021;47:503-13. [DOI: 10.1016/j.ejso.2020.03.222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
445 Chen W, Mao Y, Liu C, Wu H, Chen S. Exosome in Hepatocellular Carcinoma: an update. J Cancer 2021;12:2526-36. [PMID: 33854614 DOI: 10.7150/jca.54566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
446 Yamashita R, Long J, Saleem A, Rubin DL, Shen J. Deep learning predicts postsurgical recurrence of hepatocellular carcinoma from digital histopathologic images. Sci Rep 2021;11:2047. [PMID: 33479370 DOI: 10.1038/s41598-021-81506-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
447 Huo J, Wu L, Zang Y. A Prognostic Model of 15 Immune-Related Gene Pairs Associated With Tumor Mutation Burden for Hepatocellular Carcinoma. Front Mol Biosci 2020;7:581354. [PMID: 33282911 DOI: 10.3389/fmolb.2020.581354] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
448 Lei D, Hu G, Chen Y, Hao T, Gao Y, Luo F. Forkhead Box S1 Inhibits the Progression of Hepatocellular Carcinoma. Onco Targets Ther 2020;13:11839-48. [PMID: 33235470 DOI: 10.2147/OTT.S272596] [Reference Citation Analysis]
449 Kong W, Wang X, Zuo X, Mao Z, Cheng Y, Chen W. Development and Validation of an Immune-Related lncRNA Signature for Predicting the Prognosis of Hepatocellular Carcinoma. Front Genet 2020;11:1037. [PMID: 33101369 DOI: 10.3389/fgene.2020.01037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
450 Soares Mateus AR, Barros S, Pena A, Sanches Silva A. Mycotoxins in Pistachios (Pistacia vera L.): Methods for Determination, Occurrence, Decontamination. Toxins (Basel) 2021;13:682. [PMID: 34678975 DOI: 10.3390/toxins13100682] [Reference Citation Analysis]
451 Siddiqui S, Upadhyay S, Ahmad I, Hussain A, Ahamed M. Cytotoxicity of Moringa oleifera fruits on human liver cancer and molecular docking analysis of bioactive constituents against caspase-3 enzyme. J Food Biochem 2021;45:e13720. [PMID: 33856706 DOI: 10.1111/jfbc.13720] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
452 Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat 2021;28:493-507. [PMID: 33305479 DOI: 10.1111/jvh.13452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
453 Cho HJ, Baek GO, Yoon MG, Ahn HR, Son JA, Kim SS, Cheong JY, Eun JW. Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC. Diagnostics (Basel) 2021;11:1221. [PMID: 34359304 DOI: 10.3390/diagnostics11071221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
454 Mu X, Zhong Y, Zhang X, Qu C, Chen S. Early Diagnosis Value of DCE-MRI Hemodynamic Parameters in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-9. [DOI: 10.1155/2022/9556589] [Reference Citation Analysis]
455 Yuan G, Song Y, Li Q, Hu X, Zang M, Dai W, Cheng X, Huang W, Yu W, Chen M, Guo Y, Zhang Q, Chen J. Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients. Front Immunol 2020;11:613946. [PMID: 33488622 DOI: 10.3389/fimmu.2020.613946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
456 Liao SH, Chen CL, Hsu CY, Chien KL, Kao JH, Chen PJ, Chen TH, Chen CH. Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan. J Hepatol 2021;75:132-41. [PMID: 33689789 DOI: 10.1016/j.jhep.2021.02.029] [Reference Citation Analysis]
457 Chen Y, Zhao Y, Chen J, Peng C, Zhang Y, Tong R, Cheng Q, Yang B, Feng X, Lu Y, Xie H, Zhou L, Wu J, Zheng S. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1. Mol Cancer 2020;19:123. [PMID: 32772918 DOI: 10.1186/s12943-020-01239-w] [Cited by in Crossref: 27] [Cited by in F6Publishing: 36] [Article Influence: 13.5] [Reference Citation Analysis]
458 Lim Y, Ku NO. Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:6401. [PMID: 34203895 DOI: 10.3390/ijms22126401] [Reference Citation Analysis]
459 Guo Y, Ren Y, Dong X, Kan X, Zheng C. An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation. JHC 2022;Volume 9:343-55. [DOI: 10.2147/jhc.s358539] [Reference Citation Analysis]
460 Liu J, Kuang S, Zheng Y, Liu M, Wang L. Prognostic and predictive significance of the tumor microenvironment in hepatocellular carcinoma. Cancer Biomark 2021;32:99-110. [PMID: 34092607 DOI: 10.3233/CBM-203003] [Reference Citation Analysis]
461 Yuan G, Cheng X, Li Q, Zang M, Huang W, Fan W, Wu T, Ruan J, Dai W, Yu W, Chen M, Guo Y, Hu X, Chen J. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Onco Targets Ther 2020;13:12683-93. [PMID: 33328740 DOI: 10.2147/OTT.S286169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
462 Biterge Süt B. Computational analysis of TP53 vs. CTNNB1 mutations in hepatocellular carcinoma suggests distinct cancer subtypes with differential gene expression profiles and chromatin states. Comput Biol Chem 2020;89:107404. [PMID: 33096424 DOI: 10.1016/j.compbiolchem.2020.107404] [Reference Citation Analysis]
463 Lawal G, Xiao Y, Rahnemai-Azar AA, Tsilimigras DI, Kuang M, Bakopoulos A, Pawlik TM. The Immunology of Hepatocellular Carcinoma. Vaccines (Basel) 2021;9:1184. [PMID: 34696292 DOI: 10.3390/vaccines9101184] [Reference Citation Analysis]
464 Guan Q, Lin H, Miao L, Guo H, Chen Y, Zhuo Z, He J. Functions, mechanisms, and therapeutic implications of METTL14 in human cancer. J Hematol Oncol 2022;15:13. [PMID: 35115038 DOI: 10.1186/s13045-022-01231-5] [Reference Citation Analysis]
465 Lee HY, Hong IS. Targeting Liver Cancer Stem Cells: An Alternative Therapeutic Approach for Liver Cancer. Cancers (Basel). 2020;12. [PMID: 32987767 DOI: 10.3390/cancers12102746] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
466 Chin L, Theise ND, Loneker AE, Janmey PA, Wells RG. Lipid droplets disrupt mechanosensing in human hepatocytes. Am J Physiol Gastrointest Liver Physiol 2020;319:G11-22. [PMID: 32463334 DOI: 10.1152/ajpgi.00098.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
467 Cheng F, Wang L, Zhang J. Circular RNA 0016788 displays as a biomarker for tumor progression and poor prognosis in surgical hepatocellular carcinoma patients. J Clin Lab Anal 2020;34:e23300. [PMID: 32319701 DOI: 10.1002/jcla.23300] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
468 Qi Y, Fan L, Ran D, Xu J, Wang Y, Wu J, Zhang Z. Main Risk Factors of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J Oncol 2021;2021:7764817. [PMID: 34691178 DOI: 10.1155/2021/7764817] [Reference Citation Analysis]
469 Canale M, Foschi FG, Andreone P, Ercolani G, Marisi G, Conti F, Vukotic R, Guarneri V, Burgio V, Ratti F, Aldrighetti L, De Cobelli F, Cascinu S, Ulivi P, Casadei-Gardini A. Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery. HPB (Oxford) 2021:S1365-182X(21)00603-1. [PMID: 34366240 DOI: 10.1016/j.hpb.2021.06.421] [Reference Citation Analysis]
470 Ge J, Zhang X, Zhang B, Zhu L, Zhao M, Gao W, Chen D. Higher tumor protein kinase D1 correlates with increased tumor size, BCLC stage, CA199 level, AFP level and worse overall survival in hepatocellular carcinoma patients. Clin Res Hepatol Gastroenterol 2020:S2210-7401(20)30337-5. [PMID: 33281070 DOI: 10.1016/j.clinre.2020.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
471 Li YT, Wu HL, Liu CJ. Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. Int J Mol Sci 2021;22:9380. [PMID: 34502289 DOI: 10.3390/ijms22179380] [Reference Citation Analysis]
472 Ruiz-Margáin A, Román-Calleja BM, Moreno-Guillén P, González-Regueiro JA, Kúsulas-Delint D, Campos-Murguía A, Flores-García NC, Macías-Rodríguez RU. Nutritional therapy for hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(10): 1440-1452 [PMID: 34721776 DOI: 10.4251/wjgo.v13.i10.1440] [Reference Citation Analysis]
473 Hu K, Li NF, Li JR, Chen ZG, Wang JH, Sheng LQ. Exosome circCMTM3 promotes angiogenesis and tumorigenesis of hepatocellular carcinoma through miR-3619-5p/SOX9. Hepatol Res 2021. [PMID: 34233088 DOI: 10.1111/hepr.13692] [Reference Citation Analysis]
474 Icard P, Simula L, Wu Z, Berzan D, Sogni P, Dohan A, Dautry R, Coquerel A, Lincet H, Loi M, Fuks D. Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma? Drug Resist Updat 2021;:100790. [PMID: 34924279 DOI: 10.1016/j.drup.2021.100790] [Reference Citation Analysis]
475 Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020;111S:154170. [PMID: 32006558 DOI: 10.1016/j.metabol.2020.154170] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 29.0] [Reference Citation Analysis]
476 Zhang Y, Zhai Q, Feng X, Chen D, Lu Y, Hu J, Xie H, Zhou L, Wu J, Zheng S. Cancer cell-intrinsic STING is associated with CD8 + T-cell infiltration and might serve as a potential immunotherapeutic target in hepatocellular carcinoma. Clin Transl Oncol 2021;23:1314-24. [PMID: 33502741 DOI: 10.1007/s12094-020-02519-z] [Reference Citation Analysis]
477 Yao W, Liu C, Wang N, Zhou H, Chen H, Qiao W. An MRI-guided targeting dual-responsive drug delivery system for liver cancer therapy. J Colloid Interface Sci 2021;603:783-98. [PMID: 34246838 DOI: 10.1016/j.jcis.2021.06.151] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
478 Wang X, Zhang Y, Yang N, He H, Tao X, Kou C, Jiang J. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis. Biomed Res Int 2020;2020:5087643. [PMID: 33015170 DOI: 10.1155/2020/5087643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
479 Leone P, Solimando AG, Fasano R, Argentiero A, Malerba E, Buonavoglia A, Lupo LG, De Re V, Silvestris N, Racanelli V. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment. Vaccines (Basel) 2021;9:532. [PMID: 34065489 DOI: 10.3390/vaccines9050532] [Reference Citation Analysis]
480 Lin K, Huang Q, Huo Y, Zeng J, Ding Z, Guo P, Chen Z, Zeng Y, Liu J. Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma. Cancer Manag Res 2020;12:7771-81. [PMID: 32943923 DOI: 10.2147/CMAR.S257016] [Reference Citation Analysis]
481 Liu QQ, Liu YW, Xie YK, Zhang JH, Song CX, Wang JZ, Xie BH. Amplification of DDR2 mediates sorafenib resistance through NF-κB/c-Rel signaling in hepatocellular carcinoma. Cell Biol Int 2021;45:1906-16. [PMID: 33969575 DOI: 10.1002/cbin.11625] [Reference Citation Analysis]
482 El-Melegy MG, Eltaher HM, Gaballah A, El-Kamel AH. Enhanced oral permeability of Trans-Resveratrol using nanocochleates for boosting anticancer efficacy; in-vitro and ex-vivo appraisal. Eur J Pharm Biopharm 2021;168:166-83. [PMID: 34481049 DOI: 10.1016/j.ejpb.2021.08.020] [Reference Citation Analysis]
483 Zhao L, Ma N, Liu G, Mao N, Chen F, Li J. Lidocaine Inhibits Hepatocellular Carcinoma Development by Modulating circ_ITCH/miR-421/CPEB3 Axis. Dig Dis Sci 2021. [PMID: 33433806 DOI: 10.1007/s10620-020-06787-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
484 Li C, Chen J, Li Y, Wu B, Ye Z, Tian X, Wei Y, Hao Z, Pan Y, Zhou H, Yang K, Fu Z, Xu J, Lu Y. 6-Phosphogluconolactonase Promotes Hepatocellular Carcinogenesis by Activating Pentose Phosphate Pathway. Front Cell Dev Biol 2021;9:753196. [PMID: 34765603 DOI: 10.3389/fcell.2021.753196] [Reference Citation Analysis]
485 Xie Q, Ju T, Zhou C, Zhai L. LncRNA RNCR3 Promotes the Progression of HCC by Activating the Akt/GSK3β Signaling Pathway. Evid Based Complement Alternat Med 2020;2020:8367454. [PMID: 33062024 DOI: 10.1155/2020/8367454] [Reference Citation Analysis]
486 Huber TC, Bochnakova T, Koethe Y, Park B, Farsad K. Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies. J Hepatocell Carcinoma 2021;8:1181-93. [PMID: 34589446 DOI: 10.2147/JHC.S268300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
487 Jang SY, Tak WY, Park SY, Kweon YO, Lee YR, Kim G, Hur K, Han MH, Lee WK. Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases. Ann Lab Med 2021;41:302-9. [PMID: 33303715 DOI: 10.3343/alm.2021.41.3.302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
488 Wang MR, Fang D, Di MP, Guan JL, Wang G, Liu L, Sheng JQ, Tian DA, Li PY. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway. Int J Med Sci 2020;17:1224-34. [PMID: 32547318 DOI: 10.7150/ijms.45256] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
489 Li Z, Lin Y, Cheng B, Zhang Q, Cai Y. Identification and Analysis of Potential Key Genes Associated With Hepatocellular Carcinoma Based on Integrated Bioinformatics Methods. Front Genet 2021;12:571231. [PMID: 33767726 DOI: 10.3389/fgene.2021.571231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
490 Zheng L, Fang S, Chen A, Chen W, Qiao E, Chen M, Shu G, Zhang D, Kong C, Weng Q, Xu S, Zhao Z, Ji J. Piperlongumine synergistically enhances the antitumour activity of sorafenib by mediating ROS-AMPK activation and targeting CPSF7 in liver cancer. Pharmacol Res 2022;177:106140. [PMID: 35202819 DOI: 10.1016/j.phrs.2022.106140] [Reference Citation Analysis]
491 Xu Q, Xu H, Deng R, Li N, Mu R, Qi Z, Shen Y, Wang Z, Wen J, Zhao J, Weng D, Huang W. Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma. Cancer Cell Int 2021;21:190. [PMID: 33794886 DOI: 10.1186/s12935-021-01894-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
492 Yoneoka G, Bozhilov K, Wong LL. Prognostic ability of inflammation-based markers in radioembolization for hepatocellular carcinoma. Hepatoma Res 2020;6:67. [PMID: 33134551 DOI: 10.20517/2394-5079.2020.57] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
493 Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y, Taniai M, Ishikawa T, Yasui K, Takaki A, Takaguchi K, Ido A, Kurosaki M, Kanto T, Nishiguchi S; Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J Gastroenterol 2021;56:158-67. [PMID: 33219410 DOI: 10.1007/s00535-020-01748-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
494 Wu X, Zhang X, Tao L, Dai X, Chen P. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma. Biomed Res Int 2020;2020:2053902. [PMID: 32733931 DOI: 10.1155/2020/2053902] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
495 Lin W, Wang H, Zhong M, Yu S, Zhao S, Liang S, Du J, Cheng B, Gu W, Ling C. Effect and Molecular Mechanisms of Jiedu Recipe on Hypoxia-Induced Angiogenesis after Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2021;2021:6529376. [PMID: 33505496 DOI: 10.1155/2021/6529376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
496 Ji GW, Fan Y, Sun DW, Wu MY, Wang K, Li XC, Wang XH. Machine Learning to Improve Prognosis Prediction of Early Hepatocellular Carcinoma After Surgical Resection. J Hepatocell Carcinoma 2021;8:913-23. [PMID: 34414136 DOI: 10.2147/JHC.S320172] [Reference Citation Analysis]
497 Rui T, Xu S, Feng S, Zhang X, Huang H, Ling Q. The mir-767-105 cluster: a crucial factor related to the poor prognosis of hepatocellular carcinoma. Biomark Res 2020;8:7. [PMID: 32082574 DOI: 10.1186/s40364-020-0186-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
498 Huang R, Zhang L, Jin J, Zhou Y, Zhang H, Lv C, Lu D, Wu Y, Zhang H, Liu S, Chen H, Luan X, Zhang W. Bruceine D inhibits HIF-1α-mediated glucose metabolism in hepatocellular carcinoma by blocking ICAT/β-catenin interaction. Acta Pharm Sin B 2021;11:3481-92. [PMID: 34900531 DOI: 10.1016/j.apsb.2021.05.009] [Reference Citation Analysis]
499 Song M, Park HJ, Lee ES, Ahn HS, Park SB. Value of precontrast and portal venous phases for evaluating atypical hepatocellular carcinoma mimicking arterioportal shunt. Eur J Radiol 2021;143:109933. [PMID: 34492626 DOI: 10.1016/j.ejrad.2021.109933] [Reference Citation Analysis]
500 Qin M, Liang J, Yang D, Yang X, Cao P, Wang X, Ma N, Zhang L. Spatial analysis of dietary exposure of aflatoxins in peanuts and peanut oil in different areas of China. Food Res Int 2021;140:109899. [PMID: 33648201 DOI: 10.1016/j.foodres.2020.109899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
501 Suoh M, Hagihara A, Kageyama K, Yamamoto A, Enomoto M, Tamori A, Kawada N. Successful Transcatheter Arterial Embolization for Hemothorax from a Spontaneous Rupture of Hepatocellular Carcinoma Metastasis to the Chest Wall in an Elderly Patient. Intern Med 2021;60:2223-8. [PMID: 33612670 DOI: 10.2169/internalmedicine.6003-20] [Reference Citation Analysis]
502 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
503 Li H, Li Y, Zhang Y, Tan B, Huang T, Xiong J, Tan X, Ermolaeva MA, Fu L. MAPK10 Expression as a Prognostic Marker of the Immunosuppressive Tumor Microenvironment in Human Hepatocellular Carcinoma. Front Oncol 2021;11:687371. [PMID: 34408980 DOI: 10.3389/fonc.2021.687371] [Reference Citation Analysis]
504 da Costa AC, Sodergren M, Jayant K, Santa Cruz F, Spalding D, Pai M, Habib N. Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations. World J Gastroenterol 2020; 26(17): 2040-2048 [PMID: 32536773 DOI: 10.3748/wjg.v26.i17.2040] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
505 Marquardt JU, Edlich F. Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies. Front Oncol 2019;9:1421. [PMID: 31921676 DOI: 10.3389/fonc.2019.01421] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
506 Fu XW, Song CQ. Identification and Validation of Pyroptosis-Related Gene Signature to Predict Prognosis and Reveal Immune Infiltration in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:748039. [PMID: 34820376 DOI: 10.3389/fcell.2021.748039] [Reference Citation Analysis]
507 Favero A, Segatto I, Perin T, Belletti B. The many facets of miR-223 in cancer: Oncosuppressor, oncogenic driver, therapeutic target, and biomarker of response. Wiley Interdiscip Rev RNA 2021;:e1659. [PMID: 33951281 DOI: 10.1002/wrna.1659] [Reference Citation Analysis]
508 Pan Z, Liu C, Zhi Y, Xie Z, Wu L, Jiang M, Zhang Y, Zhou R, Zhao L. LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation. Oncogene 2021;40:2581-95. [PMID: 33686242 DOI: 10.1038/s41388-021-01736-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
509 Bansal R. Battling IL-17, the troublemaker in alcohol-induced hepatocellular carcinoma. J Hepatol 2020;72:809-12. [PMID: 32122724 DOI: 10.1016/j.jhep.2020.02.011] [Reference Citation Analysis]
510 Feng LH, Sun HC, Zhu XD, Liu XF, Zhang SZ, Li XL, Li Y, Tang ZY. Prognostic nomograms and risk classifications of outcomes in very early-stage hepatocellular carcinoma patients after hepatectomy. Eur J Surg Oncol 2021;47:681-9. [PMID: 33189491 DOI: 10.1016/j.ejso.2020.10.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
511 Chen J, Zhou J, Fu H, Ni X, Shan Y. Upregulation of oxidative stress-responsive 1(OXSR1) predicts poor prognosis and promotes hepatocellular carcinoma progression. Bioengineered 2020;11:958-71. [PMID: 32842855 DOI: 10.1080/21655979.2020.1814659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
512 Zhang J, Huang Z, Liu X, Wu C, Zhou W, Ye P, Stalin A, Lu S, Tan Y, Wu Z, Fan X, Zhang X, Wang M, Li B, Cheng G, Mou Y, Wu J, Wan S. Exploring the Multicomponent Synergy Mechanism of Yinzhihuang Granule in Inhibiting Inflammation-Cancer Transformation of Hepar Based on Integrated Bioinformatics and Network Pharmacology. BioMed Research International 2022;2022:1-13. [DOI: 10.1155/2022/6213865] [Reference Citation Analysis]
513 Sung PS, Jang JW, Lee J, Lee SK, Lee HL, Yang H, Nam HC, Lee SW, Bae SH, Choi JY, Han NI, Yoon SK. Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection. Front Oncol. 2020;10:1043. [PMID: 32695681 DOI: 10.3389/fonc.2020.01043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
514 Najafi M, Majidpoor J, Toolee H, Mortezaee K. The current knowledge concerning solid cancer and therapy. J Biochem Mol Toxicol 2021;:e22900. [PMID: 34462987 DOI: 10.1002/jbt.22900] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
515 Siegfried G, Descarpentrie J, Evrard S, Khatib AM. Proprotein convertases: Key players in inflammation-related malignancies and metastasis. Cancer Lett 2020;473:50-61. [PMID: 31899298 DOI: 10.1016/j.canlet.2019.12.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
516 Li LQ, Zhao WD, Su TS, Wang YD, Meng WW, Liang SX. Effect of Body Composition on Outcomes in Patients with Hepatocellular Carcinoma Undergoing Radiotherapy: A Retrospective Study. Nutr Cancer 2022;:1-10. [PMID: 35543186 DOI: 10.1080/01635581.2022.2074472] [Reference Citation Analysis]
517 Zhang B, Wang HY, Zhao DX, Wang DX, Zeng Q, Xi JF, Nan X, He LJ, Zhou JN, Pei XT, Yue W. The splicing regulatory factor hnRNPU is a novel transcriptional target of c-Myc in hepatocellular carcinoma. FEBS Lett 2021;595:68-84. [PMID: 33040326 DOI: 10.1002/1873-3468.13943] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
518 Yu S, Wang Y, Hou J, Li W, Wang X, Xiang L, Tan D, Wang W, Jiang L, Claret FX, Jiao M, Guo H. Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival.PLoS One. 2020;15:e0231003. [PMID: 32240238 DOI: 10.1371/journal.pone.0231003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
519 Nie X, Liu H, Wei X, Li L, Lan L, Fan L, Ma H, Liu L, Zhou Y, Hou R, Chen WD. miRNA-382-5p Suppresses the Expression of Farnesoid X Receptor to Promote Progression of Liver Cancer. Cancer Manag Res 2021;13:8025-35. [PMID: 34712060 DOI: 10.2147/CMAR.S324072] [Reference Citation Analysis]
520 Tang Y, Wu P, Li L, Xu W, Jiang J. Mesenchymal Stem Cells and Their Small Extracellular Vesicles as Crucial Immunological Efficacy for Hepatic Diseases. Front Immunol 2022;13:880523. [DOI: 10.3389/fimmu.2022.880523] [Reference Citation Analysis]
521 Zhang H, Xia P, Liu J, Chen Z, Ma W, Yuan Y. ATIC inhibits autophagy in hepatocellular cancer through the AKT/FOXO3 pathway and serves as a prognostic signature for modeling patient survival. Int J Biol Sci 2021;17:4442-58. [PMID: 34803509 DOI: 10.7150/ijbs.65669] [Reference Citation Analysis]
522 Zhang J, Chen P, Liu S, Zu Q, Shi H, Zhou C. Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma. JHC 2022;Volume 9:265-72. [DOI: 10.2147/jhc.s358658] [Reference Citation Analysis]
523 Huang C, Jiang X, Huang Y, Zhao L, Li P, Liu F. Identifying Dendritic Cell-Related Genes Through a Co-Expression Network to Construct a 12-Gene Risk-Scoring Model for Predicting Hepatocellular Carcinoma Prognosis. Front Mol Biosci 2021;8:636991. [PMID: 34109210 DOI: 10.3389/fmolb.2021.636991] [Reference Citation Analysis]
524 Cassinotto C, Nogue E, Morell M, Panaro F, Molinari N, Guiu B. Changing trends in hepatocellular carcinoma management: Results from a nationwide database in the last decade. Eur J Cancer 2021;146:48-55. [PMID: 33582392 DOI: 10.1016/j.ejca.2021.01.009] [Reference Citation Analysis]
525 Poch FG, Geyer B, Neizert CA, Gemeinhardt O, Niehues SM, Vahldiek JL, Frericks B, Lehmann KS. Periportal fields cause stronger cooling effects than veins in hepatic microwave ablation: an in vivo porcine study. Acta Radiol 2021;62:322-8. [PMID: 32493033 DOI: 10.1177/0284185120928929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
526 Gao H, Hao Y, Zhou X, Li H, Liu F, Zhu H, Song X, Niu Z, Ni Q, Chen MS, Lu J. Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma. Oncol Lett 2020;19:691-9. [PMID: 31885715 DOI: 10.3892/ol.2019.11191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
527 Huang G, Wang C, Fu X. Bidirectional deep neural networks to integrate RNA and DNA data for predicting outcome for patients with hepatocellular carcinoma. Future Oncol 2021. [PMID: 34374301 DOI: 10.2217/fon-2021-0659] [Reference Citation Analysis]
528 Zhang Z, Zeng P, Gao W, Zhou Q, Feng T, Tian X. Circadian clock: a regulator of the immunity in cancer. Cell Commun Signal 2021;19:37. [PMID: 33752691 DOI: 10.1186/s12964-021-00721-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
529 Li X, Diao W, Xue H, Wu F, Wang W, Jiang B, Bai J, Lian B, Feng W, Sun T, Yu W, Wu J, Qu M, Wang Y, Gao Z. Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma. Cancer Lett 2020;489:163-73. [PMID: 32592729 DOI: 10.1016/j.canlet.2020.06.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
530 Huo J, Cai J, Guan G, Liu H, Wu L. A Ferroptosis and Pyroptosis Molecular Subtype-Related Signature Applicable for Prognosis and Immune Microenvironment Estimation in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:761839. [PMID: 34869350 DOI: 10.3389/fcell.2021.761839] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
531 Lin H, Zhang X, Li G, Wong GL, Wong VW. Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:972-82. [PMID: 34966660 DOI: 10.14218/JCTH.2021.00201] [Reference Citation Analysis]
532 Sarno G, Montalti R, Giglio MC, Rompianesi G, Tomassini F, Scarpellini E, De Simone G, De Palma GD, Troisi RI. Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. Surg Oncol 2021;36:42-50. [PMID: 33307490 DOI: 10.1016/j.suronc.2020.11.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
533 Sharma U, Barwal TS, Malhotra A, Pant N, Vivek, Dey D, Gautam A, Tuli HS, Vasquez KM, Jain A. Long non-coding RNA TINCR as potential biomarker and therapeutic target for cancer. Life Sci 2020;257:118035. [PMID: 32622950 DOI: 10.1016/j.lfs.2020.118035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
534 Wang J, Lou J, Fu L, Jin Q. An independent poor-prognosis subtype of hepatocellular carcinoma based on the tumor microenvironment. J Int Med Res 2021;49:300060520980646. [PMID: 33567957 DOI: 10.1177/0300060520980646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
535 Gong J, Li Y, Yu J, Wang T, Duan J, Hu A, He X, Zhu X. The predictive role of preoperative serum glutamate dehydrogenase levels in microvascular invasion and hepatocellular carcinoma prognosis following liver transplantation-a single center retrospective study. PeerJ 2021;9:e12420. [PMID: 34760395 DOI: 10.7717/peerj.12420] [Reference Citation Analysis]
536 Feng YX, Li W, Wen XD, Zhang N, Liu WH, Yang ZY. Sinusoidal Endothelial Cell Progenitor Cells Promote Tumour Progression in Patients with Hepatocellular Carcinoma. Stem Cells Int 2020;2020:8819523. [PMID: 33312206 DOI: 10.1155/2020/8819523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
537 Tan S, Song X, Zhang C, Sun Y, Zhang J, Zhang Z, Zhang R, Zhang T, Zhu X, Tan H, Wang F. hsa-miR-9-5p-Mediated TSPAN9 Downregulation Is Positively Related to Both Poor Hepatocellular Carcinoma Prognosis and the Tumor Immune Infiltration. Journal of Immunology Research 2022;2022:1-10. [DOI: 10.1155/2022/9051229] [Reference Citation Analysis]
538 Ricciotti E, Wangensteen KJ, FitzGerald GA. Aspirin in Hepatocellular Carcinoma. Cancer Res 2021;81:3751-61. [PMID: 33893087 DOI: 10.1158/0008-5472.CAN-21-0758] [Reference Citation Analysis]
539 Fishbein A, Hammock BD, Serhan CN, Panigrahy D. Carcinogenesis: Failure of resolution of inflammation? Pharmacol Ther 2021;218:107670. [PMID: 32891711 DOI: 10.1016/j.pharmthera.2020.107670] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
540 Zhang K, Barry AE, Lamm R, Patel K, Schafer M, Dang H. The role of RNA binding proteins in hepatocellular carcinoma. Advanced Drug Delivery Reviews 2022. [DOI: 10.1016/j.addr.2022.114114] [Reference Citation Analysis]
541 Sadiq AM, Mashonganyika TJ, Mmbaga LG, Sadiq AM, Nkya GZ. Hepatocellular carcinoma in a non-cirrhotic liver with a tumor thrombus. Clin Case Rep 2021;9:e04800. [PMID: 34512986 DOI: 10.1002/ccr3.4800] [Reference Citation Analysis]
542 Liu W, Zhang F, Quan B, Li M, Lu S, Li J, Chen R, Yin X. The Prognostic Value of the Albumin to Gamma-Glutamyltransferase Ratio in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Dis Markers 2021;2021:3514827. [PMID: 34840628 DOI: 10.1155/2021/3514827] [Reference Citation Analysis]
543 Shibata O, Kamimura K, Ko M, Sakai N, Abe H, Morita S, Mizusawa T, Sato H, Sakamaki A, Terai S. Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature. Intern Med 2021;60:1709-15. [PMID: 33390501 DOI: 10.2169/internalmedicine.6580-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
544 He Q, Lin Z, Wang Z, Huang W, Tian D, Liu M, Xia L. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET. Oncogene 2020;39:7279-95. [PMID: 33046796 DOI: 10.1038/s41388-020-01500-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
545 Issac J, Raveendran PS, Das AV. RFX1: a promising therapeutic arsenal against cancer. Cancer Cell Int 2021;21:253. [PMID: 33964962 DOI: 10.1186/s12935-021-01952-6] [Reference Citation Analysis]
546 Li G, Du P, He J, Li Y. CircRNA circBACH1 (hsa_circ_0061395) serves as a miR-656-3p sponge to facilitate hepatocellular carcinoma progression through increasing SERBP1 expression. Biochem Biophys Res Commun 2021;556:1-8. [PMID: 33831787 DOI: 10.1016/j.bbrc.2021.03.136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
547 Khan H, Ni Z, Feng H, Xing Y, Wu X, Huang D, Chen L, Niu Y, Shi G. Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling. Phytomedicine 2021;91:153706. [PMID: 34517264 DOI: 10.1016/j.phymed.2021.153706] [Reference Citation Analysis]
548 Cucarull B, Tutusaus A, Subías M, Stefanovic M, Hernáez-Alsina T, Boix L, Reig M, García de Frutos P, Marí M, Colell A, Bruix J, Morales A. Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. Cancers (Basel) 2020;12:E332. [PMID: 32024199 DOI: 10.3390/cancers12020332] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
549 Hong Y, Ye M, Wang F, Fang J, Wang C, Luo J, Liu J, Liu J, Liu L, Zhao Q, Chang Y. MiR-21-3p Promotes Hepatocellular Carcinoma Progression via SMAD7/YAP1 Regulation. Front Oncol 2021;11:642030. [PMID: 33763375 DOI: 10.3389/fonc.2021.642030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
550 Liu LL, Zhang SW, Chao X, Wang CH, Yang X, Zhang XK, Wen YL, Yun JP, Luo RZ. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma. Cancer Immunol Immunother. 2021;70:417-429. [PMID: 32770259 DOI: 10.1007/s00262-020-02691-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
551 Govalan R, Luu M, Lauzon M, Kosari K, Ahn JC, Rich NE, Nissen N, Roberts LR, Singal AG, Yang JD. Therapeutic Underuse and Delay in Hepatocellular Carcinoma: Prevalence, Associated Factors, and Clinical Impact. Hepatol Commun 2021. [PMID: 34558830 DOI: 10.1002/hep4.1795] [Reference Citation Analysis]
552 Yan Y, Pan J, Chen Y, Xing W, Li Q, Wang D, Zhou X, Xie J, Miao C, Yuan Y, Zeng W, Chen D. Increased dopamine and its receptor dopamine receptor D1 promote tumor growth in human hepatocellular carcinoma. Cancer Commun (Lond) 2020;40:694-710. [PMID: 33017522 DOI: 10.1002/cac2.12103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
553 Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H, Yang P, Zhang H, Chen X, Xu A, Cui C, Zhu B, Wu J, Xin X, Wang J, Shan J, Chen J, Zheng Z, Xu L, Wen X, You Z, Ren Z, Liu X, Qiu M, Wu L, Chen F. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. J Clin Oncol 2021;:JCO2100163. [PMID: 34185551 DOI: 10.1200/JCO.21.00163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
554 Dietrich P, Wormser L, Fritz V, Seitz T, De Maria M, Schambony A, Kremer AE, Günther C, Itzel T, Thasler WE, Teufel A, Trebicka J, Hartmann A, Neurath MF, von Hörsten S, Bosserhoff AK, Hellerbrand C. Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer. J Clin Invest 2020;130:2509-26. [PMID: 31999643 DOI: 10.1172/JCI131919] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
555 Chen F, Wang J, Wu Y, Gao Q, Zhang S. Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy. Front Oncol 2022;12:822449. [DOI: 10.3389/fonc.2022.822449] [Reference Citation Analysis]
556 Oura K, Morishita A, Masaki T. Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review. Int J Mol Sci 2020;21:E8362. [PMID: 33171811 DOI: 10.3390/ijms21218362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
557 Song L, Luo Y, Li S, Hong M, Wang Q, Chi X, Yang C. ISL Induces Apoptosis and Autophagy in Hepatocellular Carcinoma via Downregulation of PI3K/AKT/mTOR Pathway in vivo and in vitro. Drug Des Devel Ther 2020;14:4363-76. [PMID: 33116421 DOI: 10.2147/DDDT.S270124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
558 Li LQ, Zhou Y, Huang Y, Liang P, Liang SX, Su TS. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Int 2021;15:630-41. [PMID: 33818714 DOI: 10.1007/s12072-021-10173-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
559 Su TS, Li LQ, Liang SX, Xiang BD, Li JX, Ye JZ, Li LQ. A Prospective Study of Liver Regeneration After Radiotherapy Based on a New (Su'S) Target Area Delineation. Front Oncol 2021;11:680303. [PMID: 34513671 DOI: 10.3389/fonc.2021.680303] [Reference Citation Analysis]
560 Schilf P, Srinivasulu V, Bolognesi ML, Ibrahim S, Majdalawieh AF, Abu-yousef IA, Omar HA, Elawady R, Al-tel TH. Design and synthesis of nature-inspired chromenopyrroles as potential modulators of mitochondrial metabolism. Med Chem Res 2021;30:635-46. [DOI: 10.1007/s00044-020-02669-3] [Reference Citation Analysis]
561 Li Y, Qiao L, Bai Y, Xiao C, Wu J, Gao X, Qiao C, Shi Y, Hou W, Wang J, Xie N, Liu N. Identification of SRGAP2 as a potential oncogene and a prognostic biomarker in hepatocellular carcinoma. Life Sci 2021;277:119592. [PMID: 33984363 DOI: 10.1016/j.lfs.2021.119592] [Reference Citation Analysis]
562 Li Y, Xiong H. Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways. BMC Cancer 2022;22:298. [PMID: 35313850 DOI: 10.1186/s12885-022-09398-3] [Reference Citation Analysis]
563 Zhao J, Li H, Zhao S, Wang E, Zhu J, Feng D, Zhu Y, Dou W, Fan Q, Hu J, Jia L, Liu L. Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling. Mol Cancer 2021;20:46. [PMID: 33658044 DOI: 10.1186/s12943-021-01343-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
564 Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. [DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
565 Hu H, Wang Y, Qin Z, Sun W, Chen Y, Wang J, Wang Y, Nie J, Chen L, Cai S, Yu L, Zeng S. Regulation of MRP4 Expression by circHIPK3 via Sponging miR-124-3p/miR-4524-5p in Hepatocellular Carcinoma. Biomedicines 2021;9:497. [PMID: 33946595 DOI: 10.3390/biomedicines9050497] [Reference Citation Analysis]
566 Huang PS, Liao CJ, Huang YH, Yeh CT, Chen CY, Tang HC, Chang CC, Lin KH. Functional and Clinical Significance of Dysregulated microRNAs in Liver Cancer. Cancers (Basel) 2021;13:5361. [PMID: 34771525 DOI: 10.3390/cancers13215361] [Reference Citation Analysis]
567 Tyagi A, Sarodaya N, Kaushal K, Chandrasekaran AP, Antao AM, Suresh B, Rhie BH, Kim KS, Ramakrishna S. E3 Ubiquitin Ligase APC/CCdh1 Regulation of Phenylalanine Hydroxylase Stability and Function. Int J Mol Sci 2020;21:E9076. [PMID: 33260674 DOI: 10.3390/ijms21239076] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
568 D'Agnano I, Berardi AC. Extracellular Vesicles, A Possible Theranostic Platform Strategy for Hepatocellular Carcinoma-An Overview. Cancers (Basel) 2020;12:E261. [PMID: 31973229 DOI: 10.3390/cancers12020261] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
569 Zhou J, Huang Z, Chen Z, Xu F, Tong R, Zheng S. Impact of donor age on liver transplant outcomes in patients with hepatocellular carcinoma: analysis of the SRTR database. BMC Gastroenterol 2021;21:195. [PMID: 33931011 DOI: 10.1186/s12876-021-01786-6] [Reference Citation Analysis]
570 Hayaza S, Wahyuningsih SPA, Susilo RJK, Husen SA, Winarni D, Doong RA, Darmanto W. Dual role of immunomodulation by crude polysaccharide from okra against carcinogenic liver injury in mice. Heliyon 2021;7:e06183. [PMID: 33659734 DOI: 10.1016/j.heliyon.2021.e06183] [Reference Citation Analysis]
571 Zhou Y, Yang G, Gong XQ, Tao YY, Wang R, Zheng J, Yang C, Peng J, Yang L, Li JD, Zhang XM. A study of the correlations between IVIM-DWI parameters and the histologic differentiation of hepatocellular carcinoma. Sci Rep 2021;11:10392. [PMID: 34001962 DOI: 10.1038/s41598-021-89784-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
572 Kaffe E, Magkrioti C, Aidinis V. Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer. Cancers (Basel) 2019;11:E1626. [PMID: 31652837 DOI: 10.3390/cancers11111626] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
573 Taskaeva YS, Makarova VV, Gogaeva IS, Bgatova NP. Morphological Analysis of Blood Capillaries and Transport Function of Endothelial Cells in Hepatocellular Carcinoma-29. Bull Exp Biol Med 2020;169:276-80. [PMID: 32651829 DOI: 10.1007/s10517-020-04867-w] [Reference Citation Analysis]
574 Cacicedo ML, Medina-Montano C, Kaps L, Kappel C, Gehring S, Bros M. Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy. Cells 2020;9:E1985. [PMID: 32872352 DOI: 10.3390/cells9091985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
575 Guan R, Sun B, Wang Z, Zhou C, Yang Z, Gan W, Huang J, Liu G, Zhou J, Fan J, Yi Y, Qiu S. Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma. The American Journal of Surgery 2022. [DOI: 10.1016/j.amjsurg.2022.01.008] [Reference Citation Analysis]
576 Tian Z, Zhao J, Wang Y. The prognostic value of TPM1-4 in hepatocellular carcinoma. Cancer Med 2021. [PMID: 34850589 DOI: 10.1002/cam4.4453] [Reference Citation Analysis]
577 Cao X, Cao Z, Shao Y, Liu C, Yan G, Meng X, Zhang L, Chen C, Huang G, Shu H, Lu H. Analysis of Serum Paraoxonase 1 Using Mass Spectrometry and Lectin Immunoassay in Patients With Alpha-Fetoprotein Negative Hepatocellular Carcinoma. Front Oncol 2021;11:651421. [PMID: 33889548 DOI: 10.3389/fonc.2021.651421] [Reference Citation Analysis]
578 Hu JW, Ding GY, Fu PY, Tang WG, Sun QM, Zhu XD, Shen YH, Zhou J, Fan J, Sun HC, Huang C. Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis. Biomed Res Int 2020;2020:6784138. [PMID: 32280695 DOI: 10.1155/2020/6784138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
579 Wu H, Wang MD, Liang L, Xing H, Zhang CW, Shen F, Huang DS, Yang T. Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management. Small 2021;17:e2005236. [PMID: 33448111 DOI: 10.1002/smll.202005236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
580 Sato N, Marubashi S. What is the optimal surgical treatment for hepatocellular carcinoma beyond the debate between anatomical versus non-anatomical resection? Surg Today 2021. [PMID: 34392420 DOI: 10.1007/s00595-021-02352-z] [Reference Citation Analysis]
581 Xu Q, Hu Y, Chen S, Zhu Y, Li S, Shen F, Guo Y, Sun T, Chen X, Jiang J, Huang W. Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:683240. [PMID: 34124163 DOI: 10.3389/fmolb.2021.683240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
582 Wong RJ, Kim D, Ahmed A, Singal AK. Patients with hepatocellular carcinoma from more rural and lower-income households have more advanced tumor stage at diagnosis and significantly higher mortality. Cancer 2020;127:45-55. [PMID: 33103243 DOI: 10.1002/cncr.33211] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
583 Wei H, Yan S, Hui Y, Liu Y, Guo H, Li Q, Li J, Chang Z. CircFAT1 promotes hepatocellular carcinoma progression via miR-30a-5p/REEP3 pathway. J Cell Mol Med 2020;24:14561-70. [PMID: 33179443 DOI: 10.1111/jcmm.16085] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
584 Feng Z, Li H, Zhao H, Jiang Y, Liu Q, Chen Q, Wang W, Rong P. Preoperative CT for Characterization of Aggressive Macrotrabecular-Massive Subtype and Vessels That Encapsulate Tumor Clusters Pattern in Hepatocellular Carcinoma. Radiology 2021;300:219-29. [PMID: 33973839 DOI: 10.1148/radiol.2021203614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
585 Vanderborght B, De Muynck K, Lefere S, Geerts A, Degroote H, Verhelst X, Van Vlierberghe H, Devisscher L. Effect of isoform-specific HIF-1α and HIF-2α antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse model. Oncotarget 2020;11:4504-20. [PMID: 33400730 DOI: 10.18632/oncotarget.27830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
586 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
587 Chen J, Hu X, Li Q, Dai W, Cheng X, Huang W, Yu W, Chen M, Guo Y, Yuan G. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients. Ann Transl Med 2020;8:1187. [PMID: 33241036 DOI: 10.21037/atm-20-6063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
588 Song T, Li L, Wu S, Liu Y, Guo C, Wang W, Dai L, Zhang T, Wu H, Su B. Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. Front Oncol 2021;11:583714. [PMID: 33777736 DOI: 10.3389/fonc.2021.583714] [Reference Citation Analysis]
589 Liu F, Liu W, Zhou S, Yang C, Tian M, Jia G, Wang H, Zhu B, Feng M, Lu Y, Qiao T, Wang X, Cao W, Wang X, Shi Y, Wu D. Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma. J Immunother Cancer 2020;8:e000501. [PMID: 32611686 DOI: 10.1136/jitc-2019-000501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
590 Kunjiappan S, Sankaranarayanan M, Karan Kumar B, Pavadai P, Babkiewicz E, Maszczyk P, Glodkowska-Mrowka E, Arunachalam S, Ram Kumar Pandian S, Ravishankar V, Baskararaj S, Vellaichamy S, Arulmani L, Panneerselvam T. Capsaicin-loaded solid lipid nanoparticles: design, biodistribution, in silico modeling and in vitro cytotoxicity evaluation. Nanotechnology 2021;32:095101. [PMID: 33113518 DOI: 10.1088/1361-6528/abc57e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
591 Wang J, Li X. Impact of statin use on the risk and prognosis of hepatocellular carcinoma: a meta-analysis. Eur J Gastroenterol Hepatol 2021;33:1603-9. [PMID: 33405428 DOI: 10.1097/MEG.0000000000002040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
592 Mungamuri SK, Mavuduru VA. Role of epigenetic alterations in aflatoxin‐induced hepatocellular carcinoma. Liver Cancer International 2020;1:41-50. [DOI: 10.1002/lci2.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
593 Zhang H, Chu K, Zheng C, Ren L, Tian R. Pseudogene DUXAP8 Promotes Cell Proliferation and Migration of Hepatocellular Carcinoma by Sponging MiR-490-5p to Induce BUB1 Expression. Front Genet 2020;11:666. [PMID: 32849765 DOI: 10.3389/fgene.2020.00666] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
594 Cui Y, Yun T, Zhao GG. Bioinformatics analysis of clinical significance of STMN1 gene in prognosis and immune infiltration in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2022; 30(9): 411-419 [DOI: 10.11569/wcjd.v30.i9.411] [Reference Citation Analysis]
595 Zarębska I, Gzil A, Durślewicz J, Jaworski D, Antosik P, Ahmadi N, Smolińska-Świtała M, Grzanka D, Szylberg Ł. The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers. Clin Res Hepatol Gastroenterol 2021;45:101664. [PMID: 33667731 DOI: 10.1016/j.clinre.2021.101664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
596 Fan M, Chen S, Weng Y, Li X, Jiang Y, Wang X, Bie M, An L, Zhang M, Chen B, Huang G, Wu J, Zhu M, Shi Q. Ciprofloxacin promotes polarization of CD86+CD206‑ macrophages to suppress liver cancer. Oncol Rep 2020;44:91-102. [PMID: 32377744 DOI: 10.3892/or.2020.7602] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
597 Changou CA, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. Oncologist 2021;26:e367-73. [PMID: 33140457 DOI: 10.1002/onco.13582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
598 Wang H, Xu F, Yang F, Lv L, Jiang Y. Prognostic significance and oncogene function of cathepsin A in hepatocellular carcinoma. Sci Rep 2021;11:14611. [PMID: 34272452 DOI: 10.1038/s41598-021-93998-9] [Reference Citation Analysis]
599 Gielen AHC, Samarska I, Den Dulk M, Beckervordersandforth J, Dejong KHC, Bouwense SAW, Dewulf M. Osteoclast-like giant cells in hepatocellular carcinoma case description and review of the literature. Acta Chir Belg 2021;:1-7. [PMID: 34110978 DOI: 10.1080/00015458.2021.1940443] [Reference Citation Analysis]
600 Fu J, Ding Z, Chen Q, Lin K, Liu H, Gao Y, Zeng Y, Li H, Shen F, Liu J. Distinct Impacts of Pre-Operative Antiviral Treatment on Post-Operative Outcomes of HBV-related Hepatocellular Carcinoma: A Landmark Analysis. J Cancer 2021;12:170-80. [PMID: 33391413 DOI: 10.7150/jca.47125] [Reference Citation Analysis]
601 Kim SY, Park C, Kim MY, Ji SY, Hwangbo H, Lee H, Hong SH, Han MH, Jeong JW, Kim GY, Son CG, Cheong J, Choi YH. ROS-Mediated Anti-Tumor Effect of Coptidis Rhizoma against Human Hepatocellular Carcinoma Hep3B Cells and Xenografts. Int J Mol Sci 2021;22:4797. [PMID: 33946527 DOI: 10.3390/ijms22094797] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
602 Lee ACK, Lau PM, Kwan YW, Kong SK. Mitochondrial Fuel Dependence on Glutamine Drives Chemo-Resistance in the Cancer Stem Cells of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:3315. [PMID: 33805044 DOI: 10.3390/ijms22073315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
603 Nguyen ALT, Nguyen HTT, Yee KC, Palmer AJ, Blizzard CL, de Graaff B. A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies. Value Health 2021;24:733-43. [PMID: 33933243 DOI: 10.1016/j.jval.2020.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
604 Parikh ND, Pillai A. Recent Advances in Hepatocellular Carcinoma Treatment. Clin Gastroenterol Hepatol 2021;19:2020-4. [PMID: 34116048 DOI: 10.1016/j.cgh.2021.05.045] [Reference Citation Analysis]
605 Ammar OA, El-missiry MA, Othman AI, Amer ME. Melatonin is a potential oncostatic agent to inhibit HepG2 cell proliferation through multiple pathways. Heliyon 2022;8:e08837. [DOI: 10.1016/j.heliyon.2022.e08837] [Reference Citation Analysis]
606 Guo JC, Liu Z, Yang YJ, Guo M, Zhang JQ, Zheng JF. KDM5B promotes self-renewal of hepatocellular carcinoma cells through the microRNA-448-mediated YTHDF3/ITGA6 axis. J Cell Mol Med 2021. [PMID: 33829656 DOI: 10.1111/jcmm.16342] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
607 Gangadhar KN, Rodrigues MJ, Pereira H, Gaspar H, Malcata FX, Barreira L, Varela J. Anti-Hepatocellular Carcinoma (HepG2) Activities of Monoterpene Hydroxy Lactones Isolated from the Marine Microalga Tisochrysis Lutea. Mar Drugs 2020;18:E567. [PMID: 33227960 DOI: 10.3390/md18110567] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
608 Stepanov YV, Golovynska I, Dziubenko NV, Kuznietsova HM, Petriv N, Skrypkina I, Golovynskyi S, Stepanova LI, Stohnii Y, Garmanchuk LV, Ostapchenko LI, Yevsa T, Qu J, Ohulchanskyy TY. NMDA receptor expression during cell transformation process at early stages of liver cancer in rodent models. Am J Physiol Gastrointest Liver Physiol 2021. [PMID: 34851733 DOI: 10.1152/ajpgi.00060.2021] [Reference Citation Analysis]
609 Qin S, Ren Z, Feng YH, Yau T, Wang B, Zhao H, Bai Y, Gu S, Li L, Hernandez S, Xu DZ, Mulla S, Wang Y, Shao H, Cheng AL. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. Liver Cancer 2021;10:296-308. [PMID: 34414118 DOI: 10.1159/000513486] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
610 Delaney LJ, Tantawi M, Wessner CE, Machado P, Forsberg F, Lyshchik A, O'Kane P, Liu JB, Civan J, Tan A, Anton K, Shaw CM, Eisenbrey JR. Predicting Long-Term Hepatocellular Carcinoma Response to Transarterial Radioembolization Using Contrast-Enhanced Ultrasound: Initial Experiences. Ultrasound Med Biol 2021;47:2523-31. [PMID: 34130880 DOI: 10.1016/j.ultrasmedbio.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
611 Hua H, Sheng J, Cui Y, Zhang W, Hu B, Cheng Y, Guo Y, Qian H. The Intervention and Mechanism of Action for Aloin against Subchronic Aflatoxin B1 Induced Hepatic Injury in Rats. Int J Mol Sci 2021;22:11620. [PMID: 34769051 DOI: 10.3390/ijms222111620] [Reference Citation Analysis]
612 Huang G, Liang M, Liu H, Huang J, Li P, Wang C, Zhang Y, Lin Y, Jiang X. CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p/RTKN2 axis and activating Wnt/β-catenin pathway. Cell Death Dis 2020;11:1065. [PMID: 33311442 DOI: 10.1038/s41419-020-03276-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
613 Chen W, Desert R, Ge X, Han H, Song Z, Das S, Athavale D, You H, Nieto N. The Matrisome Genes From Hepatitis B-Related Hepatocellular Carcinoma Unveiled. Hepatol Commun 2021;5:1571-85. [PMID: 34510837 DOI: 10.1002/hep4.1741] [Reference Citation Analysis]
614 Qiu S, Zhong C, Zhao B, Li G, Wang J, Jehan S, Li J, Zhao X, Li D, Sui G. Transcriptome analysis of signaling pathways targeted by Ellagic acid in hepatocellular carcinoma cells. Biochim Biophys Acta Gen Subj 2021;1865:129911. [PMID: 33862123 DOI: 10.1016/j.bbagen.2021.129911] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
615 Lin Y, Zhang J, Arroyo A, Singal AG, Parikh ND, Lubman DM. A Fucosylated Glycopeptide as a Candidate Biomarker for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation. Front Oncol 2022;12:818001. [DOI: 10.3389/fonc.2022.818001] [Reference Citation Analysis]
616 Mahmoud K, Swidan S, El-nabarawi M, Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01309-9] [Reference Citation Analysis]
617 Feldbrügge L, Langenscheidt A, Krenzien F, Schulz M, Krezdorn N, Kamali K, Hinz A, Bartels M, Fikatas P, Schmelzle M, Pratschke J, Benzing C. Health-Related Quality of Life and Mental Health after Surgical Treatment of Hepatocellular Carcinoma in the Era of Minimal-Invasive Surgery: Resection versus Transplantation. Healthcare (Basel) 2021;9:694. [PMID: 34207501 DOI: 10.3390/healthcare9060694] [Reference Citation Analysis]
618 Du Y, Liu D, Du Y. Recent advances in hepatocellular carcinoma therapeutic strategies and imaging-guided treatment. J Drug Target 2021;:1-15. [PMID: 34727794 DOI: 10.1080/1061186X.2021.1999963] [Reference Citation Analysis]
619 Ren J, Tong YM, Cui RX, Wang Z, Li QL, Liu W, Qu K, Zhang JY, Liu C, Wan Y. Comparison of survival between adolescent and young adult vs older patients with hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(12): 1394-1406 [PMID: 33362910 DOI: 10.4251/wjgo.v12.i12.1394] [Reference Citation Analysis]
620 Ho CM, Hu RH, Wu YM, Ho MC, Lee PH. Cross-Match as an Immuno-Oncological Risk Factor for Hepatocellular Carcinoma Recurrence and Inferior Survival After Living Donor Liver Transplantation: A Call for Further Investigation. Clin Med Insights Oncol 2020;14:1179554920968774. [PMID: 33343205 DOI: 10.1177/1179554920968774] [Reference Citation Analysis]
621 Nair A, Reece K, Donoghue MB, Yuan WV, Rodriguez L, Keegan P, Pazdur R. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma. Oncologist 2021;26:e484-91. [PMID: 33044793 DOI: 10.1002/onco.13566] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
622 Tao PY, Zhang ZS, Wang TC, Yu MQ, Xiao YD. A predictive model of incomplete response after transarterial chemoembolization for early or intermediate stage of hepatocellular carcinoma: consideration of hepatic angiographic and cross-sectional imaging. Abdom Radiol (NY) 2021;46:581-9. [PMID: 32761406 DOI: 10.1007/s00261-020-02701-5] [Reference Citation Analysis]
623 Lu H, Wu L, Yuan R, Liao W, Lei J, Shao J. Modified median hepatic fissure approach for resection of liver tumours located in the angle between the root of the middle and right hepatic veins. BMC Surg 2021;21:410. [PMID: 34861838 DOI: 10.1186/s12893-021-01412-y] [Reference Citation Analysis]
624 Digifico E, Balinzo S, Belgiovine C. The Dark Side of the Force: When the Immune System Is the Fuel of Tumor Onset. Int J Mol Sci 2021;22:1224. [PMID: 33513730 DOI: 10.3390/ijms22031224] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
625 Zhang Y, Xu J, Qiu Z, Guan Y, Zhang X, Zhang X, Chai D, Chen C, Hu Q, Wang W. STK25 enhances hepatocellular carcinoma progression through the STRN/AMPK/ACC1 pathway. Cancer Cell Int 2022;22:4. [PMID: 34986838 DOI: 10.1186/s12935-021-02421-w] [Reference Citation Analysis]
626 Dirchwolf M, Marciano S, Ruf AE, Singal AG, D'Ercole V, Coisson P, Zerega A, Orozco F, Palazzo A, Fassio E, Arufe D, Anders M, D'Amico C, Gaite L, Thompson M, Perez D, Haddad L, Demirdjian E, Zunino M, Gadano A, Murga MD, Bermudez C, Tomatis J, Grigera N, Antinucci F, Baravalle M, Gazari MMR, Ferreiro M, Barbero M, Curia A, Demonte M, Gualano G. Failure in all steps of hepatocellular carcinoma surveillance process is frequent in daily practice. Ann Hepatol 2021;25:100344. [PMID: 33819695 DOI: 10.1016/j.aohep.2021.100344] [Reference Citation Analysis]
627 Cen D, Ge Q, Xie C, Zheng Q, Guo J, Zhang Y, Wang Y, Li X, Gu Z, Cai X. ZnS@BSA Nanoclusters Potentiate Efficacy of Cancer Immunotherapy. Adv Mater 2021;:e2104037. [PMID: 34622500 DOI: 10.1002/adma.202104037] [Reference Citation Analysis]
628 Cohen O, Aleem M, Wolberink S, Perenyei MA. Giant pedunculated liver mass: primary hepatocellular carcinoma masquerading as hepatic haemangioma. BMJ Case Rep 2021;14:e242625. [PMID: 34593547 DOI: 10.1136/bcr-2021-242625] [Reference Citation Analysis]
629 Ahn JC, Qureshi TA, Singal AG, Li D, Yang JD. Deep learning in hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2021; 13(12): 2039-2051 [DOI: 10.4254/wjh.v13.i12.2039] [Reference Citation Analysis]
630 Ogawa H, Kaji K, Nishimura N, Takagi H, Ishida K, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis. J Cell Mol Med 2021;25:4001-13. [PMID: 33609067 DOI: 10.1111/jcmm.16363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
631 Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, He Y, Swiatek-de Lange M, Morgenstern D, Chan HL. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. Hepatol Commun 2021. [PMID: 34796691 DOI: 10.1002/hep4.1847] [Reference Citation Analysis]
632 Kaps L, Schuppan D. Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers. Cells 2020;9:E2027. [PMID: 32899119 DOI: 10.3390/cells9092027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
633 Meng F, Liu J, Lu T, Zang L, Wang J, He Q, Zhou A. SNHG1 knockdown upregulates miR-376a and downregulates FOXK1/Snail axis to prevent tumor growth and metastasis in HCC. Mol Ther Oncolytics 2021;21:264-77. [PMID: 34095464 DOI: 10.1016/j.omto.2021.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
634 Mossenta M, Busato D, Dal Bo M, Toffoli G. Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers (Basel) 2020;12:E1668. [PMID: 32585931 DOI: 10.3390/cancers12061668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
635 Carroll HK, Duffy AG, O'Farrelly C. Liver Immunology, Immunotherapy, and Liver Cancers: Time for a Rethink? Semin Liver Dis 2022. [PMID: 35263795 DOI: 10.1055/s-0042-1744143] [Reference Citation Analysis]
636 Aghabi YO, Yasin A, Kennedy JI, Davies SP, Butler AE, Stamataki Z. Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer. Front Immunol 2021;12:662134. [PMID: 33953725 DOI: 10.3389/fimmu.2021.662134] [Reference Citation Analysis]
637 Khaled J, Kopsida M, Lennernäs H, Heindryckx F. Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma. Cells 2022;11:632. [DOI: 10.3390/cells11040632] [Reference Citation Analysis]
638 Hou X, Liu W, Yang X, Shao C, Gao L, Zhang L, Wei L. Extracellular microparticles derived from hepatic progenitor cells deliver a death signal to hepatoma-initiating cells. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01280-5] [Reference Citation Analysis]
639 Wang H, Luo J, Tian X, Xu L, Zhai Z, Cheng M, Chen L, Luo S. DNAJC5 promotes hepatocellular carcinoma cells proliferation though regulating SKP2 mediated p27 degradation. Biochim Biophys Acta Mol Cell Res 2021;1868:118994. [PMID: 33662413 DOI: 10.1016/j.bbamcr.2021.118994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
640 Yu Q, Chen W, Li Y, He J, Wang Y, Yang S, Zhou J. The novel circular RNA HIPK3 accelerates the proliferation and invasion of hepatocellular carcinoma cells by sponging the micro RNA-124 or micro RNA-506/pyruvate dehydrogenase kinase 2 axis. Bioengineered 2022;13:4717-29. [PMID: 35212603 DOI: 10.1080/21655979.2022.2031398] [Reference Citation Analysis]
641 Krishnamurthy S, Gilot D, Ahn SB, Lam V, Shin JS, Guillemin GJ, Heng B. Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5180. [PMID: 34680327 DOI: 10.3390/cancers13205180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
642 Nasereldin DS, White LJ, Hodge DO, Roberts LR, Patel T, Antwi SO. Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk. Dig Liver Dis 2021:S1590-8658(21)00889-6. [PMID: 34953761 DOI: 10.1016/j.dld.2021.12.002] [Reference Citation Analysis]
643 Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. World J Clin Oncol 2021; 12(8): 623-645 [PMID: 34513597 DOI: 10.5306/wjco.v12.i8.623] [Reference Citation Analysis]
644 Golonka RM, Vijay-Kumar M. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome. Adv Cancer Res 2021;149:171-255. [PMID: 33579424 DOI: 10.1016/bs.acr.2020.10.004] [Reference Citation Analysis]
645 Zhang L, Ke W, Zhao X, Lu Z. Resina Draconis extract exerts anti-HCC effects through METTL3-m6A-Survivin axis. Phytother Res 2022. [PMID: 35443090 DOI: 10.1002/ptr.7467] [Reference Citation Analysis]
646 Liu P, Wei J, Mao F, Xin Z, Duan H, Du Y, Wang X, Li Z, Qian J, Yao J. Establishment of a Prognostic Model for Hepatocellular Carcinoma Based on Endoplasmic Reticulum Stress-Related Gene Analysis. Front Oncol 2021;11:641487. [PMID: 34094926 DOI: 10.3389/fonc.2021.641487] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
647 Wang J, Huang Z, Lu H, Zhang R, Feng Q, He A, Kloczkowski A. A Pyroptosis-Related Gene Signature to Predict Patients’ Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma. Computational and Mathematical Methods in Medicine 2022;2022:1-17. [DOI: 10.1155/2022/1258480] [Reference Citation Analysis]
648 Sakr MA, Mohamed KAH, Hussein AM, Fouad MH, Allam AS, Safwat E. Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00090-y] [Reference Citation Analysis]
649 Paik JM, Golabi P, Younossi Y, Srishord M, Mishra A, Younossi ZM. The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007-2017. Hepatol Commun 2020;4:1769-80. [PMID: 33305148 DOI: 10.1002/hep4.1599] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
650 Guo D, Ma D, Liu P, Lan J, Liu Z, Liu Q. DNASE1L3 arrests tumor angiogenesis by impairing the senescence-associated secretory phenotype in response to stress. Aging (Albany NY) 2021;13:9874-99. [PMID: 33744849 DOI: 10.18632/aging.202740] [Reference Citation Analysis]
651 Lin CY, Liu YS, Pan KT, Chen CB, Hung CF, Chou CT. The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment. Sci Rep 2021;11:12277. [PMID: 34112836 DOI: 10.1038/s41598-021-91021-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
652 Fujiwara N, Hoshida Y. Viral Exposure Signature Associated with Liver Cancer Risk. Trends Mol Med 2020;26:711-3. [PMID: 32654969 DOI: 10.1016/j.molmed.2020.06.008] [Reference Citation Analysis]
653 Zhu C, Ho YJ, Salomao MA, Dapito DH, Bartolome A, Schwabe RF, Lee JS, Lowe SW, Pajvani UB. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. J Hepatol 2021;74:613-26. [PMID: 33038431 DOI: 10.1016/j.jhep.2020.09.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
654 Chen H, Tao M, Li D, Han J, Cheng C, Ma Y, Wu Y, Shelat VG, Tustumi F, Satapathy SK, Kang KJ, Wang Q. An evaluation of the reporting quality in clinical practice guidelines for hepatocellular carcinoma using the RIGHT checklist. Ann Transl Med 2021;9:1004. [PMID: 34277804 DOI: 10.21037/atm-21-2611] [Reference Citation Analysis]
655 Liu C, Yang S, Zhang Y, Wang C, Du D, Wang X, Liu T, Liang G. Emerging Roles of N6-Methyladenosine Demethylases and Its Interaction with Environmental Toxicants in Digestive System Cancers. Cancer Manag Res 2021;13:7101-14. [PMID: 34526822 DOI: 10.2147/CMAR.S328188] [Reference Citation Analysis]
656 Cheung MLM, Kan MWK, Yeung VTY, Poon DMC, Kam MKM, Lee LKY, Chan ATC. The radiobiological effect of using Acuros XB vs anisotropic analytical algorithm on hepatocellular carcinoma stereotactic body radiation therapy. Med Dosim 2022:S0958-3947(22)00014-0. [PMID: 35241348 DOI: 10.1016/j.meddos.2022.01.004] [Reference Citation Analysis]
657 Li Y, Wu B, Sun R, Zhao M, Li N. miR-93-5p knockdown repressed hepatocellular carcinoma progression via increasing ERBB4 and TETs-dependent DNA demethylation. Autoimmunity 2021;:1-14. [PMID: 34435526 DOI: 10.1080/08916934.2021.1969552] [Reference Citation Analysis]
658 Chen M, Li J, Shu G, Shen L, Qiao E, Zhang N, Fang S, Chen X, Zhao Z, Tu J, Song J, Du Y, Ji J. Homogenous multifunctional microspheres induce ferroptosis to promote the anti-hepatocarcinoma effect of chemoembolization. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01385-x] [Reference Citation Analysis]
659 Chen YS, Sun R, Chen WL, Yau YC, Hsu FT, Chung JG, Tsai CJ, Hsieh CL, Chiu YM, Chen JH. The In Vivo Radiosensitizing Effect of Magnolol on Tumor Growth of Hepatocellular Carcinoma. In Vivo 2020;34:1789-96. [PMID: 32606148 DOI: 10.21873/invivo.11973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
660 Huo J, Wu L, Zang Y. Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma. J Cell Mol Med 2021;25:1151-65. [PMID: 33300278 DOI: 10.1111/jcmm.16181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
661 Liu H, Gao Y, Hu S, Fan Z, Wang X, Li S. Bioinformatics Analysis of Differentially Expressed Rhythm Genes in Liver Hepatocellular Carcinoma. Front Genet 2021;12:680528. [PMID: 34149816 DOI: 10.3389/fgene.2021.680528] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
662 Deldar Abad Paskeh M, Mirzaei S, Ashrafizadeh M, Zarrabi A, Sethi G. Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways. J Hepatocell Carcinoma 2021;8:1415-44. [PMID: 34858888 DOI: 10.2147/JHC.S336858] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
663 Wang Q, Bin C, Xue Q, Gao Q, Huang A, Wang K, Tang N. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell Death Dis 2021;12:426. [PMID: 33931597 DOI: 10.1038/s41419-021-03718-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
664 Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, Guan Y, Jia H, Chen J, Lu L, Xie F, Qin L. 68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma. Front Oncol 2021;11:693640. [PMID: 34249748 DOI: 10.3389/fonc.2021.693640] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
665 Atwa SM, Odenthal M, M El Tayebi H. Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4343. [PMID: 34503153 DOI: 10.3390/cancers13174343] [Reference Citation Analysis]
666 Chen Z, Zou Y, Zhang Y, Chen Z, Wu F, Jin H, Shi N, Rai SN. A Pyroptosis-Based Prognostic Model for Immune Microenvironment Estimation of Hepatocellular Carcinoma. Disease Markers 2022;2022:1-17. [DOI: 10.1155/2022/8109771] [Reference Citation Analysis]
667 Albhaisi S, Shamsaddini A, Fagan A, McGeorge S, Sikaroodi M, Gavis E, Patel S, Davis BC, Acharya C, Sterling RK, Matherly S, Fuchs M, Gillevet PM, Bajaj JS. Gut Microbial Signature of Hepatocellular Cancer in Men With Cirrhosis. Liver Transpl 2021;27:629-40. [PMID: 33492761 DOI: 10.1002/lt.25994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
668 Li B, Lam KO, Lee VH, Fang W. Editorial: Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2021;11:698515. [PMID: 34178698 DOI: 10.3389/fonc.2021.698515] [Reference Citation Analysis]
669 Giannakoulis VG, Dubovan P, Papoutsi E, Kataki A, Koskinas J. Senescence in HBV-, HCV- and NAFLD- Mediated Hepatocellular Carcinoma and Senotherapeutics: Current Evidence and Future Perspective. Cancers (Basel) 2021;13:4732. [PMID: 34572959 DOI: 10.3390/cancers13184732] [Reference Citation Analysis]
670 Cabiati M, Salvadori C, Basta G, Del Turco S, Aretini P, Cecchettini A, Del Ry S. miRNA and long non-coding RNA transcriptional expression in hepatocellular carcinoma cell line-secreted extracellular vesicles. Clin Exp Med 2021. [PMID: 34319456 DOI: 10.1007/s10238-021-00744-6] [Reference Citation Analysis]
671 Zhou F, Lei Y, Xu X, Zhou H, Liu H, Jiang J, Yang Y, Wu B. LINC00355:8 promotes cell proliferation and migration with invasion via the MiR-6777-3p/Wnt10b axis in Hepatocellular Carcinoma. J Cancer 2020;11:5641-55. [PMID: 32913459 DOI: 10.7150/jca.43831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
672 Wang W, Deng Z, Jin Z, Wu G, Wang J, Zhu H, Xu B, Wen Z, Guo Y. Bioinformatics analysis and experimental verification of five metabolism-related lncRNAs as prognostic models for hepatocellular carcinoma. Medicine (Baltimore) 2022;101:e28694. [PMID: 35089224 DOI: 10.1097/MD.0000000000028694] [Reference Citation Analysis]
673 Lücke J, Sabihi M, Zhang T, Bauditz LF, Shiri AM, Giannou AD, Huber S. The good and the bad about separation anxiety: roles of IL-22 and IL-22BP in liver pathologies. Semin Immunopathol 2021. [PMID: 33851257 DOI: 10.1007/s00281-021-00854-z] [Reference Citation Analysis]
674 Ivanics T, Shwaartz C, Claasen MPAW, Patel MS, Yoon P, Raschzok N, Wallace D, Muaddi H, Murillo Perez CF, Hansen BE, Selzner N, Sapisochin G. Trends in indications and outcomes of liver transplantation in Canada: A multicenter retrospective study. Transpl Int 2021;34:1444-54. [PMID: 33977568 DOI: 10.1111/tri.13903] [Reference Citation Analysis]
675 Zeng Z, Cao Z, Tang Y. Identification of diagnostic and prognostic biomarkers, and candidate targeted agents for hepatitis B virus-associated early stage hepatocellular carcinoma based on RNA-sequencing data. Oncol Lett 2020;20:231. [PMID: 32968453 DOI: 10.3892/ol.2020.12094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
676 Frager SZ, Schwartz JM. Hepatocellular carcinoma: epidemiology, screening, and assessment of hepatic reserve. Curr Oncol 2020;27:S138-43. [PMID: 33343207 DOI: 10.3747/co.27.7181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
677 Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the Early Detection of Hepatocellular Carcinoma.Cancer Epidemiol Biomarkers Prev. 2020;29:2495-2503. [PMID: 32238405 DOI: 10.1158/1055-9965.EPI-20-0005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
678 Dai X, Jiang W, Ma L, Sun J, Yan X, Qian J, Wang Y, Shi Y, Ni S, Yao N. A metabolism-related gene signature for predicting the prognosis and therapeutic responses in patients with hepatocellular carcinoma. Ann Transl Med 2021;9:500. [PMID: 33850897 DOI: 10.21037/atm-21-927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
679 Thangavelu L, Geetha RV, Devaraj E, Dua K, Chellappan DK, Balusamy SR. Acacia catechu seed extract provokes cytotoxicity via apoptosis by intrinsic pathway in HepG2 cells. Environ Toxicol 2021. [PMID: 34800081 DOI: 10.1002/tox.23411] [Reference Citation Analysis]
680 Huang X, Xiong Y, Yang J, Yang G, Li J. The Prognostic Significance of miR-21 Expression among Surgically Resected Hepatocellular Carcinoma Patients: Evidence from a Meta-Analysis and Retrospective Cohort Study. Biomed Res Int 2020;2020:8848158. [PMID: 33415165 DOI: 10.1155/2020/8848158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
681 Gull N, Arshad F, Naikoo GA, Hassan IU, Pedram MZ, Ahmad A, Aljabali AAA, Mishra V, Satija S, Charbe N, Negi P, Goyal R, Serrano-Aroca Á, Al Zoubi MS, El-Tanani M, Tambuwala MM. Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from Curcuma longa in Hepatocellular Carcinoma. J Gastrointest Cancer 2022. [PMID: 35285010 DOI: 10.1007/s12029-022-00809-z] [Reference Citation Analysis]
682 Li Q, Xu H, Sui C, Zhang H. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. Clin Res Hepatol Gastroenterol 2021;:101781. [PMID: 34332136 DOI: 10.1016/j.clinre.2021.101781] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
683 Kole C, Charalampakis N, Tsakatikas S, Vailas M, Moris D, Gkotsis E, Kykalos S, Karamouzis MV, Schizas D. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers (Basel) 2020;12:E2859. [PMID: 33020428 DOI: 10.3390/cancers12102859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
684 Yim SY, Lee JS. An Overview of the Genomic Characterization of Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1077-88. [PMID: 34522690 DOI: 10.2147/JHC.S270533] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
685 Ji D, Chen GF, Niu XX, Zhang M, Wang C, Shao Q, Wu V, Wang Y, Cheng G, Hurwitz SJ, Schinazi RF, Lau G. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Metabol Open 2021;10:100090. [PMID: 33889834 DOI: 10.1016/j.metop.2021.100090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
686 Shuyao W, Mingyang B, Feifei M, Xiaoqin H. CK19 Predicts Recurrence and Prognosis of HBV Positive HCC. J Gastrointest Surg 2021. [PMID: 34506016 DOI: 10.1007/s11605-021-05107-w] [Reference Citation Analysis]
687 Liang X, Liangliang X, Peng W, Tao Y, Jinfu Z, Ming Z, Mingqing X. Combined prognostic nutritional index and albumin-bilirubin grade to predict the postoperative prognosis of HBV-associated hepatocellular carcinoma patients. Sci Rep 2021;11:14624. [PMID: 34272447 DOI: 10.1038/s41598-021-94035-5] [Reference Citation Analysis]
688 Jing-jing Z, Xiao-jie C, Wen-dong Y, Ying-hui W, Hang-sheng Z, Hong-yue Z, Zhi-hong Z, Bin-hui W, Fan-zhu L. Fabrication of A Folic Acid-Modified Arsenic Trioxide Prodrug Liposome and Assessment of its Anti-Hepatocellular Carcinoma Activity. Digital Chinese Medicine 2020;3:260-74. [DOI: 10.1016/j.dcmed.2020.12.005] [Reference Citation Analysis]
689 Singh SK, Mishra MK, Rivers BM, Gordetsky JB, Bae S, Singh R. Biological and Clinical Significance of the CCR5/CCL5 Axis in Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 32260550 DOI: 10.3390/cancers12040883] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
690 Yang D, Yao M, Yan Y, Liu Y, Wen X, Chen X, Lu F. Deoxycholic Acid Upregulates Serum Golgi Protein 73 through Activating NF-κB Pathway and Destroying Golgi Structure in Liver Disease. Biomolecules 2021;11:205. [PMID: 33540642 DOI: 10.3390/biom11020205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
691 Lim J, Chon YE, Kim MN, Lee JH, Hwang SG, Lee HC, Ha Y. Cirrhosis, Age, and Liver Stiffness-Based Models Predict Hepatocellular Carcinoma in Asian Patients with Chronic Hepatitis B. Cancers (Basel) 2021;13:5609. [PMID: 34830764 DOI: 10.3390/cancers13225609] [Reference Citation Analysis]
692 Hu Y, Qin T, Li S, Zhang T, Xue J. Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial. Front Oncol. 2020;10:1589. [PMID: 32984021 DOI: 10.3389/fonc.2020.01589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
693 Lim MS, Goh GB, Chang JP, Low JK, Shelat VG, Huey TC, Dan YY, Kow A, Shridhar I, Tan PS, Junnarkar SP, Tan CK. A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade. JGH Open 2021;5:1015-8. [PMID: 34584969 DOI: 10.1002/jgh3.12624] [Reference Citation Analysis]
694 Kardani K, Sadat SM, Kardani M, Bolhassani A. The next generation of HCV vaccines: a focus on novel adjuvant development. Expert Rev Vaccines 2021;20:839-55. [PMID: 34114513 DOI: 10.1080/14760584.2021.1941895] [Reference Citation Analysis]
695 Li K, Tharwat M, Larson EL, Felgendreff P, Hosseiniasl SM, Rmilah AA, Safwat K, Ross JJ, Nyberg SL. Re-Endothelialization of Decellularized Liver Scaffolds: A Step for Bioengineered Liver Transplantation. Front Bioeng Biotechnol 2022;10:833163. [DOI: 10.3389/fbioe.2022.833163] [Reference Citation Analysis]
696 Wei H, Jiang H, Qin Y, Wu Y, Lee JM, Yuan F, Zheng T, Duan T, Zhang Z, Qu Y, Chen J, Chen Y, Ye Z, Yao S, Zhang L, Yang T, Song B. Comparison of a preoperative MR-based recurrence risk score versus the postoperative score and four clinical staging systems in hepatocellular carcinoma: a retrospective cohort study. Eur Radiol 2022. [PMID: 35554652 DOI: 10.1007/s00330-022-08811-6] [Reference Citation Analysis]
697 Huang L, Songyang Z, Dai Z, Xiong Y. Field cancerization profile-based prognosis signatures lead to more robust risk evaluation in hepatocellular carcinoma. iScience 2022;25:103747. [DOI: 10.1016/j.isci.2022.103747] [Reference Citation Analysis]
698 Liu B, Shang X, Shi J, Cui G, Li X, Wang N. Early Alpha-Fetoprotein Response Is Associated With Survival in Patients With HBV-Related Hepatocellular Carcinoma Receiving Lenvatinib. Front Oncol 2022;12:807189. [DOI: 10.3389/fonc.2022.807189] [Reference Citation Analysis]
699 Agostinho N, Bains HK, Douglas CP, Walcott J, Brown KGM, Rawson R, Sandroussi C, Perera MRS. Pop goes the tumour! Spontaneous haemorrhage of a hepatocellular carcinoma tumour. J Surg Case Rep 2021;2021:rjaa598. [PMID: 33569166 DOI: 10.1093/jscr/rjaa598] [Reference Citation Analysis]
700 Zhou J, Wang W, Li Q. Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages. J Exp Clin Cancer Res 2021;40:73. [PMID: 33596985 DOI: 10.1186/s13046-021-01873-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
701 Chen YH, Wu WK, Wu MS. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. Int J Mol Sci 2020;21:E5999. [PMID: 32825440 DOI: 10.3390/ijms21175999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
702 Arif D, Mettler T, Adeyi OA. Mimics of hepatocellular carcinoma: a review and an approach to avoiding histopathological diagnostic missteps. Hum Pathol 2021;112:116-27. [PMID: 33346018 DOI: 10.1016/j.humpath.2020.12.002] [Reference Citation Analysis]
703 Wang X, Chen Y, Dong K, Ma Y, Jin Q, Yin S, Zhu X, Wang S. Effects of FER1L4-miR-106a-5p/miR-372-5p-E2F1 regulatory axis on drug resistance in liver cancer chemotherapy. Mol Ther Nucleic Acids 2021;24:449-61. [PMID: 33868788 DOI: 10.1016/j.omtn.2021.02.006] [Reference Citation Analysis]
704 Ma T, Ma Y, Du Y, Wei Z, Wang J, Jun Y, Xiao F. Circular RNA hsa_circ_0013958 Functions as an Oncogenic Gene Through Modulating miR-532-3p/WEE1 Axis in Hepatocellular Carcinoma. Front Oncol 2021;11:585172. [PMID: 33937016 DOI: 10.3389/fonc.2021.585172] [Reference Citation Analysis]
705 Ma E, Li J, Xing H, Li R, Shen C, Zhang Q, Ma Z, Tao Y, Qin L, Zhao J, Wang Z. Development of a predictive nomogram for early recurrence of hepatocellular carcinoma in patients undergoing liver transplantation. Ann Transl Med 2021;9:468. [PMID: 33850865 DOI: 10.21037/atm-21-334] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
706 Wang Z, Li M, Liu Y, Qiao Z, Bai T, Yang L, Liu B. Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response‑induced upregulation of CHAC1 expression. Oncol Rep 2021;46:240. [PMID: 34558645 DOI: 10.3892/or.2021.8191] [Reference Citation Analysis]
707 Alves AF, Moura AC, Andreolla HF, Veiga ABGD, Fiegenbaum M, Giovenardi M, Almeida S. Gene expression evaluation of antioxidant enzymes in patients with hepatocellular carcinoma: RT-qPCR and bioinformatic analyses. Genet Mol Biol 2021;44:e20190373. [PMID: 33821873 DOI: 10.1590/1678-4685-GMB-2019-0373] [Reference Citation Analysis]
708 Wen DG, Zhao XP, You Y, Liu ZJ. Systematic analysis of immune-related genes based on a combination of multiple databases to build a diagnostic and a prognostic risk model for hepatocellular carcinoma. Cancer Immunol Immunother 2021;70:773-86. [PMID: 32989553 DOI: 10.1007/s00262-020-02733-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
709 Kido T, Tabatabai ZL, Chen X, Lau YC. Potential dual functional roles of the Y-linked RBMY in hepatocarcinogenesis. Cancer Sci 2020;111:2987-99. [PMID: 32473614 DOI: 10.1111/cas.14506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
710 Liu C, Chen H, Zhou H, Yu S, Wang N, Yao W, Lu AH, Qiao W. Magnetic Resonance Imaging-Guided Multi-Stimulus-Responsive Drug Delivery Strategy for Personalized and Precise Cancer Treatment. ACS Appl Mater Interfaces 2021;13:50716-32. [PMID: 34668377 DOI: 10.1021/acsami.1c13853] [Reference Citation Analysis]
711 Harkus U, Wankell M, Palamuthusingam P, Mcfarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.005] [Reference Citation Analysis]
712 Shi Q, Xue C, Yuan X, He Y, Yu Z. Gene signatures and prognostic values of m1A-related regulatory genes in hepatocellular carcinoma. Sci Rep 2020;10:15083. [PMID: 32934298 DOI: 10.1038/s41598-020-72178-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
713 Keshavarz P, Raman SS. Comparison of combined transarterial chemoembolization and ablations in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Abdom Radiol. [DOI: 10.1007/s00261-021-03368-2] [Reference Citation Analysis]
714 Dai T, Deng M, Ye L, Lin G, Liu R, Deng Y, Li R, Liu W, Li H, Yang Y, Chen G, Wang G. Nomograms based on clinicopathological factors and inflammatory indicators for prediction of early and late recurrence of hepatocellular carcinoma after surgical resection for patients with chronic hepatitis B.Ann Transl Med. 2021;9:12. [PMID: 33553305 DOI: 10.21037/atm-20-1353] [Reference Citation Analysis]
715 Gessain G, Blériot C, Ginhoux F. Non-genetic Heterogeneity of Macrophages in Diseases-A Medical Perspective. Front Cell Dev Biol 2020;8:613116. [PMID: 33381508 DOI: 10.3389/fcell.2020.613116] [Reference Citation Analysis]
716 Wei T, Lin R, Fu X, Lu Y, Zhang W, Li Z, Zhang J, Wang H. Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergizes the anticancer effects of sorafenib in hepatocellular carcinoma. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106244] [Reference Citation Analysis]
717 Panayotova G, Lunsford KE, Latt NL, Paterno F, Guarrera JV, Pyrsopoulos N. Expanding indications for liver transplantation in the era of liver transplant oncology. World J Gastrointest Surg 2021; 13(5): 392-405 [PMID: 34122730 DOI: 10.4240/wjgs.v13.i5.392] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
718 de Mattos ÂZ, Debes JD, Boonstra A, Yang JD, Balderramo DC, Sartori GDP, de Mattos AA. Current impact of viral hepatitis on liver cancer development: The challenge remains. World J Gastroenterol 2021; 27(24): 3556-3567 [PMID: 34239269 DOI: 10.3748/wjg.v27.i24.3556] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
719 Mostafa AM, Saafan HA, Al-Tawashi AS, Kasem MH, Alaa AM, Eltobgy MM, Moubarak AS, Gharib MM, Awwad MA, Omar HM, El-Derany MO. Interleukin-17 haplotyping predicts hepatocellular carcinoma in sofosbuvir, pegylated interferon-alpha-2a & ribavirin treated chronic hepatitis C patients. Virus Res 2021;292:198226. [PMID: 33171166 DOI: 10.1016/j.virusres.2020.198226] [Reference Citation Analysis]
720 Cucarull B, Tutusaus A, Hernáez-Alsina T, García de Frutos P, Reig M, Colell A, Marí M, Morales A. Antioxidants Threaten Multikinase Inhibitor Efficacy against Liver Cancer by Blocking Mitochondrial Reactive Oxygen Species. Antioxidants (Basel) 2021;10:1336. [PMID: 34572967 DOI: 10.3390/antiox10091336] [Reference Citation Analysis]
721 Zhang C, Ke Y, Lei X, Liu X, Li H, Shi R, Wang L. The relationship among Girdin DNA methylation, its high expression, and immune infiltration in hepatocellular carcinoma: Clues from in silico analysis. Biosci Rep 2021;41:BSR20204006. [PMID: 33660763 DOI: 10.1042/BSR20204006] [Reference Citation Analysis]
722 Teran-Saavedra NG, Sarabia-Sainz JA, Velázquez-Contreras EF, Ramos-Clamont Montfort G, Pedroza-Montero M, Vazquez-Moreno L. Albumin-Albumin/Lactosylated Core-Shell Nanoparticles: Therapy to Treat Hepatocellular Carcinoma for Controlled Delivery of Doxorubicin. Molecules 2020;25:E5432. [PMID: 33233564 DOI: 10.3390/molecules25225432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
723 Moni SS, Alam MF, Safhi MM, Sultan MH, Makeen HA, Elmobark ME. Development of Formulation Methods and Physical Characterization of Injectable Sodium Selenite Nanoparticles for the Delivery of Sorafenib tosylate. Curr Pharm Biotechnol 2020;21:659-66. [PMID: 31886748 DOI: 10.2174/1389201021666191230124041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
724 Ou D, Tseng S, Kempson IM, Hsu C, Yang P, Liao Z. Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti‐PD1 in Liver Cancer. Adv Therap 2021;4:2100048. [DOI: 10.1002/adtp.202100048] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
725 Shang BB, Chen J, Wang ZG, Liu H. Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma. PeerJ 2021;9:e12315. [PMID: 34754620 DOI: 10.7717/peerj.12315] [Reference Citation Analysis]
726 Yuan G, Li R, Li Q, Hu X, Ruan J, Fan W, Wang J, Huang W, Zang M, Chen J. Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study. Ann Transl Med 2021;9:1412. [PMID: 34733964 DOI: 10.21037/atm-21-3020] [Reference Citation Analysis]
727 Ladju RB, Ulhaq ZS, Soraya GV. Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma. World J Gastroenterol 2022; 28(2): 176-187 [DOI: 10.3748/wjg.v28.i2.176] [Reference Citation Analysis]
728 Xu W, Zhao ZY, An QM, Dong B, Lv A, Li CP, Guan XY, Tian XY, Wu JH, Hao CY. Comprehensive comparison of patient-derived xenograft models in Hepatocellular Carcinoma and metastatic Liver Cancer. Int J Med Sci 2020;17:3073-81. [PMID: 33173428 DOI: 10.7150/ijms.46686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
729 Ramai D, Dang-Ho KP, Kewalramani A, Bandaru P, Sacco R, Giacomelli L, Shah A, Papa S, Cappellini F, Perversi F, di Nunzio S, Facciorusso A. Hospital Frailty Risk Score Is Independently Associated with Mortality and Encephalopathy in Hospitalized Patients with Hepatocellular Carcinoma. Biomedicines 2021;9:1693. [PMID: 34829921 DOI: 10.3390/biomedicines9111693] [Reference Citation Analysis]
730 Woo HY, Yoo SY, Heo J. Peretinoin, an Acyclic Retinoid, for the Secondary Prevention of Hepatocellular Carcinoma. Molecules 2021;26:E295. [PMID: 33435572 DOI: 10.3390/molecules26020295] [Reference Citation Analysis]
731 Lee SE, Alcedo KP, Kim HJ, Snider NT. Alternative Splicing in Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol. 2020;10:699-712. [PMID: 32389640 DOI: 10.1016/j.jcmgh.2020.04.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
732 Al-shami A, Oweis RJ, Al-fandi MG. Developing an electrochemical immunosensor for early diagnosis of hepatocellular carcinoma. SR 2021;41:125-34. [DOI: 10.1108/sr-02-2020-0030] [Reference Citation Analysis]
733 Han SR, Lee CH, Im JY, Kim JH, Kim JH, Kim SJ, Cho YW, Kim E, Kim Y, Ryu JH, Ju MH, Jeong JS, Lee SW. Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation. Mol Ther Nucleic Acids 2021;23:154-68. [PMID: 33335800 DOI: 10.1016/j.omtn.2020.10.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
734 Chen L, Yi C, Li W, Tseng Y, Zhang J, Liu J. Inhibition of SPATS2 Suppresses Proliferation and Invasion of Hepatocellular Carcinoma Cells through TRIM44-STAT3 Signaling Pathway. J Cancer 2021;12:89-98. [PMID: 33391405 DOI: 10.7150/jca.47526] [Reference Citation Analysis]
735 Wang Y, Yang F, Shang J, He H, Yang Q. Integrative analysis reveals the prognostic value and functions of splicing factors implicated in hepatocellular carcinoma. Sci Rep 2021;11:15175. [PMID: 34312475 DOI: 10.1038/s41598-021-94701-8] [Reference Citation Analysis]
736 Choi HI, An GY, Baek M, Yoo E, Chai JC, Lee YS, Jung KH, Chai YG. BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4. Sci Rep 2021;11:11799. [PMID: 34083693 DOI: 10.1038/s41598-021-91284-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
737 Zhou H, Chen Y. CircRNA has_circ_0001806 promotes hepatocellular carcinoma progression via the miR-193a-5p/MMP16 pathway. Braz J Med Biol Res 2021;54:e11459. [PMID: 34730679 DOI: 10.1590/1414-431X2021e11459] [Reference Citation Analysis]
738 Sharma A, Seow JJW, Dutertre C, Pai R, Blériot C, Mishra A, Wong RMM, Singh GSN, Sudhagar S, Khalilnezhad S, Erdal S, Teo HM, Khalilnezhad A, Chakarov S, Lim TKH, Fui ACY, Chieh AKW, Chung CP, Bonney GK, Goh BK, Chan JK, Chow PK, Ginhoux F, Dasgupta R. Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell 2020;183:377-394.e21. [DOI: 10.1016/j.cell.2020.08.040] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 23.5] [Reference Citation Analysis]
739 Xie Y, Wang Y, Xue W, Zou H, Li K, Liu K, Zhao W, Zhu C, Cao J. Profiling and Integrated Analysis of Differentially Expressed MicroRNAs as Novel Biomarkers of Hepatocellular Carcinoma. Front Oncol 2022;11:770918. [DOI: 10.3389/fonc.2021.770918] [Reference Citation Analysis]
740 Feng X, Mu S, Ma Y, Wang W. Development and Verification of an Immune-Related Gene Pairs Prognostic Signature in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:715728. [PMID: 34660693 DOI: 10.3389/fmolb.2021.715728] [Reference Citation Analysis]
741 Zhen Z, Shen Z, Hu Y, Sun P. Screening and identification of angiogenesis-related genes as potential novel prognostic biomarkers of hepatocellular carcinoma through bioinformatics analysis. Aging (Albany NY) 2021;13:17707-33. [PMID: 34252885 DOI: 10.18632/aging.203260] [Reference Citation Analysis]
742 Lee CW, Lin SE, Yu MC, Kou HW, Lee CH, Kuo T, Lee KC, Tsai HI. Does Neutrophil to Lymphocyte Ratio Have a Role in Identifying Cytokeratin 19-Expressing Hepatocellular Carcinoma? J Pers Med 2021;11:1078. [PMID: 34834430 DOI: 10.3390/jpm11111078] [Reference Citation Analysis]
743 Hedrich V, Breitenecker K, Djerlek L, Ortmayr G, Mikulits W. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers (Basel) 2021;13:5448. [PMID: 34771611 DOI: 10.3390/cancers13215448] [Reference Citation Analysis]
744 Lei P, Chen H, Feng C, Yuan X, Xiong Z, Liu Y, Liao W. Noninvasive Visualization of Sub-5 mm Orthotopic Hepatic Tumors by a Nanoprobe-Mediated Positive and Reverse Contrast-Balanced Imaging Strategy. ACS Nano 2022. [PMID: 35005889 DOI: 10.1021/acsnano.1c08477] [Reference Citation Analysis]
745 Maevskaya M, Kotovskaya Y, Ivashkin V, Tkacheva O, Troshina E, Shestakova M, Breder V, Geyvandova N, Doschitsin V, Dudinskaya E, Ershova E, Kodzoeva K, Komshilova K, Korochanskaya N, Mayorov A, Mishina E, Nadinskaya M, Nikitin I, Pogosova N, Tarzimanova A, Shamkhalova M. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii arkhiv. [DOI: 10.26442/00403660.2022.02.201363] [Reference Citation Analysis]
746 Aby ES, Sultan A, Bane A, Wondifraw Z, Debes JD. Outcomes of sorafenib therapy in advanced hepatocellular carcinoma in a single center in Ethiopia. Eur J Gastroenterol Hepatol 2020;32:1407-8. [PMID: 32858664 DOI: 10.1097/MEG.0000000000001818] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
747 Chen YS, Yang SY, Wang PM, Wang CC, Yong CC, Chen DW, Liu YW, Chuang CH, Huang PY, Yao CC, Lin YP, Tsai MC. Concurrent Cholecystectomy Is Associated with a Lower Risk of Recurrence after Curative Resection in Early-Stage Hepatocellular Carcinoma: A 10 Year Observational Single-Center Study. J Pers Med 2021;11:1261. [PMID: 34945733 DOI: 10.3390/jpm11121261] [Reference Citation Analysis]
748 Ge Y, Gu P, Wang W, Cao L, Zhang L, Li J, Mu W, Wang H. Benzo[a]pyrene stimulates miR-650 expression to promote the pathogenesis of fatty liver disease and hepatocellular carcinoma via SOCS3/JAK/STAT3 cascades. J Mol Cell Biol 2021:mjab052. [PMID: 34450627 DOI: 10.1093/jmcb/mjab052] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
749 Zhang S, Liu Y, Chen J, Shu H, Shen S, Li Y, Lu X, Cao X, Dong L, Shi J, Cao Y, Wang X, Zhou J, Liu Y, Chen L, Fan J, Ding G, Gao Q. Autoantibody signature in hepatocellular carcinoma using seromics. J Hematol Oncol 2020;13:85. [PMID: 32616055 DOI: 10.1186/s13045-020-00918-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
750 Guo X, Wang Z, Deng X, Lu Y, Huang X, Lin J, Lan X, Su Q, Wang C. Circular RNA CircITCH (has-circ-0001141) suppresses hepatocellular carcinoma (HCC) progression by sponging miR-184. Cell Cycle. [DOI: 10.1080/15384101.2022.2057633] [Reference Citation Analysis]
751 Deng F, Chen D, Wei X, Lu S, Luo X, He J, Liu J, Meng T, Yang A, Chen H. Development and validation of a prognostic classifier based on HIF-1 signaling for hepatocellular carcinoma. Aging (Albany NY) 2020;12:3431-50. [PMID: 32084009 DOI: 10.18632/aging.102820] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
752 Vu M, Huynh VN, Berg CJ, Allen CG, Nguyen PH, Tran NA, Srivanjarean Y, Escoffery C. Hepatitis B Testing Among Vietnamese in Metropolitan Atlanta: The Role of Healthcare-Related and Acculturation-Related Factors. J Community Health 2021;46:767-76. [PMID: 33180219 DOI: 10.1007/s10900-020-00947-0] [Reference Citation Analysis]
753 Cao L, Han Y, Wang Y, Pei L, Yue Z, Qin L, Liu B, Cui J, Jia M, Wang H. Metabolic Profiling Identified a Novel Biomarker Panel for Metabolic Syndrome-Positive Hepatocellular Cancer. Front Endocrinol 2022;12:816748. [DOI: 10.3389/fendo.2021.816748] [Reference Citation Analysis]
754 Gao J, Yin Z, Wu Z, Sheng Z, Ma C, Chen R, Zhang X, Tang K, Fei J, Cao Z. Probing Synergistic Targets by Natural Compounds for Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:715762. [PMID: 34395446 DOI: 10.3389/fcell.2021.715762] [Reference Citation Analysis]
755 Xu Q, Wang Y, Huang W. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma. Int Immunopharmacol 2021;92:107333. [PMID: 33486322 DOI: 10.1016/j.intimp.2020.107333] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
756 Bhagavathula AS, Woolf B, Rahmani J, Vidyasagar K, Tesfaye W. Selective serotonin reuptake inhibitors use and the risk of hepatocellular carcinoma: a systematic review and dose-response analysis of cohort studies with one million participants. Eur J Clin Pharmacol 2022. [PMID: 35274148 DOI: 10.1007/s00228-022-03309-y] [Reference Citation Analysis]
757 Chen J, Yang J, Xu Q, Wang Z, Wu J, Pan L, Huang K, Wang C. Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Biosci Rep 2021;41:BSR20202063. [PMID: 33605411 DOI: 10.1042/BSR20202063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
758 Zhang Y, Zeng F, Zeng M, Han X, Cai L, Zhang J, Weng J, Gao Y. Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model. Int J Biol Sci 2021;17:3554-72. [PMID: 34512165 DOI: 10.7150/ijbs.62168] [Reference Citation Analysis]
759 Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing Epidemiology of Hepatocellular Carcinoma in Asia. Liver Int 2022. [PMID: 35319165 DOI: 10.1111/liv.15251] [Reference Citation Analysis]
760 Ma XL, Tang WG, Yang MJ, Xie SH, Wu ML, Lin G, Lu RQ. Serum STIP1, a Novel Indicator for Microvascular Invasion, Predicts Outcomes and Treatment Response in Hepatocellular Carcinoma. Front Oncol 2020;10:511. [PMID: 32426271 DOI: 10.3389/fonc.2020.00511] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
761 Zong J, Peng H, Qing X, Fan Z, Xu W, Du X, Shi R, Zhang Y. pH-Responsive Pluronic F127-Lenvatinib-Encapsulated Halogenated Boron-Dipyrromethene Nanoparticles for Combined Photodynamic Therapy and Chemotherapy of Liver Cancer. ACS Omega 2021;6:12331-42. [PMID: 34056385 DOI: 10.1021/acsomega.1c01346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
762 Xu D, Wang Y, Zhou K, Wu J, Zhang Z, Zhang J, Yu Z, Liu L, Liu X, Li B, Zheng J. Development and Validation of a Novel 8 Immune Gene Prognostic Signature Based on the Immune Expression Profile for Hepatocellular Carcinoma. Onco Targets Ther 2020;13:8125-40. [PMID: 32884295 DOI: 10.2147/OTT.S263047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
763 Shapey IM, Malik HZ, de Liguori Carino N. Data driven decision-making for older patients with hepatocellular carcinoma. Eur J Surg Oncol 2021;47:576-82. [PMID: 32600896 DOI: 10.1016/j.ejso.2020.05.023] [Reference Citation Analysis]
764 Patarat R, Riku S, Kunadirek P, Chuaypen N, Tangkijvanich P, Mutirangura A, Puttipanyalears C. The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma. Sci Rep 2021;11:14838. [PMID: 34290294 DOI: 10.1038/s41598-021-94330-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
765 Wu L, Quan W, Luo Q, Pan Y, Peng D, Zhang G. Identification of an Immune-Related Prognostic Predictor in Hepatocellular Carcinoma. Front Mol Biosci 2020;7:567950. [PMID: 33195412 DOI: 10.3389/fmolb.2020.567950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
766 Pan J, Chen S, Tian G, Jiang T. Preoperative Albumin-Bilirubin Grade With Prognostic Nutritional Index Predicts the Outcome of Patients With Early-Stage Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation. Front Med (Lausanne) 2020;7:584871. [PMID: 33240907 DOI: 10.3389/fmed.2020.584871] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
767 Qiu Z, Wang G, Yan H, Qi H, Zuo M, Wang G, Jiang W, Chen Z, Xue J, Lu L, Zhang F, Gao F. TIPS plus sequential systemic therapy of advanced HCC patients with tumour thrombus-related symptomatic portal hypertension. Eur Radiol 2022. [PMID: 35441840 DOI: 10.1007/s00330-022-08705-7] [Reference Citation Analysis]
768 Webel AR, Schexnayder J, Cioe PA, Zuñiga JA. A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science. J Assoc Nurses AIDS Care 2021;32:322-46. [PMID: 33595986 DOI: 10.1097/JNC.0000000000000240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
769 Sun Q, Liu P, Long B, Zhu Y, Liu T. Screening of significant biomarkers with poor prognosis in hepatocellular carcinoma via bioinformatics analysis. Medicine (Baltimore) 2020;99:e21702. [PMID: 32769939 DOI: 10.1097/MD.0000000000021702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
770 Luo D, Zhao D, Zhang M, Hu C, Li H, Zhang S, Chen X, Huttad L, Li B, Jin C, Lin C, Han B. Alternative Splicing-Based Differences Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Genes, Immune Microenvironment, and Survival Prognosis. Front Oncol 2021;11:731993. [PMID: 34760694 DOI: 10.3389/fonc.2021.731993] [Reference Citation Analysis]
771 Fujiwara N, Qian T, Koneru B, Hoshida Y. Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatol Res 2020;50:817-30. [PMID: 32323426 DOI: 10.1111/hepr.13506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
772 Post J, Langohr IM, Webster CRL, Mottram P, Liu CC, Johnston A. Hepatocyte ploidy in cats with and without hepatocellular carcinoma. BMC Vet Res 2021;17:104. [PMID: 33663494 DOI: 10.1186/s12917-021-02812-1] [Reference Citation Analysis]
773 Li TE, Wang S, Shen XT, Zhang Z, Chen M, Wang H, Zhu Y, Xu D, Hu BY, Wei R, Zheng Y, Dong QZ, Qin LX. PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment. Front Immunol 2020;11:589997. [PMID: 33193421 DOI: 10.3389/fimmu.2020.589997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
774 Diesinger T, Lautwein A, Bergler S, Buckert D, Renz C, Dvorsky R, Buko V, Kirko S, Schneider E, Kuchenbauer F, Kumar M, Günes C, Genze F, Büchele B, Simmet T, Haslbeck M, Masur K, Barth T, Müller-Enoch D, Wirth T, Haehner T. A New CYP2E1 Inhibitor, 12-Imidazolyl-1-dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:8854432. [PMID: 33604316 DOI: 10.1155/2021/8854432] [Reference Citation Analysis]
775 Bao SX, Wang CH, Jin S, Hu KW, Lu JT. miR-135b-5p Suppresses Androgen Receptor-Enhanced Hepatocellular Carcinoma Cell Proliferation via Regulating the HIF-2α/c-Myc/P27 Signals in vitro. Onco Targets Ther 2020;13:9991-10000. [PMID: 33116584 DOI: 10.2147/OTT.S268214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
776 Zeng L, Su J, Qiu W, Jin X, Qiu Y, Yu W. Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials. Cancer Control 2022;29:10732748221092924. [PMID: 35418272 DOI: 10.1177/10732748221092924] [Reference Citation Analysis]
777 Ni W, Bian S, Zhu M, Song Q, Zhang J, Xiao M, Zheng W. Identification and Validation of Ubiquitin-Specific Proteases as a Novel Prognostic Signature for Hepatocellular Carcinoma. Front Oncol 2021;11:629327. [PMID: 33718205 DOI: 10.3389/fonc.2021.629327] [Reference Citation Analysis]
778 Li SY, Zhu Y, Li RN, Huang JH, You K, Yuan YF, Zhuang SM. LncRNA Lnc-APUE is Repressed by HNF4α and Promotes G1/S Phase Transition and Tumor Growth by Regulating MiR-20b/E2F1 Axis. Adv Sci (Weinh) 2021;8:2003094. [PMID: 33854885 DOI: 10.1002/advs.202003094] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
779 Trevisan França de Lima L, Broszczak D, Zhang X, Bridle K, Crawford D, Punyadeera C. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer 2020;1874:188451. [PMID: 33065194 DOI: 10.1016/j.bbcan.2020.188451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
780 Zhang X, Zhang X, Li X, Bao H, Li G, Li N, Li H, Dou J. Connection Between CDC20 Expression and Hepatocellular Carcinoma Prognosis. Med Sci Monit 2021;27:e926760. [PMID: 33788826 DOI: 10.12659/MSM.926760] [Reference Citation Analysis]
781 Zhang L, Chang S, Zhao Y, Cao G, Zhang D. MicroRNA-4317 suppresses the progression of hepatocellular carcinoma by targeting ZNF436-mediated PI3K/AKT signaling pathway. Tissue Cell 2021;74:101696. [PMID: 34861581 DOI: 10.1016/j.tice.2021.101696] [Reference Citation Analysis]
782 Wang X, Liu G, Chen S, Bi H, Xia F, Feng K, Ma K, Ni B. Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis. Int J Hyperthermia 2021;38:1519-28. [PMID: 34702122 DOI: 10.1080/02656736.2021.1991011] [Reference Citation Analysis]
783 Guarino M, Cucchetti A, Pontillo G, Farinati F, Benevento F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Rodolfo S, Cabibbo G, Marra F, Mega A, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F, Giannini EG, Morisco F; ITA.LI.CA Group. Pattern of macrovascular invasion in hepatocellular carcinoma. Eur J Clin Invest 2021;51:e13542. [PMID: 33755196 DOI: 10.1111/eci.13542] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
784 . Retraction. American Journal of Physiology-Gastrointestinal and Liver Physiology 2020;319:G636-G636. [DOI: 10.1152/ajpgi.00161.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
785 Liu Y, Xue M, Cao D, Qin L, Wang Y, Miao Z, Wang P, Hu X, Shen J, Xiong B. Multi-omics characterization of WNT pathway reactivation to ameliorate BET inhibitor resistance in liver cancer cells. Genomics 2021;113:1057-69. [PMID: 33667649 DOI: 10.1016/j.ygeno.2021.02.017] [Reference Citation Analysis]
786 Mai Q, Sheng D, Chen C, Gou Q, Chen M, Huang X, Yin H, Chen X, Chen Z. Steroid 5 alpha-reductase 3 (SRD5A3) promotes tumor growth and predicts poor survival of human hepatocellular carcinoma (HCC). Aging (Albany NY) 2020;12:25395-411. [PMID: 33229626 DOI: 10.18632/aging.104142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
787 Pang S, Sun Z, Lu W, Si-ma H, Lin Z, Shi Y, Yang Y, Zhao X, Yang G, Jin G, Yang N. Integrated Bioinformatics Analysis and Validation of the Prognostic Value of RBM10 Expression in Hepatocellular Carcinoma. CMAR 2022;Volume 14:969-80. [DOI: 10.2147/cmar.s349884] [Reference Citation Analysis]
788 Coral GP, Branco F, Meurer R, Marcon PDS, Fontes PRO, Mattos AA. RESULTS OF IMMUNOHISTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF EARLY HEPATOCELLULAR CARCINOMA AND NODULES WITH HIGH-GRADE DYSPLASIA IN PATIENTS WITH CIRRHOSIS. Arq Gastroenterol 2021;58:82-6. [PMID: 33909802 DOI: 10.1590/S0004-2803.202100000-14] [Reference Citation Analysis]
789 Hu Q, Ma X, Li C, Zhou C, Chen J, Gu X. Downregulation of THRSP Promotes Hepatocellular Carcinoma Progression by Triggering ZEB1 Transcription in an ERK-dependent Manner. J Cancer 2021;12:4247-56. [PMID: 34093825 DOI: 10.7150/jca.51657] [Reference Citation Analysis]
790 Tsai HM, Han MZ, Lin YJ, Chang TT, Chen CY, Cheng PN, Chuang CH, Wu IC, Chen PJ, Kang JW, Chiu YC, Chiu HC, Chien SC, Kuo HY. Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis. Cancer Immunol Immunother 2021;70:1929-37. [PMID: 33409737 DOI: 10.1007/s00262-020-02845-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
791 Liu B, Bai C. Regulatory Mechanisms of Coicis Semen on Bionetwork of Liver Cancer Based on Network Pharmacology. Biomed Res Int 2020;2020:5860704. [PMID: 33294448 DOI: 10.1155/2020/5860704] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
792 Quitt O, Luo S, Meyer M, Xie Z, Golsaz-Shirazi F, Loffredo-Verde E, Festag J, Bockmann JH, Zhao L, Stadler D, Chou WM, Tedjokusumo R, Wettengel JM, Ko C, Noeßner E, Bulbuc N, Shokri F, Lüttgau S, Heikenwälder M, Bohne F, Moldenhauer G, Momburg F, Protzer U. T cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice. J Hepatol 2021:S0168-8278(21)00443-8. [PMID: 34171437 DOI: 10.1016/j.jhep.2021.06.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
793 Sun L, Zhang J, Wen K, Huang S, Li D, Xu Y, Wu J. The Prognostic Value of Lysine Acetylation Regulators in Hepatocellular Carcinoma. Front Mol Biosci 2022;9:840412. [DOI: 10.3389/fmolb.2022.840412] [Reference Citation Analysis]
794 Yang CJ, Wang CK, Fang YD, Wang JY, Su FC, Tsai HM, Lin YJ, Tsai HW, Yeh LR. Clinical application of mask region-based convolutional neural network for the automatic detection and segmentation of abnormal liver density based on hepatocellular carcinoma computed tomography datasets. PLoS One 2021;16:e0255605. [PMID: 34375365 DOI: 10.1371/journal.pone.0255605] [Reference Citation Analysis]
795 Wu J, Zhang L, Wang X. Host Sex Steroids Interact With Virus Infection: New Insights Into Sex Disparity in Infectious Diseases. Front Microbiol 2021;12:747347. [PMID: 34803967 DOI: 10.3389/fmicb.2021.747347] [Reference Citation Analysis]
796 Shih WL, Fang CT, Chen PJ. Chapter XX Antiviral Treatment and Cancer Control. Recent Results Cancer Res 2021;217:325-54. [PMID: 33200371 DOI: 10.1007/978-3-030-57362-1_13] [Reference Citation Analysis]
797 Attal N, Sullivan MT, Girardi CA, Thompson KJ, McKillop IH. Fatty acid binding protein-4 promotes alcohol-dependent hepatosteatosis and hepatocellular carcinoma progression. Transl Oncol 2021;14:100975. [PMID: 33290990 DOI: 10.1016/j.tranon.2020.100975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
798 Li X, Li Y, Bai S, Zhang J, Liu Z, Yang J. NR2F1-AS1/miR-140/HK2 Axis Regulates Hypoxia-Induced Glycolysis and Migration in Hepatocellular Carcinoma. Cancer Manag Res 2021;13:427-37. [PMID: 33488124 DOI: 10.2147/CMAR.S266797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
799 Cheung MLM, Kan MWK, Yeung VTY, Poon DMC, Kam MKM, Lee LKY, Chan ATC. Analysis of Hepatocellular Carcinoma Stereotactic Body Radiation Therapy Dose Prescription Method Using Uncomplicated Tumor Control Probability Model. Adv Radiat Oncol 2021;6:100739. [PMID: 34355107 DOI: 10.1016/j.adro.2021.100739] [Reference Citation Analysis]
800 Shi M, Li ZY, Zhang LM, Wu XY, Xiang SH, Wang YG, Zhang YQ. Hsa_circ_0007456 regulates the natural killer cell-mediated cytotoxicity toward hepatocellular carcinoma via the miR-6852-3p/ICAM-1 axis. Cell Death Dis 2021;12:94. [PMID: 33462208 DOI: 10.1038/s41419-020-03334-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
801 Niu M, Yi M, Li N, Wu K, Wu K. Advances of Targeted Therapy for Hepatocellular Carcinoma. Front Oncol 2021;11:719896. [PMID: 34381735 DOI: 10.3389/fonc.2021.719896] [Reference Citation Analysis]
802 Das JP, Thulasidasan N, Ahmed I, Diamantopoulos A. Transarterial chemoembolization for hepatocellular carcinoma: a bibliometric analysis of the most cited articles. Jpn J Radiol 2020;38:1190-6. [PMID: 32767200 DOI: 10.1007/s11604-020-01028-x] [Reference Citation Analysis]
803 Liu Q, You N, Li J, Wu K, Peng X, Wang Z, Wang L, Zhu Y, Zheng L. Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis. Front Oncol 2021;11:694409. [PMID: 34737945 DOI: 10.3389/fonc.2021.694409] [Reference Citation Analysis]
804 Nikolaou S, Qiu S, Fiorentino F, Simillis C, Rasheed S, Tekkis P, Kontovounisios C. The role of Neurotensin and its receptors in non-gastrointestinal cancers: a review. Cell Commun Signal 2020;18:68. [PMID: 32336282 DOI: 10.1186/s12964-020-00569-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
805 D'souza S, Lau KCK, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol 2020; 26(38): 5759-5783 [PMID: 33132633 DOI: 10.3748/wjg.v26.i38.5759] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
806 Li M, Yu X, Zheng Q, Zhang Q, He Y, Guo W. Promising role of long non-coding RNA PCAT6 in malignancies. Biomed Pharmacother 2021;137:111402. [PMID: 33761616 DOI: 10.1016/j.biopha.2021.111402] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
807 Nomura K, Kitanaka A, Iwama H, Tani J, Nomura T, Nakahara M, Ohura K, Tadokoro T, Fujita K, Mimura S, Yoneyama H, Kobara H, Morishita A, Okano K, Suzuki Y, Tsutsi K, Himoto T, Masaki T. Association between microRNA-527 and glypican-3 in hepatocellular carcinoma. Oncol Lett 2021;21:229. [PMID: 33613718 DOI: 10.3892/ol.2021.12490] [Reference Citation Analysis]
808 Zhang X, Xin Y, Yang Y, Chen Y, Cao X, Wang Y, Fan Q, Zhou X, Li X. Aspartate aminotransferase-to-platelet ratio index for predicting late recurrence of hepatocellular carcinoma after radiofrequency ablation. International Journal of Hyperthermia 2022;39:437-45. [DOI: 10.1080/02656736.2022.2043457] [Reference Citation Analysis]
809 Lu Q, Lou J, Cai R, Han W, Pan H. Emerging roles of a pivotal lncRNA SBF2-AS1 in cancers. Cancer Cell Int 2021;21:417. [PMID: 34372871 DOI: 10.1186/s12935-021-02123-3] [Reference Citation Analysis]
810 Yang SY, Wang CC, Chen KD, Liu YW, Lin CC, Chuang CH, Tsai YC, Yao CC, Yen YH, Hsiao CC, Hu TH, Tsai MC. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer 2021;21:70. [PMID: 33446127 DOI: 10.1186/s12885-021-07796-7] [Reference Citation Analysis]
811 Zhang Y, Tan Y, Liu S, Yin H, Duan J, Fan L, Zhao X, Jiang B. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis. Toxicol Mech Methods 2022;:1-9. [PMID: 35592903 DOI: 10.1080/15376516.2022.2075297] [Reference Citation Analysis]
812 Li L, Xiao C, He K, Xiang G. Circ_0072088 promotes progression of hepatocellular carcinoma by activating JAK2/STAT3 signaling pathway via miR-375. IUBMB Life 2021;73:1153-65. [PMID: 34148288 DOI: 10.1002/iub.2520] [Reference Citation Analysis]
813 Shen Q, Xia Y, Yang L, Wang B, Peng J, Tang M. Midazolam Suppresses Hepatocellular Carcinoma Cell Metastasis and Enhances Apoptosis by Elevating miR-217. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/2813521] [Reference Citation Analysis]
814 Tsuchiya K, Ohki T, Sato K, Kondo M, Toda N, Tagawa K. Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged ≥80 years. Liver Research 2020;4:206-11. [DOI: 10.1016/j.livres.2020.11.005] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
815 Sadiq AM, Mjemmas MG, Sadiq AM, Nkya GZ. Sarcomatoid hepatocellular carcinoma in a young African female. SAGE Open Med Case Rep 2021;9:2050313X211052452. [PMID: 34646567 DOI: 10.1177/2050313X211052452] [Reference Citation Analysis]
816 Huo J, Fan X, Qi B, Sun P. A Five-Gene Signature Associated With DNA Damage Repair Molecular Subtype Predict Overall Survival for Hepatocellular Carcinoma. Front Genet 2022;13:771819. [DOI: 10.3389/fgene.2022.771819] [Reference Citation Analysis]
817 Giraud J, Chalopin D, Blanc JF, Saleh M. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. Front Immunol 2021;12:655697. [PMID: 33815418 DOI: 10.3389/fimmu.2021.655697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
818 Zhao L, Deng C, Lin Z, Giovannucci E, Zhang X. Dietary Fats, Serum Cholesterol and Liver Cancer Risk: A Systematic Review and Meta-Analysis of Prospective Studies. Cancers (Basel) 2021;13:1580. [PMID: 33808094 DOI: 10.3390/cancers13071580] [Reference Citation Analysis]
819 Liang JY, Wang DS, Lin HC, Chen XX, Yang H, Zheng Y, Li YH. A Novel Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with Hepatocellular Carcinoma. Int J Biol Sci 2020;16:2430-41. [PMID: 32760210 DOI: 10.7150/ijbs.45050] [Cited by in Crossref: 55] [Cited by in F6Publishing: 68] [Article Influence: 27.5] [Reference Citation Analysis]
820 Zhang C, Bao T, Ke Y, Liu X, Wang X, Liao W, He Y, Wang L. Integrated analysis of ceRNA network reveals potential prognostic Hint1-related lncRNAs involved in hepatocellular carcinoma progression. World J Surg Oncol 2022;20:67. [PMID: 35241097 DOI: 10.1186/s12957-022-02535-z] [Reference Citation Analysis]
821 Shi Q, Liu J, Li T, Zhou C, Wang Y, Huang S, Yang C, Chen Y, Xiong B. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: a single-center propensity score matching analysis: DEB-TACE vs cTACE for HCC beyond up-to-seven criteria. Clin Res Hepatol Gastroenterol 2022;:101893. [PMID: 35247625 DOI: 10.1016/j.clinre.2022.101893] [Reference Citation Analysis]
822 Lan HY, An P, Liu QP, Chen YY, Yu YY, Luan X, Tang JY, Zhang H. Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway. J Ethnopharmacol 2021;274:114073. [PMID: 33794335 DOI: 10.1016/j.jep.2021.114073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
823 Hetta HF, Mekky MA, Zahran AM, Abdel-Malek MO, Ramadan HK, Shafik EA, Abbas WA, Abbas El-Masry M, Mohamed NA, Kamel AA, Marraiki N, Beshbishy AM, Batiha GE, Osman HA, Koneru G, El-Mokhtar MA. Regulatory B Cells and Their Cytokine Profile in HCV-Related Hepatocellular Carcinoma: Association with Regulatory T Cells and Disease Progression. Vaccines (Basel) 2020;8:E380. [PMID: 32664587 DOI: 10.3390/vaccines8030380] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
824 Wu MZ, Yuan YC, Huang BY, Chen JX, Li BK, Fang JH, Zhuang SM. Identification of a TGF-β/SMAD/lnc-UTGF positive feedback loop and its role in hepatoma metastasis. Signal Transduct Target Ther 2021;6:395. [PMID: 34785655 DOI: 10.1038/s41392-021-00781-3] [Reference Citation Analysis]
825 Cucchetti A, Gramenzi A, Johnson P, Giannini EG, Tovoli F, Rapaccini GL, Marra F, Cabibbo G, Caturelli E, Gasbarrini A, Svegliati-Baroni G, Sacco R, Zoli M, Morisco F, Di Marco M, Mega A, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. Eur J Cancer 2021;158:133-43. [PMID: 34666215 DOI: 10.1016/j.ejca.2021.09.018] [Reference Citation Analysis]
826 He Y, Shi Q, Zhang Y, Yuan X, Yu Z. Transcriptome-Wide 5-Methylcytosine Functional Profiling of Long Non-Coding RNA in Hepatocellular Carcinoma. Cancer Manag Res 2020;12:6877-85. [PMID: 32801911 DOI: 10.2147/CMAR.S262450] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
827 Li C, Wang X, Song Q. MicroRNA 885-5p Inhibits Hepatocellular Carcinoma Metastasis by Repressing AEG1. Onco Targets Ther 2020;13:981-8. [PMID: 32099401 DOI: 10.2147/OTT.S228576] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
828 Yang Z, Wu X, Li J, Zheng Q, Niu J, Li S. CCNB2, CDC20, AURKA, TOP2A, MELK, NCAPG, KIF20A, UBE2C, PRC1, and ASPM May Be Potential Therapeutic Targets for Hepatocellular Carcinoma Using Integrated Bioinformatic Analysis. Int J Gen Med 2021;14:10185-94. [PMID: 34992437 DOI: 10.2147/IJGM.S341379] [Reference Citation Analysis]
829 Wu H, Li Y, Shi G, Du S, Wang X, Ye W, Zhang Z, Chu Y, Ma S, Wang D, Li Y, Chen Z, Birnbaumer L, Wang Z, Yang Y. Hepatic IRF8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-PD-1 therapy. Hepatology 2022. [PMID: 34989013 DOI: 10.1002/hep.32316] [Reference Citation Analysis]
830 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol. 2021;18:223-238. [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 24.5] [Reference Citation Analysis]
831 Pereira C, Tauro LF, Diaz E. Policeman to the Rescue; A Case of Ruptured Hepatocellular Carcinoma. Curr Health Sci J 2020;46:447-9. [PMID: 33717522 DOI: 10.12865/CHSJ.46.04.18] [Reference Citation Analysis]
832 Ghamari SH, Yoosefi M, Abbasi-Kangevari M, Malekpour MR, Saeedi Moghaddam S, Shahin S, Esfahani Z, Koolaji S, Shobeiri P, Ghaffari A, Sohrabi H, Kazemi A, Rezaei N, Larijani B, Farzadfar F. Trends in Global, Regional, and National Burden and Quality of Care Index for Liver Cancer by Cause from Global Burden of Disease 1990-2019. Hepatol Commun 2022. [PMID: 35134275 DOI: 10.1002/hep4.1910] [Reference Citation Analysis]
833 Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therap Adv Gastroenterol 2020;13:1756284820931734. [PMID: 32647536 DOI: 10.1177/1756284820931734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
834 Chen RY, Yen CJ, Lin YJ, Wang JM, Tasi TF, Huang YC, Liu YW, Tsai HW, Lee MH, Hung LY. CPAP enhances and maintains chronic inflammation in hepatocytes to promote hepatocarcinogenesis. Cell Death Dis 2021;12:983. [PMID: 34686650 DOI: 10.1038/s41419-021-04295-2] [Reference Citation Analysis]
835 Chao X, Wu J, Zhang W, Feng X, Zhao L, Huang F, Jiang C. A new discovery of STAT4 single nucleotide polymorphisms associated with hepatocellular carcinoma risk in Chinese Han population: a case-control study. Biosci Rep 2021:BSR20210124. [PMID: 34100914 DOI: 10.1042/BSR20210124] [Reference Citation Analysis]
836 Chen M